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ABSTRACT 
 
Background 
 
Overweight and obesity are serious conditions that place a significant health and 
financial burden on individuals and the wider community. While the knowledge of the 
issues producing obesity are well known, the prevalence of the condition continues to 
rise.  Despite advances in treatments, the cornerstone of management remains a 
combined lifestyle intervention.  
 
Recently, insights from novel research have shed light on different aspects of obesity: 
from aetiology to weight loss and obesity remission. 
 
The experiments 
 
In the first experiment, the effect of covertly and randomly varying the protein content 
of the diet was tested in lean and healthy adults (n=22).  Following 4 days of an ad 
libitum diet and a standardised in energy intake breakfast, for the lowest protein diet, 
fasting ghrelin was highest while post-prandial cholecystokinin lowest.  The direction 
of these changes favoured increased appetite and decreased satiety. 
 
In the second experiment, isocaloric low and high protein diets were tested in obese 
and lean mice (n=20 per group).  The daily food intake varied and 12 - 15% more 
consumed with the low protein compared to the high protein chow.   
 iv 
These novel results demonstrate the intake for dietary protein is prioritised, even at 
the expense of an increased total energy intake and it occurs in the obese state.  
 
In the third experiment, the effects of a combined lifestyle intervention on the 
secretion of key gut hormones and adipokines that are involved in the regulation of 
appetite and body weight was tested.  Following a 12 weeks of the weight loss 
intervention, obese subjects (n=60) lost a mean 5.6% off baseline weight and this was 
associated with changes in the fasting levels of ghrelin and glucagon-like peptide-1.  
The direction of the changes would prevent further weight loss whilst favouring weight 
regain. 
 
Discussion 
 
The results from these experiments challenge conventional thinking about overweight 
and obesity.  The secular trends of reduced protein consumption may be a powerful 
driver for the increased rate of overweight and obesity. Changes arise in the peripheral 
mediators of appetite and body weight after successful conventional weight loss 
therapies, which militate against further weight loss while promoting weight regain. 
These changes help explain the high rates of recidivism seen following weight loss by 
lifestyle interventions. 
 
Further research into these different aspects of obesity may provide new therapeutic 
opportunities in the management of overweight and obesity:  to reduce its incidence; 
to help facilitate weight loss; and to increase the rates of obesity remission. 
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CHAPTER 1 
 
Aspects of Obesity: the challenges of aetiology, weight loss and 
remission 
 
 
1.1  INTRODUCTION 
 
1.1.1  Definitions, epidemiology, global trends, burden of illness 
 
Definitions, epidemiology and global trends 
 
An individual who continually accumulates excess body fat will become overweight 
and/or obese.  These conditions are defined by the Body Mass Index (BMI), a 
calculated ratio of weight to height and a simple method of quantifying excess 
adiposity.  The BMI is calculated by dividing body weight (in kilograms [kg]) by height 
(in meters [m]) squared (BMI = kg/m2).   
 
Adults with a BMI ≥ 25 kg/m2 are defined as overweight while those with a BMI ≥ 30 
kg/m2 are obese.  Obese range BMIs are graded into three degrees of severity (Grade I: 
30 – 34.9 kg/m2, Grade II: 35 – 39.9 kg/m2, and Grade III: ≥40 kg/m2)1 with severe 
obesity defined as a BMI ≥40 kg/m2 (or ≥ 35 kg/m2 in the presence of multiple co-
morbidities). 
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National and international studies of overweight and obesity have shown a high 
prevalence of overweight and obesity in children, adolescents and in adults.  The 
Australian Bureau of Statistics has estimated that in 2011- 20122, 63.4% of adult 
Australians were overweight or obese, with the prevalence increasing compared to 
previous.  This trend has also been noted in other high-income nations and in these 
countries for the last three decades the prevalence of overweight and obesity has 
increased rapidly (though the most recent five year Australian and U.S. health surveys 
showed that the rate of increase had slowed)1-6. 
 
Finally it is worth noting that these conditions are no longer a problem of high-income 
nations alone but also a problem for countries in transition.  The World Health 
Organisation has estimated that in 2008 1.4 billion adults were overweight and of 
these over 200 million men and nearly 300 million women were obese.  For the same 
period more global deaths were linked to overweight and obesity than to underweight1.   
 
The health burden from overweight and obesity 
 
Obesity is a major risk factor for conditions such as cardiovascular disease, Type 2 
diabetes mellitus, osteoarthritis, chronic kidney disease and cancers including those of 
the breast, prostate, oesophagus, kidney and colon7-10.  Elevated BMI has long been 
correlated with an increased mortality risk10 with the results of a meta-analysis of close 
to 100 studies and 2.9 million subjects confirming the strength of the relationship 
between mortality and severe obesity11, the category of elevated BMI of which the 
prevalence has continued to increase5,6. 
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The economic burden from overweight and obesity 
 
The increasing global prevalence and the impact on health from overweight and 
obesity is well recognised and this has led to a focus on assessing the burden that it 
places not just on individuals, but on health care services and the wider community.   
 
It has been estimated that overweight and obesity accounts for between 0.7 – 2.8% of a 
nation’s total healthcare expenditure and that the obese have 30% greater health care 
costs than their lean counterparts12.  In Australia, the annual direct health care cost 
from overweight and obesity has been calculated to range from $8.3 to 10.7 billion.  
When indirect costs such as lost productivity, cost of carers and government welfare 
are considered, the annual figure rises to an astonishing $45 to 58 billion13,14.   
 
With costs rising by 3 – 10% per annum, there are strong incentives to develop and 
implement effective strategies to reduce the burden of the condition, especially as 
noted earlier, the rates of Australian overweight and obesity have continued to rise.   
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1. 1.2  Challenges in managing overweight and obesity 
 
The recommended clinical management of overweight and obesity is to assist patients 
to implement a combined lifestyle intervention with the goals of decreasing energy 
intake (by reducing food consumption) and increasing energy expenditure (through 
regular physical activity).  This should also include promoting positive behavioural 
changes to alter habits that lead to increased energy intake and providing 
psychological methods and support to achieve such changes. 
 
The antecedents of this current approach go as far back as Hippocrates15 and Galen16, 
physicians of classical antiquity, who perceptively recognised that obesity was a disease 
of imbalance (though of the humours rather than of hormones).  Their treatment 
strategies involved recommending that their corpulent patients re-balance their 
humours by increasing their levels of physical activity and by decreasing their 
indulgence of fine foods. 
 
Since these times, while our knowledge of obesity’s underlying pathophysiology has 
significantly improved, the guidelines for the prevention and clinical management of 
overweight and obesity, as put forward by the national bodies of Australia (National 
Health and Medical Research Council17), the United Kingdom (National Institute for 
Health and Clinical Excellence18) and the United States of America (National Heart 
Lung and Blood Institute19) all still recommend the same type of combined lifestyle 
intervention as the cornerstone of management.  The now three decade old increases 
in rates of overweight and obesity places the effectiveness of these strategies into 
question.   
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Weight loss or weight regain? 
 
Meta-analyses of combined lifestyle-based weight loss studies have shown that 5 years 
after any lifestyle intervention only 17 – 30% of subjects maintained weight loss while 
an even smaller 2 - 7% of subjects continued to lose weight20.  This suggests that on 
following a lifestyle intervention, the norm is not long-term weight loss but rather 
recidivism or weight regain.   
 
Modern advances: pharmacotherapy and bariatric surgery 
 
Modern advances in the management of obesity include several pharmacological 
agents including Phentermine, Sibutramine, Rimonabant and Orlistat, which target 
central appetite centres or influence the intestinal absorption of macronutrients.  
While these agents are modestly effective at facilitating weight loss21,22 studies into 
their clinical use have been marked by high rates of subject drop-out, which have also 
been a feature of their clinical use in the “real world”.   
 
Furthermore all of these agents have their own individual and problematic side-effect 
profiles and over the last 5 years Sibutramine and Rinomabant have had to be 
withdrawn from national pharmaceutical registries across several jurisdictions 
(including Australia) due to an increased rate of significant adverse events 
(cardiovascular for Sibutramine and psychiatric for Rinomabant)23.  
 
The most effective advance in obesity management has been with modern bariatric 
surgery, which functionally either restricts the capacity of the stomach (e.g. 
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laparoscopic adjustable gastric band or sleeve gastrectomy), leads to nutritional 
malabsorption (switch and bypass procedures) or combines both effects in a single 
procedure (Roux-en-Y gastric bypass).  The effectiveness of these procedures 
compared to conventional lifestyle interventions in producing greater and more 
sustained weight-loss and in inducing the remission of obesity related complications 
has been firmly established24. 
 
Interestingly, while originally it was thought that the reason for the success of bariatric 
surgery was due to the procedures themselves, more recently focus has shifted to the 
favourable effects on the peripherally secreted hormonal regulators of appetite and 
body weight that are seen following bariatric surgery25,26.   
 
The superior weight loss, weight maintenance and remission of obesity complications 
associated with bariatric surgery has led to an increase in its popularity.  However 
there remain problems when considering bariatric surgery as first line in the 
management of obesity.  In particular, surgery itself carries a (small) risk of morbidity 
and mortality27,28, and a considerable financial cost with access to surgery not 
distributed equitably across national health care sectors29,30. 
 
In summary, despite their limitations, conventional weight loss strategies remain the 
cornerstone of the management of overweight and obesity.  Insights gained from 
reviewing the aetiology of obesity may shed light and provide opportunities to address 
these limitations.  
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1.1.3  Multi-factorial aetiology of obesity 
 
Most individuals gain weight due to a complex and dynamic interaction between 
evolutionary, genetic, prenatal, environmental, psychological and behavioural factors 
that contribute to a long-term misalignment between their diet and energy intake and 
their levels of physical activity and energy expenditure.  The resulting excessive energy 
intake leads to fat deposition and weight gain9,31. 
 
Genetic, pre-natal and social factors 
 
Only a minority of people excessive weight gain is due to a specific genetic defect which 
comprises a clinical syndrome (the best known of these being Prader-Willi and Bardet-
Biedl syndromes). However research into these and other genetic conditions has 
advanced the knowledge of common overweight and obesity32.  More broadly, studies 
of adoptees, families and twins suggest that important metabolic traits, including the 
regulation of energy intake, energy expenditure and fat storage, have a genetic 
component and are in part heritable33-35, although attenuating these factors remains 
beyond the scope of current therapies. 
 
In contrast, the prenatal environment has long been recognised as both contributing to 
offspring overweight and obesity while providing an opportunity to implement obesity 
prevention strategies.  Maternal factors such as smoking history36, nutrition and 
weight change37 and diabetes status38,39 are all independently associated with an 
increased risk for obesity in the woman’s offspring.  More recently novel factors such 
as the weight profile of an individual’s social network, incorporating family members, 
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spouses and friends, has been independently associated with a risk of obesity40, raising 
this as another area of possible intervention. 
 
Diet and lifestyle 
 
Internationally there has been a several decades long increase in the global food 
supply, which has been driven by innovation in agricultural technology that has 
become coupled with changes in food manufacture favouring the increased use of 
refined carbohydrates (CHO) and fats (F) at the expense of protein (P)41.   
 
While research into the aetiology of overweight and obesity has traditionally focused 
on the role of CHO and F, there has recently been a focus on the role dietary P, which 
has declined in a smaller magnitude than the increases in the consumption of CHO 
and F.  Whether the modest reduction in the consumption of dietary P has contributed 
to the increased prevalence of overweight and obesity is an open and relevant 
question42. 
 
Across high-income nations on a population level, the well-recognised decline in the 
levels of physical activity across all age groups has been associated with an increased 
risk of obesity43-46.  Some of this decline can be attributed to a shift in mass 
entertainment to types which are less participatory and more sedentary47, while factors 
such as the increase in vehicular transportation, the increase use of technology and the 
design of work spaces and urban living areas all contribute to this problem41. 
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Taking diet and lifestyle together, it is unsurprisingly that the availability of cheap, 
energy dense foods and a decline in physical activity both play highly significant roles 
in the increased rates of overweight and obesity41. 
 
Evolutionary and environmental factors 
 
Evolutionary theory has lessons for the aetiology of overweight and obesity.  As 
modern man (homo sapiens) spent much of his existence living in a small hunter-
gatherer bands and following a subsistence lifestyle, the theory predicts that homo 
sapiens adapted to the reality of unpredictable food supplies by evolving to be able to 
readily accumulate fat stores whenever food sources became available48.   
 
The complex homeostatic system of appetite and body weight regulation that evolved 
during homo sapiens’ long existence living in subsistence nutrient environments is 
much more sensitive to states of energy deficit than to states of energy excess.  The 
secretion of multiple peripheral hormones is quickly altered by any sustained decrease 
in food intake, which triggers a central response that involves increases to hunger and 
to food seeking behaviour. In comparison the physiological response to chronically 
increased food intake is blunted and easily down-regulated48,49.   
 
While this system was advantageous for the hundreds of thousands of years, when 
homo sapiens lived in small, nomadic band societies, the rapid transit from pre-
agricultural societies to the modern post-industrial age has seen technological 
advances in agricultural productivity and the creation of labour saving devices that 
have become coupled with physically less demanding employment, more sedentary 
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lifestyles and greater urban living.  In a little over 6,000 years, this has resulted in 
homo sapiens facing a completely different living environment than was encountered 
for much of human history50.  The modern lifestyle is one where energy dense foods 
are readily available and where little physical effort is required to obtain and consume 
this food.  This results in modern living conflicting with our evolutionary heritage, 
creating a situation where living in the here and now is to live in an “obesogenic” 
world51.  Furthermore, the maladaptive interplay between the obesogenic world and 
our evolutionary heritage is highlighted when considering the neuro-endocrine 
homeostatic regulation of appetite and body weight.  This results in an insidious 
conflict between human physiology, that always seeks to retain body weight, and the 
modern living environment, where excess energy intake is the norm.  It is not 
surprising that the physiological response to this world is one of overweight and 
obesity50. 
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1.2  AIMS OF THE THESIS 
 
Overweight and obesity are complex clinical conditions the prevalence of which has 
increased globally.  This due to multiple factors including an evolutionary 
susceptibility, technological and socio-economic shifts, changes to agricultural and 
food manufacture practices in addition to individual lifestyle choices.  It is a significant 
health and economic issue both for individuals and their wider society.  Despite 
pharmacological and surgical advances, the cornerstone of clinical management is the 
combined lifestyle intervention, which is marked by (at best) modest long-term 
outcomes. 
 
Recent studies focusing on the role of dietary protein in the regulation of food intake 
and the impact of weight loss on peripheral regulators of appetite and body weight 
have challenged conventional theories as to the aetiology of obesity and to the 
limitations of combined lifestyle therapies.  Further research in these areas will 
provide novel insights and approaches for the complex condition. 
 
The aims of this thesis are: 
 
1. To review the role of dietary protein in the homeostatic control of body weight and 
the role of declining dietary protein intake in the causation of overweight and 
obesity.  Whether short and medium term changes in the intake of dietary protein 
are associated with changes in total energy intake, hunger and satiety will be tested 
and changes in the peripheral mediators of appetite and body weight regulation 
with differences in protein intake will be tested.  This will be examined in detail in 
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Chapter 2: Testing the Protein Leverage Hypothesis in lean humans: The Fixed 
Energy Meal Experiment. 
 
2.  To examine whether the intake of dietary protein is prioritised by obese 
phenotypes, as it is in their lean counterparts and to examine whether changes in 
dietary protein influence the secretion of peripheral mediators of the appetite and 
body weight regulation and markers of obesity related sub-clinical inflammation.  
This will be examined in detail in Chapter 3: Testing the Protein Leverage 
Hypothesis in lean and obese mice. 
 
3. To review the effects of weight change, produced by a combined lifestyle 
intervention, on the homeostatic regulation of body weight with a particular focus 
on the impact on the secretion of key peripheral mediators of appetite and body 
weight regulation. This will be examined in detail in Chapter 4: Lessons from 
South Korea and its diet: Lifestyle-induced weight loss and the secretion of appetite 
and body weight influencing hormones. 
 
Finally the results of the three experiments will be reviewed in Chapter 5 with focus 
on the insights that the experiments bring to different aspects of the challenging 
conundrum of overweight and obesity. 
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CHAPTER 2 
 
Testing the Protein Leverage Hypothesis in lean humans:       
The Fixed Energy Meal Experiment 
 
 
2.1  INTRODUCTION 
 
2.1.1 Dietary Protein 
 
It has been well established that when dietary protein (P) is compared isocalorically to 
the other macronutrients (carbohydrates [CHO] and fat [F]), P is the most satiating.  
Additionally, following the consumption of a standard unit of each macronutrient P 
will provide the lowest net energy output because of its greater thermogenic 
properties.  When these two facts are taken together, it suggests that modestly 
increasing the consumption of P at the expense of CHO and F will promote satiety and 
facilitate weight loss through two means; a decrease in total energy consumption and 
an increase in diet induced thermogenesis52-55.   
 
2.1.1.1  High Protein Diets 
 
There have been four recent reviews52-55 that have examined the evidence from 
randomised controlled trials (RCTs) on the relationship between high P diets, 
increased satiety and decreased total energy intake critically. As a summary of their 
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findings and while acknowledging the differing methodologies of the individual 
studies, it is apparent when higher P meals (20-80% of Energy Intake as P - hence 
abbreviated as 20-80% P) were compared to isocaloric meals of lower protein content 
(5- 18% P or 100% CHO or 100% F) higher % P meals were associated with greater 
post-meal satiety for up to 24 hours and a decrease in ad libitum food intake.  
 
The typical design of those RCTs that included healthy lean to overweight subjects 
used a single meal test study protocol with diets randomly crossed over, following an 
overnight fast.  The test meals were presented as either “real-world” foods (such as 
sandwiches or yogurt) or liquid meals made from protein powder in combination with 
milk or water.  The types of dietary P varied with animal (meat, egg, whole milk, whey 
or casein) and plant (soy) sources being used.  Following the consumption of the 
experimental meal, satiety was measured subjectively in the post-prandial period by 
the use of a Visual Analogue Score56.  The RCTs that included an assessment of protein 
and its effects on subsequent caloric intake compared isocaloric liquid or solid snacks 
of differing %P (randomly allocated and crossed over) followed by a main standardised 
meal.  However the reviews all noted that to date, large-scale and conventional meta-
analyses techniques were not feasible because of the large methodological variance in 
the RCTs.   
 
One of the limitations of these reviews is that only Halton et al52 commented in detail 
on studies with negative findings.  Regarding dietary P, satiety and energy intake in 
adults they found six of nine studies reported positive findings57-62 but the three that 
reported negative findings63-65 were marked by unique methodological traits such as 
the use of nose clips, subjects being placed in whole body calorimeter chambers rather 
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than free living arrangements and the use of foods of significantly different palatability 
and caloric content.  These non-standard design traits made it more difficult to 
generalise from the negative studies and Halton et al concluded that the weight of 
evidence supported the notion that higher P diets are associated with increased satiety 
and reduced energy intake, especially as the six positive studies used design 
methodologies closer to “real life (living) situations”. 
 
2.1.1.2  Dietary Protein, Satiety and Appetite Hormones 
 
While there is strong evidence to support a relationship that diets higher in P increase 
satiety and decrease energy intake, the mechanisms remain unresolved.   
 
The first explanation put forward to explain the link between higher P diets and 
increased satiety was by Mellinkoff66 in 1956.  He suggested that plasma levels of 
amino acids act directly on then unidentified centres in the brain to regulate and 
control appetite and satiety.  In a recent review by Westerterp-Plantenga et al55 the 
authors re-examined the still fragmentary evidence to support Mellinkoff’s hypothesis, 
highlighting the evidence from neurophysiology, clinical trials and appetite studies 
that show that elevated levels of the amino acids of tryptophan, tyrosine and histidine, 
known precursors for the neuro-transmitters of serotonin, dopamine, noradrenaline 
and histamine respectively appear to influence central satiety centres and are slightly 
elevated in high P diets.  However the authors of the review readily acknowledged that 
there still remains insufficient evidence to support or refute Mellinkoff’s hypothesis.  
 
 16 
A second hypothesis put forward to explain the relationship between P and satiety is 
based on the observation that the consumption of diets higher in P are associated with 
post-prandial changes in secretion of appetite and satiety hormones:  increased 
secretion of anorexigenic hormones and significantly decreased secretion of the 
orexigenic hormone ghrelin54.  
 
Bowen et al67 demonstrated in 72 lean and overweight men fed pre-meal soups (high 
protein [70% P] vs. low protein [87% CHO, 1.5% P]) in a randomised, cross-over 
fashion that during the post-prandial period up to 180 minutes, there was a prolonged 
suppression of ghrelin secretion and an elevation in Glucagon-like peptide-1 (GLP-1) 
secretion.  The authors also reported that while no differences on subjective 
assessments of hunger and satiety were found between the high and low P soups, the 
higher P soups were associated with a reduction in ad libitum food intake from a buffet 
lunch offered afterwards.  
 
Raben et al68 studied 19 healthy, lean men and women offered ad libitum breakfasts 
differing in ratios of %P | %CHO | %F (High P: 32% | 3% | 31%; High CHO:  11% | 65% 
| 24% and High F:  11% | 24% | 65%) in an randomised, crossover fashion.  The 
authors reported the high P breakfasts were associated with post-prandial increased 
diet-induced thermogenesis and greater secretion of GLP-1 to 300 minutes but failed 
to find any relationship between the high P breakfasts and increased subjective 
measures of satiety. 
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Lejeune et al69 and Westererp-Plantenga et al70 demonstrated in lean women and men 
respectively fed a high (30% P) or low (10% P) P diet for 24 hours in a randomised, 
cross-over fashion, that the high P diet was associated with increased meal-related and 
24-hour levels of satiety, increased diet induced thermogenesis and increased GLP-1 
secretion to 12 hours but there were no differences in the 24-hour levels of ghrelin. 
 
In contrast, Veldhorst et al71 studied 25 healthy lean people offered an ad libitum 
standardised breakfast varying in % P but fixed in % CHO (10% or 25% P) in a 
randomised, cross over fashion.  These authors found that the higher P breakfast was 
associated with increased satiety and decreased hunger but not with any changes to the 
post-prandial secretion of ghrelin and GLP-1 up to 180 minutes. 
 
However, not all have reported a link between higher P diets and increased levels of 
satiety hormones.  Smeets et al72 studied 30 lean to overweight but healthy men and 
women fed a fixed energy breakfast followed four hours later by a fixed energy lunch 
both fixed in %F (30%) but varying in % P and % CHO (High P: 25% P |45% CHO; Low 
P: 10% P | 60% CHO) in a randomised, cross-over fashion and reported that the high P 
meal was associated with increased diet-induced thermogenesis and post-prandial 
satiety but also with a reduced peak in the secretion of GLP-1 and with no changes in 
the secretion of ghrelin for up to 180 minutes after lunch. 
 
Similarly Weigle et al73 assessed 19 healthy, lean to overweight men and women 
provided with 2 and then 12 weeks of diets fixed in % CHO (50%) but varied in % P and 
% F (% P | % F:  15% | 35% vs. 30% | 20%) and reported that the high P diet was 
associated with increased satiety and decreased energy intake but, in contrast to the 
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studies above, the high P diet was also associated with increased (and not decreased) 
24-hour levels of ghrelin when assessed at the end of each diet treatment. 
 
On balance the evidence from these studies suggest that following a high P meal, there 
is an increased secretion of GLP-1 and a reduced secretion of ghrelin and that these 
changes are not always correlated with differences to subjective satiety, however the 
presence of negative studies suggests that the strength of the relationships remains 
unresolved. 
 
Compared to the studies above, examining the relationships between ghrelin, GLP-1 
and high P diets, the relationship between cholecystokinin (CCK) and dietary P is even 
more under-explored with only three studies found.  Two studies that measured CCK 
relative to the intake of dietary P have been identified with both studies being by the 
same team of authors67,74.  In both studies, isocaloric liquid meals of 70% P or 100% 
CHO were provided to healthy, lean to obese men in a randomised, cross-over fashion 
and the authors reported that the high P meals were associated with the following 
changes to CCK: prolonged post-prandial elevation (120 minutes compared to 30 
minutes) and increased total secretion to 180 minutes.   
 
In the third study75 liquid drinks made from 100 % P from different sources of P 
(mixed whey and casein vs. whey vs. casein vs. pea protein) were compared.  The 
authors reported that after the consumption of a milk drink made up of a mix of 
dietary P (whey and casein proteins), an increase in the post-prandial secretion of CCK 
(up to 120 minutes) was demonstrated compared to the other drinks.  This suggests 
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that CCK secretion is influenced by very high dietary P meals and that it may be more 
responsive to meals composed of mixed rather than single source dietary P. 
 
The third theory explaining the finding of increased post-prandial satiety after high P 
diets links satiety with increased diet-induced thermogenesis (DIT) with high P diets 
and assumes that it is DIT itself which contributes to increased satiety.  This 
association was initially reported in 1999 by Westerterp-Plantenga et al76 in healthy, 
lean subjects who had resided in a respiratory chamber for 36 hours and were fed 
isocaloric, matched for palatability high and low P diets (9% P vs. 29% P).  Compared 
to the low P diet, measures of DIT and of short- and long- term satiety were 
significantly greater on the high P diet and increased satiety significantly correlated 
with DIT.  However due to the practical difficulties of measuring DIT this has 
remained relatively unexplored with the exception being Smeets et al72 who used 
indirect-calorimetry to assess DIT.  In their study of thirty healthy, lean to overweight 
men and women, they found no correlation between DIT and increased satiety. 
 
2.1.1.3  High Protein Diets and Weight 
 
High P diets are also associated with the metabolically favourable changes of increased 
total weight loss, increased % fat loss and following weight loss, decreased weight 
regain.  Paddon-Jones et al53 and Westerterp- Plantenga et al55 summarised the 
evidence from individual studies that explored these relationships and noted that the 
evidence supporting these findings comes from studies with small numbers and short 
follow-up (between 6 - 12 months).   
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More contemporary studies have re-examined these issues but the results from the two 
largest studies are mixed.  Sacks et al77 examined 811 overweight and obese adults for 
two years who were randomised to one of four low energy diets varying in CHO, P and 
F (% CHO | % P | % F: 65 | 15 | 20 or 55 | 25 | 20 or 45 | 15 | 40 or 35 | 25 | 40).  The 
authors found between the four interventions neither significant differences for weight 
loss at 6 or 24 months nor differences in satiety or to compliance with the diets.  
However one significant criticism of the study was that the between the diet 
treatments, the measured differences in % P were small (2.5 – 3.4%) and lower than 
that reported in other studies of dietary P.   
 
The DIOGENES group78 studied 1209 overweight and obese adults for 6 months and 
compared ad libitum diets varying in glycaemic index (high vs. low) and dietary 
protein (%P: 13 vs. 25).  The diet treatments were prescribed for weight maintenance 
after at least 8% weight loss was achieved by 8 weeks of a liquid meal replacement / 
very low calorie diet.  The authors reported that the high P and low glycaemic index 
diets were associated with less weight regain and lower study drop-out rates.  While 
these results are generally positive for the role of dietary P, a subset of the participants 
had active support in the form of financial payments, more regular contact and the 
direct provision of high P food and these protocol differences may have affected 
compliance and the study outcomes. 
 
2.1.1.4  Secular Trends in Dietary Protein 
 
Epidemiological evidence from large health surveys from the United States79,80, 
Australia81,82 and Spain83 demonstrate that in these Western countries there is a 
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secular pattern of a reduction in the % energy intake derived from P compared to the 
CHO and F.   
 
Data from 1970 to 2000 from the United States National Health and Nutrition 
Examination Surveys ([NHANES] an annual survey of 5000 nationally representative 
Americans) demonstrates that among adult Americans, over the last 30 years the total 
daily EI has increased by 5%80, made up of an increase from CHO (+7%) and a 
decrease from P (-1.4%).  Among American men dietary P has fallen by -1.1% to 15.4% 
of daily EI and among American women it has fallen by -1.8% to 15.1% of daily EI.  
Futhermore an updated analysis79 incorporating results from NHANES surveys to 
2008 has confirmed that over the last 10 years, these trends have remained constant. 
 
Analysis of the two Australian nutrition surveys, the 1983 National Dietary Survey of 
Adults and the National Nutrition Survey 199581,45,82 (surveys of 6254 and 2367 capital 
city based Australian adults aged 25 – 64 years) demonstrated that between 1983 - 
1995 while the daily consumption of P remained relatively constant (+0.9% to 112 
gm/day in men; -1.2% to 76 gm/day in women) over the same period total EI rose by 
on average +350 kj/day (+3.5% in men and +4.5% in women).  This increase was 
predominately made up by an increased intake of CHO (+17% in men and +16% in 
women) and so when dietary P is calculated as a % of total EI over the period 1983  to 
1995 the contribution of % total EI from P actually fell (-0.3% in men and -1% in 
women).  By the end of 2013, the 2011/2013 Australian Health Survey, which 
incorporates a detailed assessment of dietary and physical activity habits, will be 
completed and the release of an updated national nutritional data and analysis is 
expected afterwards. 
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The most applicable European study, which was of 8470 randomly selected adults in 
regional Spain83 and surveyed in 2000 and in 2005, did not demonstrate a similar 
significant increase in total EI but did show a significant drop in % EI obtained from 
dietary P (-0.3%) and an increased intake of dietary F, unlike the US and Australian 
data. 
 
In summary, diets higher in P are associated with increased satiety (though the 
mechanisms for this remains unclear), increased thermogenesis and in the overweight 
and obese favourable changes to body weight.  However the broader historical trends 
in macronutrient consumption have been towards an overall increased total EI but 
with a slight but significant reduction in EI derived from dietary P. 
 
2.1.2  The Protein Leverage Hypothesis  
 
In 2005 Simpson and Raubenheimer published the Protein Leverage Hypothesis42, 
which holds that the driver of food consumption is the prioritisation of the absolute 
intake of dietary P at the expense of regulating the intake of CHO and F.  It follows that 
the effort to maintain the intake of P constant in a food environment that has 
experienced even a small decline in the availability of P will lead to increased total food 
consumption and greater energy intake.  Unless this is matched by a commensurate 
increase in energy expenditure, it will lead to weight gain.  This is the process that is 
hypothesised to be a key and previously under recognised contributor to the increased 
rates of overweight and obesity. 
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2.1.2.1  The Geometric Framework 
 
The precursor to the Protein Leverage Hypothesis (or PLH) was published in 2003 by 
Simpson et al84. The interaction between the Geometric Frameworks and the Protein 
Leverage Hypothesis are illustrated in Figure 2.1. 
 
In the article, the authors described the Geometric Framework model that envisaged a 
state-space model which framed the animal’s nutritional environment as an 
interaction between the macronutrients that make up the diet and the metabolic 
responses of the animal when feeding upon diets of differing macronutrient ratios.  
The animal’s nutritional intake targets are visualised in the model and represent the 
optimal points that balance the nutritional and physiological needs of the animal. 
These are represented as target points within the model.  Whether an animal can meet 
its intake target is determined by the availability of food in the dietary environment 
and these are illustrated as linear lines or “nutrient rails” which reflect the 
macronutrient balance of a particular diet (see Figure 2.1 (a) below for the nutrient 
target intake and nutrient target rails)  
 
The Geometric Framework model demonstrates that when an animal is in a food 
environment that is unbalanced in macronutrients, it can still achieve its 
macronutrient intake targets by over-consuming some macronutrients whilst under-
consuming others.   
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Figure 2.1   The prioritisation of dietary P in humans:  Balancing dietary P
    versus CHO + F  
 
From Simpson et al84 with the kind permission of the author 
 
 
 
A Different nutrient rails reflecting diets of differing P to CHO + F ratios.  The optimal intake 
target presented here is 15% P: 85% CHO + F.   
B  The effects of shifting from a diet of 14% P to 12.5% P: To maintain the same absolute amount of 
dietary P, there needs to be an associated 14% increase in the consumption of CHO + F 
C The effects from an increase in P requirements by 1.5% such as might occur due to enhanced 
needs secondary to obesity and Type 2 Diabetes Mellitus; if diet composition is maintained, a 13% 
increase in CHO + F is required to meet the relatively small increased dietary P need. 
 
Key:  Figures not to scale, the X axis represents the % of daily EI as Protein, the Y axis represents the % 
of daily EI as CHO + F  
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2.1.2.2  Evidence to support the Geometric Framework and Protein Leverage
  Hypothesis 
 
Evidence supporting the Geometric Framework model and PLH has been found in 
several animal studies including locusts85,86 (which showed that over differing food 
pairings varying in distance and frequency protein intake was maintained despite 
dilution of food with indigestible bulk); rats87 (where with over 8 different 
complementary food pairings varying in macronutrient ratios, the absolute amount of 
protein consumed by the rats remained relatively constant); and mice and pigs88 
(which demonstrated that over numerous diets varying in macronutrient ratios, P 
intake was prioritised above CHO and F).  The evidence from these studies supports 
the notion that animals of many species regulate their nutrient intake to prioritise the 
intake of dietary P above that of CHO and F.   
 
The evidence for the PLH in humans to date has come from a pilot study84 published in 
2003 with ten healthy volunteers demonstrating that diets with low %P then CHO + F 
were over-consumed to keep the absolute intake of P relatively constant.  Conversely, 
when diets with a high %P were offered, CHO + F were proportionately more under-
consumed than P intake over-consumed.   
 
While the strength of protein regulation appeared to vary between species, what was 
striking was that in the many species examined, when %P was lowered, total energy 
intake increased in an effort to maintain constant the absolute intake of protein.  
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The PLH developed from the above animal studies, the evidence of a secular decline in 
the intake of %P and the Geometric Framework model.  It is proposed that humans 
also balance their intake of dietary P against that of CHO and F.  If this theory is 
proven correct, it will have important implications and help explain the recent trends 
in human overweight and obesity. 
 
The nutritional survey data demonstrates a trend for the dilution of P in the diet, which 
is linked with or possibly caused by an economically driven increase in the use of 
cheaper sources of fat and sugar by food manufacturers.  If this is coupled with the 
evolutionary tendency for humans to find fat and sugar highly palatable then the food 
environment becomes nutritionally unbalanced.  Human physiology is being forced to 
trade-off the intake of protein against the intake carbohydrate and fat.  In the words of 
the proposers of the PLH42 “... it is unsurprising that the regulatory systems 
controlling (energy) intake by modern humans are prone to becoming unstable, 
driving a catastrophic cycle of over-consumption and obesity”. 
 
The PLH in humans had yet to be assessed and confirmed under controlled 
experimental conditions and what else remained unclear was the relative power of 
protein leveraging in humans.  A further area of uncertainly was the physiological 
mechanisms that underlie protein leveraging and whether the hormones that 
influenced satiety and appetite have any role to play. 
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2.1.3  The regulation of appetite and satiety: Key gut hormones and  
  adipokines  
 
2.1.3.1  Cholecystokinin 
 
Cholecystokinin (CCK) is secreted by the proximal small intestine in response to the 
detection of the nutrients that arise from the consumption and digestion of food.  Its 
secretion is followed by local intestinal effects that include delayed gastric emptying, 
altered intestinal motility and the regulation of the secretions from the gallbladder and 
pancreas.  Distal CCK effects include the inhibition of food consumption via action on 
the local and central centres that regulate appetite and satiety. 
 
CCK was first isolated by Mutt and Jorpes89,90 in work published in the late 1960’s and 
early 1970’s.  The CCK polypeptide is initially expressed as a 115-residue pre-
prohormone precursor which is processed to carboxyl-terminal amino-polypeptides of 
various lengths including 8 and 33 unit length residues.  The CCK polypeptides are 
widely distributed throughout the gastrointestinal tract (GIT) and the central nervous 
system (CNS) with CCK-8 the most abundant form in the CNS while CCK-8, -33 and -
58 all present in GIT in significant amounts91-93.   
 
Thus far two CCK receptors have been identified94 and were initially named according 
to their locations (CCK Receptor A for “alimentary” and CCK Receptor B for “brain”).  
As it has since been established that there is significant overlap in their distribution, 
the receptors have been renamed CCK1 and CCK295.   
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Following the ingestion of food and processing in the stomach, the digested food 
moves into the small intestine where the presence of intestinal nutrients of fatty acids, 
amino acids and glucose (the digestive products that arise from dietary F, P and CHO) 
trigger the secretion of CCK, which is otherwise secreted at a basal rate.  It is known 
that the products arising from the breakdown of fat and protein are more potent 
stimulators of the secretion of CCK than those from carbohydrates.  Post-prandial 
secretion is rapid and within 30 minutes from the ingestion of food, concentrations 
increase over five-fold (to 5-8 pMol/L) before gradually falling back to basal levels 
(normally~1 pMol/L) over a period of three to five hours96. 
 
CCK has local effects on the gut and is the main regulator of gall bladder function and 
through action on CCK1 receptors modulates post-prandial biliary contraction and the 
release of bile into the duodenum.  Through action on the vagus nerve CCK also 
stimulates pancreatic enzyme release96,97.  CCK has inhibitory properties that include 
inhibiting gastric emptying through altering gut motility of the antrum and pylorus of 
the stomach and the duodenum98,99.  These effects are seen in studies of exogenously 
administered CCK that demonstrate that levels of CCK are associated with delayed 
gastric emptying99 and in studies using CCK1 receptor antagonists that demonstrate 
accelerated gastric emptying especially after the ingestion of fat- and protein- rich 
meals100. 
 
CCK is also known to have actions on central centres that regulate appetite and satiety.  
This was first demonstrated by Gibbs et al101 in a landmark experiment published in 
1973.  The authors showed that following the administration of exogenous CCK-8 to 
rats, the intake of both solid and liquid foods was suppressed in a dose related fashion 
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for up to three hours.  The administration of CCK-8 was also associated with reduced 
meal sizes and a reduction in the time the rats spent consuming food.  Finally the 
authors noted that the rats demonstrated behaviours that were suggestive of within-
meal fullness (or satiation) and postulated that this was due to action on CCK 
receptors located in the brain.  These findings have been replicated in numerous 
species including in humans.  In studies of healthy volunteers (lean and overweight) 
administered physiological amounts of exogenous CCK-8102-104, a reduction in meal 
size and subjective levels of hunger as assessed by Visual Analogue Scores proportional 
to the rate of infusion of CCK has repeatedly been demonstrated.   
 
2.1.3.2  Ghrelin 
 
Ghrelin is a 28 amino-acid peptide first isolated from the stomachs of rats in 1999.  
Ghrelin is primarily released from specialised endocrine cells found in the gastric 
mucosa but is also expressed by cells in the small intestine and CNS105.  To become 
physiologically active, ghrelin undergoes a post-translational modification to its third 
amino acid –serine- residue105 and it was as recent as in 2008 that the enzyme 
responsible for the acylation process was first reported106.  Ghrelin’s physiological 
effects on the central nervous107 and gastrointestinal systems105 are predominately 
mediated by its acylated form. Studies suggest its physiological effects are correlated 
when measured in either acylated or total form108.  To date, ghrelin is still the only 
orexigenic gut hormone identified.   
 
Ghrelin levels rise during the fasting period before rapidly falling after meal initiation 
and food consumption.  The pre-prandial rise of ghrelin is thought to serve as a 
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physiological signal to initiate meal consumption and the subsequent fall proportional 
to the caloric and macronutrient content of the meal109,110. 
 
The acute and chronic administration of ghrelin to rats was found to increase their 
intake of food and weight111,112 and similar effects have been reported in healthy human 
volunteers who received intravenous ghrelin and who then increased their food intake 
by +25% (kcals) when compared to a sham infusion113.   
 
Physiologically, ghrelin is thought to increase food intake by actions in the CNS; by 
stimulating the arcuate nucleus region of the hypothalamus and increasing the 
production of neuropeptide Y and agouti-related peptide114.  It has other CNS mediated 
properties that include acting on the same hypothalamic receptors to reduce the 
utilisation of stored body fat111 and on pituitary receptors to stimulate growth hormone 
production105. 
 
In studies of obese humans compared to normal weight controls, the obese display 
suppressed levels of fasting ghrelin115,116 and an attenuated 24 hour ghrelin secretion 
profile116.  In contrast fasting ghrelin and 24hr ghrelin profiles are increased in those 
with anorexia nervosa116,117 compared to normal weight individuals.  
 
In states of negative energy balance, long term prandial changes to ghrelin secretion 
have been reported with ghrelin secretion up-regulated.  The opposite occurs in states 
of positive energy balance with post-prandial ghrelin secretion down-regulated115.  
These findings suggest that ghrelin has both a short and long term role in the 
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regulation of food consumption and in the physiological processes involved in body 
homeostasis and the maintenance of body weight.  
 
The relationship between meals of varying macronutrient content and ghrelin 
secretion has been studied in rodents and in humans118-121.  The studies report that 
high F meals suppress ghrelin secretion less than meals high in CHO or P.  
 
Comparing CHO and P, studies in humans using a single meal test diet protocol have 
found that CHO is the most powerful macronutrient suppressing post-prandial ghrelin 
secretion122-124.  However experiments using liquid drinks differing in their ratio of 
CHO to P to F have demonstrated only weakly that P suppressed post-prandial ghrelin 
secretion more than either CHO or F67,74,125.  Finally other studies using liquid and 
solid meal protocols have failed to demonstrate differences between the 
macronutrients for post-prandial ghrelin secretion126,122,123,127.  With this conflicting 
evidence it has recently been suggested that the signal that influences post-prandial 
ghrelin secretion does not arise directly from the macronutrient content of meals but 
rather is due to shifts in intestinal osmolarity arising from the passage of amino acids, 
glucose and fatty acids from intestine into the circulation of the gut120. 
 
It has also been suggested that the post-prandial secretion of insulin effects the post-
prandial secretion of ghrelin109 but the evidence to support this hypothesis remains 
limited to few studies reporting conflicting results121,128. 
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2.1.3.3  Glucagon-like peptide-1  
 
Glucagon-like peptide-1 (GLP-1) is a 30 amino-acid peptide that is released from the L-
cells of the distal gut in response to sensed nutrients (in particular CHO129) in mixed 
solid / liquid meals130.  GLP-1 is synthesised by the L-cells in two forms that undergo 
post-synthesis cleavage at their N-terminals to produce two active forms: GLP-1 7-37 
amide and GLP-1 7-36 amide with the -7-36 amide the most biologically active isoform131.  
Within 30 minutes of the ingestion of a meal, GLP-1 levels peak remaining elevated for 
over 120 minutes130.  GLP-1 exhibits physiological effects on satiety, meal termination 
and post-prandial insulin secretion. 
 
GLP-1 exerts this activity through the GLP-1 receptor, which is expressed throughout 
the CNS, gut and other peripheral tissues132. The central GLP-1 receptors located in the 
hypothalamus and brainstem play a role in inhibiting food intake while receptors 
located in other tissues are involved in meal termination, satiety and gastric 
emptying133.  The latter effects have been demonstrated in rodents and humans from 
studies that exogenously administered GLP-1 and examined food consumption134,135 
with the studies demonstrating a dose dependent relationship between the rate of the 
GLP-1 infusion and food intake.   
 
GLP-1 is also a powerful stimulator of pancreatic β cell mediated post-prandial insulin 
release129 and it is due to this property that GLP-1 was historically classified as 
belonging to a group of gut-derived hormones known as incretins.  These incretin 
effects are demonstrated by the efficacy of the novel Type 2 Diabetes mellitus (T2DM) 
medications: Exenatide and Liraglutide; both belonging to the same pharmacological 
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class and whose main action is to activate the GLP-1 receptor136.  These agents have 
been widely studied in randomised, placebo controlled clinical trials in T2DM prior to 
their global release and not only did the agents demonstrate improved glycaemic 
control but their use was also associated with increased satiety, reduced food intake 
and clinically significant weight loss136. 
 
The effects of dietary P, either compared to meals made entirely from the other 
macronutrients or consumed as differing %P ratios, on post-prandial GLP-1 secretion 
remains unclear with the few studies reporting conflicting findings. 
 
In one of the earliest studies on GLP-1, Elliot et al137 examined the effects of consuming 
isocaloric meals consisting entirely of CHO, F or P on post-prandial GLP-1 secretion 
and reported that there were no significant differences for post-prandial GLP-1 
secretion between the meals.  More recently in 2009, Veldhorst et al71 compared 
breakfasts differing in % P (CHO | P | F: 55| 10| 25 vs. 55| 25| 35) on post-prandial 
GLP-1 secretion.  As in the earlier study, the authors reported that varying dietary %P 
had no significant effects on post-prandial GLP-1 secretion.  In a third study, Diepvens 
et al75 compared different types of dietary P (100% plant based vs. mixed plant and 
animal-based) that were consumed as pre-meal liquid drinks on post-prandial GLP-1 
secretion and subjective assessments of satiety. They also failed to demonstrate any 
link between the different P pre-loads and post-prandial GLP-1 secretion or to satiety. 
 
In contrast Bowen et al67 examined the effects of consuming pre-meal liquid snacks 
made entirely of the different macro-nutrients on post-prandial GLP-1 secretion, the 
ad libitum consumption of a standardised meal and subjective satiety. The authors 
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demonstrated that compared to the 100% CHO pre-load; the 100% P pre-loads, 
regardless of whether they were animal, plant or mixed, all prolonged post-prandial 
GLP-1 secretion and reduced the caloric intake from the subsequent meal.   
 
2.1.3.4  Insulin 
 
Insulin is a well-studied 51 amino-acid peptide synthesised, packaged and secreted by 
pancreatic β cells primarily in response to the concentration of glucose in blood.  Its 
major action is to regulate the concentration of glucose in serum through action on 
almost all the tissues of the body, mediated by binding to the insulin receptor on the 
surface of cells.   
 
It is well known that insulin affects the concentration of serum glucose directly by 
inhibiting glycogenolysis and gluconeogenesis, by increasing transport of glucose into 
fat and muscle cells and by stimulating glycogen synthesis.   
 
Insulin also moderates the body’s use of the alternative fuel substrates of fat (by 
promoting the storage of triglyceride into fat cells and decreasing lipolysis) and protein 
(by facilitating intra-cellular transportation of amino acids and inhibiting protein 
breakdown to support protein synthesis). 
 
While virtually no insulin is produced in the brain, it is present in the cerebral 
circulation after transport through the blood brain barrier via a saturable, receptor 
mediated process138.  Once present in the intra-cerebral circulation, insulin exerts an 
anorexigenic effect by acting on insulin receptors predominately distributed in the 
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hippocampus and hypothalamus139.  This has been shown by studies that have 
demonstrated that the sustained intra-cerebral administration of insulin in 
rodents140,141 and primates142 leads to a dose-dependent reduction in food consumption 
and to body weight. 
 
Circulating levels of insulin are predominately regulated by, and are highly sensitive to, 
changes in the concentration of glucose in the serum.  However, basal insulin secretion 
is also influenced by body fat143 and the strong relationship between body weight, 
abdominal adiposity, increased fasting serum glucose concentrations and elevated 
levels of fasting insulin, highlights the link between adiposity (in particular visceral fat) 
and insulin sensitivity144. 
 
2.1.4  Rationale for the experiment 
 
The Human PLH trial was designed to the test the validity of the Protein Leverage 
Hypothesis in a healthy population.  In its overall design, the Human PLH trial 
allowed for the testing of three associated hypotheses:  that the key gut and fat 
hormones impacting on appetite and satiety are in turn influenced by the 
macronutrient composition of the diet; that diets higher in protein (P) are associated 
with higher levels of the hormones that increase satiety and lower levels of the 
hormones that reduce satiety when compared to lower P diets; and that diets higher in 
P are associated with higher levels of subjective satiety.  The author was an associate 
investigator for the Human PLH trial and had direct responsibility for the design and 
implementation of the experiment that tested the associated hypotheses. 
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The National Health and Research Council provided funds for this clinical trial:  
Research Project Grant no. 457522 “Testing the Protein Leverage Hypothesis in 
Humans or, can humans lose weight by eating a diet with a higher percentage of 
protein”. 
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2.2  MATERIALS AND METHODS 
 
2.2.1  Study participants 
 
Participants were recruited through advertising placed on the casual employment 
websites of five Sydney based tertiary academic institutions:  Macquarie University, 
the University of New South Wales, the University of Sydney, the University of 
Technology Sydney and the University of Western Sydney.  While advertising was 
placed in other forms of media, it did not result in any successful participant 
recruitment.   
 
To be eligible for the study participants had to be healthy, not be taking regular 
prescribed medications, have a normal body weight (defined as BMI= 18.5 – 24.9 
kg/m2) and have had at least three months of a stable body weight and be on no diet 
for weight loss.  Participants had to be willing to follow the Human PLH trial study 
protocols.   
 
Volunteers who were pregnant or had any form of Diabetes Mellitus were 
automatically excluded.  Specific exclusion criteria included these chronic medical 
conditions:  inflammatory bowel disease or other gastro-intestinal disorders, 
hypertension, dyslipidaemia, thyroid disease, asthma and chronic kidney or hepatic 
disease.   
 
Vegans and vegetarians and those with a strong dislike of any of the study foods or 
food allergies were also automatically excluded.  Potential participants then completed 
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the Eating Attitudes Test-26 questionnaire145 and excluded if they revealed a previous 
history of an eating disorder, displayed current disordered eating habits or scored 
higher than 20 (which correlates with increased risk of disordered eating) on the 
questionnaire.   
 
All participants were given detailed verbal and written information regarding the 
design and purpose of the study and its protocols.  All participants provided their 
written, informed and personally signed and dated consent prior to commencing any 
study related matters.  “Testing the Protein Leverage hypothesis in humans” was 
approved by the human ethics committees of the University of Sydney: Protocol ID No. 
10153 and the Sydney South West Area Health Service: Royal Prince Alfred Hospital: 
Protocol ID No. X07-0044. 
 
Eighty-one people (53 females and 28 males) responded to the advertising and 
attended screening interviews.  From these eighty-one, thirty (20 female and 10 male) 
signed informed consent forms and were placed onto the waiting list for the 
investigators to organise a start time for their involvement in study.  
 
From these thirty, three females withdrew before they commenced the study due to 
logistical difficulties, extreme phlebotomy-related phobia and inter-current illnesses.  
Three males and two females who commenced their first study diet treatment were 
subsequently withdrawn; one male was newly diagnosed with overt hyperthyroidism, 
another male expressed a previous unrevealed extreme dislike of the trial foods and 
the remainder were due to logistical difficulties.  The results from these five individuals 
have not been included in any of the following analyses. 
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Here we report on the analysed results from twenty-two participants (15 female and 7 
male) who enrolled in the Human PLH trial and completed all of the study protocols.  
The twenty-two participants were aged 24.7 ± 1.4 years (mean ± SEM; range 18-51 
years) and had a mean BMI of 21.8 ± 0.4 (17.7 – 25.2) kg/m2  
 
2.2.2  Study design and experimental protocols 
 
The primary outcome was change in total energy intake after 4 days of ad libitum diet.  
Participants attended for three 4 day trial periods (diet treatments) that consisted of 
in-house covert dietary manipulation Monday to Friday culminating in the Fixed 
Energy Meal Experiment on the Friday morning.  Each diet treatment was separated 
by at least one 1 week washout period where participants were instructed to return to 
their regular pre-study eating habits. 
 
Participants were placed into single-sex groupings of two to four participants with each 
study group remaining together throughout the whole experiment.  Groups of 
participants resided in the long-stay facilities of the Woolcock Medical Research 
Institute (Glebe, NSW). 
 
Prior to commencing their first residential diet treatment period, participants attended 
the Endocrine and Metabolism Unit, Royal Prince Alfred Hospital for the 
measurement of their resting metabolic rate and for the collection of baseline blood 
and urine samples.   
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The resting metabolic rate was determined by assessing each participant’s oxygen and 
carbon dioxide exchange while they rested (awake) for 60 minutes underneath a 
plastic canopy attached to the indirect calorimeter (Parvo Medics True One 2400- 
Metabolic Analyser System; software version OUSW 4.3 (20080219), USA).  This 
allowed the investigators to calculate the energy requirements of each participant 
accurately. 
 
During each diet treatment, participants consumed ad libitum diets matched for 
palatability and variety but differing in % energy intake by P (% Energy Intake (EI) as 
P: 10% P, 15% P or 25% P) in a random order.  For example during the first diet 
treatment one group consumed food contained 10% P; for the next diet treatment, they 
consumed food that contained 25% P and for the last diet treatment, all of the 
consumed food contained 15% P.  The order of three diet treatments was randomly 
determined by computer program prior to the group commencing their first treatment.   
 
Food was prepared in advance of each diet treatment by Human PLH trial staff 
working in the kitchens located in the Old Teacher’s College, University of Sydney.  
Palatability was assessed on day 4 of each diet treatment to ensure that this was kept 
consistent across each study period and throughout the trial.  Food was kept 
refrigerated or frozen until required. 
 
The participants’ daily ad libitum food menu was made up of three main meals and 
free access to sweet and savoury snacks throughout the day. The diet treatments 
followed the same menu of 28 food items, which included 12 sweet and 16 savoury 
foods as has been reported earlier146.  During the diet treatments, participants were 
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instructed to only consume foods provided by the study investigators and their food 
intake was measured by recording the weight of main meals before and after food 
service, by returning the snack wrappings and by the return of any uneaten food.  
Participants were instructed to consume 150 millilitres of skim milk per day and were 
provided with free access to chilled and boiled water, tea and decaffeinated coffee.  
 
The energy values for the food was provided by reference to manufacturers’ food 
labelling or by reference to the Nutrient Tables used in Australia (NUTTAB 2006, Food 
Standards Australia New Zealand147).  In these tables the assigned energy value of the 
macronutrients was: protein 17 kJ/g, simple carbohydrates 16 kJ/g, complex 
carbohydrates 17 kJ/g and fat 37 kJ/g.  
 
The % Energy from F was fixed at 30% for all three diet treatments.  The % Energy 
from CHO and P was manipulated by the addition of maltodextrin (Polyjule, Nutricia 
Australia Pty Ltd) and/or 1:1:1 mix of whey protein, calcium caseinate and egg white 
powder (Whey, casein and egg white protein powders, Mycopure, Sydney, Australia).  
Food contained all essential amino acids at levels exceeding WHO requirements.  
Table 2.1 describes the macronutrient content and standardised menu for the diet 
treatments. 
 
Further and more detailed descriptions of the design and testing of the study menu 
and the process of dietary manipulation were reported in 2010146 and in 2011148. 
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Table 2.1 (a) % Energy Intake by macronutrient for each diet treatment 
 
% Protein % Carbohydrates % Fat 
10 60 30 
15 55 30 
25 45 30 
 
Table 2.1 (b)  Weekly & standardised menu for the diet treatments 
MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY 
BREAKFAST BREAKFAST BREAKFAST BREAKFAST BREAKFAST 
  Apricot Muesli Raspberry Muesli Apricot Muesli   
FASTING  
Pear, Raspberry 
and Coconut 
Bread Banana Bread 
Pear, Raspberry 
and Coconut 
Bread 
Raspberry 
Yoghurt 
  
Savoury Breakfast 
Muffins 
Savoury Breakfast 
Muffins 
Savoury Breakfast 
Muffins   
          
LUNCH LUNCH LUNCH LUNCH LUNCH 
          
Tuna Bake 
Savoury Mince 
and rice wrap 
Tandoori Chicken 
Wrap Pasta Salad  
          
Beef and Vege 
pastry 
Teriyaki Chicken 
Sushi 
Beef and Vege 
Pastry 
Sweet Potato and 
Ricotta Wrap 
END OF DIET 
TREATMENT 
Green Salad mix Green salad mix Green Salad mix    
fruit salad 
yoghurt 
apple crumble 
muffins fruit salad yoghurt 
apple crumble 
muffins   
          
DINNER DINNER DINNER DINNER DINNER 
Goulash Chow Mein Mince Pasta Bolognaise Hokkien Noodles   
Cheese Scones Mushroom Pasta Cheese Scones 
Beef Massaman 
Curry   
Green salad mix   Green salad mix     
Orange and 
Poppyseed cake 
Choc, Apple & 
Ricotta Cake 
Orange and 
Poppyseed cake 
Choc, Apple & 
Ricotta Cake   
          
Custard Custard Custard Custard   
          
SNACKS SNACKS SNACKS SNACKS SNACKS 
carrot cake raspberry yoghurt apricot muffins raspberry yoghurt NOT AVAILABLE  
savoury scones cheese scones savoury scones cheese scones   
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2.2.3  The Protocol for the Fixed Energy Meal Experiment 
 
The Fixed Energy Meal Experiment was conducted on the Friday morning at the end of 
the week of each diet treatment and involved study subjects consuming a standardised 
breakfast and for the next 180 minutes having their blood collected whilst completing a 
standardised appetite questionnaire.  
 
2.2.3.1  Breakfast 
 
The subjects were asked to fast from Friday midnight.  Prior to their waking, the study 
investigators prepared a standard breakfast with a fixed Energy content (0.3 X Resting 
Metabolic Rate) for each participant.  The macronutrient composition (by % Energy) of 
the breakfasts differed according to the current experimental week diet treatment of 
the subjects.  Between 0800 - 0845 the subjects were instructed to consume all of their 
breakfast within 15 minutes and afterwards, not to eat or drink anything further for the 
remainder of the Fixed Energy Meal Experiment. 
 
Breakfast itself consisted of a fruit and yoghurt mix made up of packaged raspberries 
(Coles Brand, Coles Pty Ltd, Australia), vanilla yoghurt (Yoplait Creamy Lite, Lion 
Dairy & Drinks Pty Ltd, Australia).  The %P was varied by the addition of different 
quantities of the 1:1:1 whey: casein: egg white protein powder mix (Mycopure, Sydney, 
Australia).  Breakfast was accompanied by a glass of water.  Photographs illustrating 
the Fixed Energy Meal breakfasts are show in Figure 2.2 below. 
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Figure 2.2  Breakfast as part of the Fixed Energy Meal Experiment 
 
 
 
2.2.3.2 The Appetite Visual Analogue Scale 
 
Visual Analogue Scale (VAS) instruments for appetite have been validated56 and 
accepted and generate reproducible results149.  They are used in clinical research as a 
means of subjectively assessing study subjects’ appetite, hunger, taste, and their 
enjoyment of and desire to consume food.   
 
A four question Appetite VAS was used to subjectively assess the participants’ sense of 
hunger, fullness (satiety), desire to eat (appetite) and prospective food consumption.   
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The four questions asked in the Appetite VAS were: 
 
“1.  How hungry are you?” 
“2.  How full do you feel?” 
“3.  How strong is your desire to eat?”  
“4.  How much food do you think you could eat?” 
 
Below each question was a 100mm response line.  Each response line was anchored at 
the 0 mm end with the one extreme (e.g. “not at all hungry”) and at the 100 mm end 
with the opposite extreme (e.g. “very full”). 
 
Participants completed the Appetite VAS by placing a mark on each of the four 
response lines.  They were instructed to complete the questionnaire before the start of 
breakfast and then at 30, 60, 120 and 180 minutes post-breakfast. A copy of a 
completed 60-minute Appetite VAS, representative of all the five Appetite VASs used 
in this experiment is presented in Figure 2.3 below.  Each set of Appetite VAS 
questions were completed immediately prior to the collection of participants’ blood.  
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Figure 2.3  A completed 60-minute Appetite VAS 
 
 
NB:  The scoring of the completed Appetite VAS was done at the end of the experiment.  
 
2.2.3.3 Phlebotomy 
 
10 minutes before the start of breakfast, an intravenous cannula was inserted into each 
participant’s antecubital space or posterior aspect of the hand.  Sixteen mL of blood 
was collected within 5 minutes of commencing breakfast and the same volume again 
collected at 30, 60, 120 and 180 minutes.  The experiment was terminated at 180 
minutes after which participants had their intravenous cannula removed, an occlusive 
dressing applied and they were provided with a transport allowance to return home. 
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2.2.4  Collection and processing of blood samples 
 
The 16 mL of blood collected was used for the measurement of the fasting and post-
prandial levels of cholecystokinin, total ghrelin, active GLP-1, insulin, urea and 
glucose.  
 
For plasma 4 mL of whole blood was placed into each of three K2EDTA BD 
Vacutainers (Becton, Dickinson and Company, Sydney, Australia) while for serum 4 
mL of blood was placed into a SSTII Advance with gel separator BD Vacutainer. 
 
The 4 mL of blood collected for CCK was immediately transferred into a BD K2EDTA 
Vacutainer that was pre-loaded with 2000 kIU of Aprotinin (500 kIU per 1mL whole 
blood; as Trasylol; Bayer HealthCare, NJ, USA). This was added to the tube to prevent 
the rapid degradation of CCK.   
 
The 4 mL of blood collected for GLP-1 was immediately placed in a BD K2EDTA 
Vacutainer that contained 40 µL of dipeptidyl peptidase-IV inhibitor (10 µL per 1mL 
whole blood; Millipore Corp, Billerica, MA, USA).  This was previously added to the BD 
K2EDTA tube to prevent rapid GLP-1 degradation.   
 
The BD vacutainers containing additives were kept frozen at -20oC until the morning 
of the experiment and removed from the freezer only immediately before phlebotomy.   
 
Collected samples were immediately stored at 40C.  Within 10 minutes of collection, 
samples were centrifuged for 15 minutes at 3000g 4oC.  Collected serum and plasma 
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were aliquotted into 1.5mL micro-centrifuge tubes (Eppendorf South Pacific Pty Ltd, 
Sydney, Australia) that were kept frozen at -80oC until analysis.  All serum and plasma 
samples were subjected to fewer than five freeze/thaw cycles and all of the collection 
and preparation of blood samples was carried out by the author. 
 
2.2.5  Biochemistry measurements 
 
Stored serum was used to measure fasting and post-prandial glucose, serum urea, total 
cholesterol and triglycerides by an immuno-chemiluminometric technique on an 
automated Architect ci16200 platform (Abbott Diagnostics, Il, USA).  Stored plasma 
was used to measure fasting and post-prandial levels of free fatty acids by enzymatic 
colorimetric technique on the automated COBAS-MIRA platform (Roche Diagnostics 
Ltd, West Sussex, UK).  These tests were kindly performed by scientists in the 
Biochemistry Laboratory of Royal Prince Alfred Hospital, NSW.  
 
2.2.6  Radioimmunoassays  
 
Fasting and post-prandial levels of CCK, total ghrelin, GLP-1 and insulin were all 
measured by manual radioimmunoassay (RIA) technique. All control and unknown 
samples were measured in duplicate.  Over 12 months from early 2010, the author 
performed all of these RIAs in the Endocrinology Laboratory of Royal Prince Alfred 
Hospital, NSW. 
 
The principle of the RIA technique and list of the equipment use is presented in the 
Appendix: Item A.   
 49 
2.2.6.1 The cholecystokinin RIA 
 
The Euria CCK RB 302 radioimmunoassay kit (Euro-Diagnostica AB, Malmo, Sweden) 
was used to measure levels of CCK from the stored plasma containing Trasylol.  As per 
the Euria-Diagnostica CCK Product Information Statement (PIS)150 the assay is based 
on antiserum with a very low cross-reactivity to gastrin and optimised to a very high 
sensitivity of 0.3 pmol/L.  The kit has little cross-reactivity to non-sulphated forms of 
CCK or to gastrin (0.01-0 .5%).  The CCK assay requires two steps; the first being the 
extraction of CCK from the frozen plasma samples, the second being the RIA of the 
unknown CCK extracts.  As per the PIS, the intra assay coefficient of variation was 
5.5% for 4.4 pmol/L CCK and 2.0% for 20.6 pmol/L CCK while the inter assay 
coefficient of variation was 13.7% for 4.2 pmol/L CCK and 4.1% for 20.6 pmol/L CCK.  
Figure 2.4 outlines the CCK RIA procedure 
 
Figure 2.4  Outline of the CCK RIA 
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Reagents 
 
Anti-CCK, CCK 50mpl/L standard, Quality Controls (QCs) high and low and iodinated 
CCK were reconstituted as per the manufacturer’s recommendations150.  When not in 
use the reconstituted reagents were kept frozen at -20oC.  The ready-to-use diluent and 
double-antibody solid phase solutions were kept refrigerated at 3.5oC.  Unless specified 
antigen, standards, quality controls and iodinated CCK were thawed out at room 
temperature prior to use.  
 
Extraction of CCK from stored Plasma  
 
The ethanol-based extraction process was performed to the PIS.  Frozen samples of 
plasma were thawed in an ice-bath kept below 40C.  1000 µL of thawed plasma was 
then transferred into a borosilicate glass tube, which had been previously placed in the 
same ice-bath.  2000 µL of 96% EtOH was then added to each borosilicate glass tube 
with the mixture vigorously vortex mixed for 20 seconds.  The EtOH - plasma mixture 
was removed from the ice bath and allowed to stand at room temperature for a further 
10 minutes.  This was then placed into a centrifuge at 2000g at 20oC for 15 minutes.  
The resulting supernatant was carefully decanted into another borosilicate glass tube 
and placed in a 36-well heating block kept constant at 37oC.  The extract was 
evaporated to dryness under a continuous nitrogen stream with the dried extracts 
either immediately used in a CCK RIA run or kept frozen at -80oC until use.  
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Preparation of Recovery Controls 
 
To assess the recovery of plasma CCK under our experimental conditions, two recovery 
controls (Ctr Rec) of known CCK concentration were prepared and assayed beside the 
extracts of unknown CCK. 
 
A %Recovery of control of >50% was required to ensure assay validity.  % Recovery of 
control was calculated by the following formula.   
 
% Recovery control = 
(pmol/L found with CCK standard – pmol/L found with diluent) x 100 
 
10 
 
The first Ctr Rec was made up of 200 µL of the 50 pmol/L CCK standard added to 800 
µL of donor plasma that had been collected without the additive Trasylol.  This Ctr Rec 
had a known concentration of CCK of 10 pmol/L.  The second Ctr Rec was made up of 
200 µL of diluent added to 800 µL of donor plasma (again without additive) that 
produced a sample with a known concentration of CCK of 0 pmol/L.   
 
The mean recovery of CCK from the assay runs was 80%. 
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CCK Radioimmunoassay 
 
The duration of a RIA run for unknown CCK extracts was 6 days.  On the first day, 
dried plasma CCK extract was rehydrated with 1000 µL diluent, vortex mixed and left 
to stand on the bench for at least 30 minutes prior to the assay.  Tubes were 
consecutively numbered, labelled and prepared for total count (TOT), non-specific 
binding (NSB), blank, the standard curve of known CCK concentrations (0.78, 1.56, 
3.12, 6.25, 12.5, and 25 pmol/L), low QC (1.8-2.8 pmol/L CCK), high QC (9.9 – 13.1 
pmol/L CCK), recovery controls and unknown samples.  700 µL of diluent was 
transferred into the NSB tube and 200 µL into the blank tube by manual pipette.  200 
µL of standard, QCs, recovery controls and unknown samples were transferred into 
their corresponding tubes by manual pipette.  500 µL of Anti-CCK was added to all 
tubes by multi-pipette except to the total count and non-specific binding tubes.  The 
tubes were vortex mixed, covered and placed in the 3.5oC refrigerator to incubate at 
2.5oC for 44-48 hours. 
 
On day three, 500 µL of tracer (Iodinated CCK) was added to all tubes using an 
Eppendorf multi-pipette. The tubes were then vortex mixed, covered and placed in the 
3.5oC refrigerator to incubate for a further 92-96 hours. 
On day six, 100 µL of the double antibody solid phase solution was added to all tubes 
except the TOT tube by manual pipette.  This reagent had to be placed onto a magnetic 
stirrer to ensure it was constantly mixed.  The tubes were vortex mixed, covered and 
left to incubate in the 3.5oC refrigerator for 45 minutes.  The TOT tube was placed 
aside and all remaining tubes put into the HD Scientific / Hettich Zentrifuger Rotixa 
50RS refrigerated centrifuge and centrifuged at 4000g for 20 minutes at 4oC.  The 
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supernatant was decanted from the centrifuged tubes by inverting them onto 
absorbent paper.  Great care was taken not to dislodge the pellet at the bottom of each 
tube.  All tubes were then placed into the automatic gamma counter and the CCK 
specific program (#18), which produced standard curve, QC and Ctr Rec and the assay 
results used.  The % recovery control was calculated with all runs exceeding 50%. 
 
2.2.6.2 The total ghrelin RIA 
 
The GHRT- 89HK Total Ghrelin RIA kit (Millipore Corp, Billerica, MA, USA) was used 
to measure total Ghrelin in stored plasma.  As per the manufacturer’s PIS151, the kit 
utilises a highly specific antibody for total ghrelin that has no cross-reactivity to 
glucagon, leptin or insulin.  With a 100 µL unknown sample, the assay achieves a 
sensitivity of 27.6 pmol/L and recoveries of >90% are obtained when known 
concentrations of ghrelin are added to plasma.  The coefficient of variation was 3.3 - 
10% (intra-assay) and 14.7 – 17.8% (inter-assay) for concentrations of (total) ghrelin of 
296.7 – 889.9 pmol/L.  Each RIA run was carried out as a continuous procedure over 
three consecutive days.  Figure 2.5 outlines the ghrelin RIA 
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Figure 2.5  The outline of the ghrelin RIA 
 
 
 
Reagents 
 
When not immediately used, rehydrated reagents were kept frozen at -20oC.  Prior to 
their use the reagents of iodinated Ghrelin, quality controls, and standards were 
thawed at room temperature.  The ready-to-use assay buffer, antibody and 
precipitating reagent were all stored at 3.5OC when not in use.  
 
Total Ghrelin Radioimmunoassay 
 
On the morning of Day 1 of the RIA, the frozen plasma samples were thawed at 3.5oC 
together with the stored standard curve samples and QCs.  Pointed polypropylene 
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tubes were consecutively numbered and labelled for TOT, NSB, blank, the standard 
curve of known (total) ghrelin concentrations (32.5, 64.9, 129.8, 259.6, 519.1, 1038.3 
and 2076.5 pmol/L), the low QC (110.7 – 229.6 pmol/L), the high QC (260.8 – 541.4 
pmol/L) and unknown samples.  Assay buffer was transferred into the NSB tube (300 
µL) and blank tube (200 µL).  100 µL of assay buffer was transferred into each of the 
tubes for the standard curve, QCs and unknown samples.  100 µL of standard, QCs or 
unknown samples were transferred into their corresponding tubes by manual pipette.  
100 µL of ghrelin antibody was added to all tubes except the TOT and NSB.  Tubes 
were vortex mixed, covered and incubated in the refrigerator at 3.5oC for 20 - 24 hours. 
 
On the second day, 100 µL of iodinated Ghrelin was added to all of the tubes.  The 
tubes were then mixed, covered and incubated at 3.5oC for 22 - 24 hours.   
 
On the third day, 1000 µL of cold precipitating reagent was added to all tubes, which 
had been placed in an ice bath at <4oC, except for the TOT, which was placed aside.  
The tubes were vortex-mixed and incubated for 20 minutes at 3.50C.  These tubes were 
then centrifuged at 3000g for 20 minutes at 4oC (HD Scientific / Hettich Zentrifuger 
Rotixa 50RS refrigerated centrifuge).  The supernatant was decanted by inverting the 
tubes onto absorbent paper.  All of the tubes were then placed into the automatic 
gamma counter and the total ghrelin specific program (#19) run, which produced 
results for the standard curve, QCs and the unknown samples. 
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2.2.6.3 The active glucagon-like peptide-1 RIA 
 
The Millipore GLP-1A-35HK kit (Millipore Corp, Billerica, MA, USA) was used to 
measure the levels of active GLP-1 from stored samples of plasma containing the 
additive: DPP-IV inhibitor.  As per the manufacturer’s PIS152, when 300 µL of 
extracted plasma is processed the assay achieved a sensitivity of 3 pmol/L.  The assay 
is highly specific for both of the biologically active forms of GLP-1 (7-36 amide and 7-
37amide) but does not detect GLP-2, glucagon, insulin or gastro-intestinal-peptide.  As 
per the PIS, the intra-assay coefficient of variation was 27 - 30% and the inter-assay 
coefficient of variation 12 - 34% for concentrations of GLP-1 of 14 - 40 pmol/L. 
 
The first stage of the assay was an ethanol-based extraction of GLP-1 from stored 
plasma and the second stage was the RIA of the extract.  Following the addition of 
known concentrations of GLP-1 to donor plasma, the extraction process resulted in 60-
80% recovery of GLP-1.  The extraction process was carried out over a single day and 
the RIA of the extract over 3 consecutive days. Figure 2.6 outlines the active GLP-1 
RIA. 
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Figure 2.6  The outline of the active GLP-1 RIA 
 
 
 
Reagents 
 
Iodinated GLP-1 was rehydrated with the provided assay buffer and iodinated GLP-1 
and the ready-to-use reagents of anti-GLP-1, standards and QCs were all frozen at -
200C when not in use.  The ready-to-use assay buffer, precipitating reagent, guinea pig 
carrier and sample rehydrating solution were stored at 3.5oc when not in use.  
 
Extraction of GLP-1 from frozen plasma 
 
Stored plasma was thawed in an ice bath (kept at <4oC) and 300 µL of plasma used for 
each extraction.  1100 µL of 96% EtOH was added to each microfuge tube, which were 
then capped, inverted and vortex mixed before being incubated in the ice bath for 30 
minutes.  At the end of incubation the microfuge tubes were again inverted and 
centrifuged at 5800g for 10 minutes at room temperature.  For the final step of the 
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extraction process, the supernatant was carefully decanted into pre-labelled 
borosilicate glass tubes and then placed into a 36-well heating block at 37oC.  Under a 
continuous nitrogen stream the extracts were dried completely.  Any dried extract not 
immediately used in a GLP-1 RIA run was stored at -80oC until use. 
 
Active GLP-1 Radioimunoassay 
 
On the first day dried extract was rehydrated by the addition of 300 µL of sample 
rehydrating solution.  These tubes with rehydrated samples were incubated in an ice 
bath (at <4oC) for 30 minutes and then gently vortex mixed.   
 
Borosilicate glass tubes were labelled for TOT, NSB, blank, for the standard curve (5, 
10, 20, 50, 200, 500 pmol/L), low QC (29-61 pmol/L), high QC (175-364 pmol/L) and 
for the rehydrated samples with unknown levels of GLP-1.  Assay buffer was added to 
the following tubes as follows:  TOT and NSB 400 µL, blank 300 µL and standards and 
QCs 200 µL. 
 
100 µLs of standards, 100 µLs of high and low QCs and 300 µLs of unknown GLP-1 
extract were transferred to their corresponding borosilicate glass tubes.  100 µL of 
anti-GLP-1 was added to all of the tubes except for the TOT and NSB tubes.  
Afterwards, all of the tubes were vortex mixed, covered and incubated at 3.5oC for 20 – 
24 hours. 
 
On the second day, 100 µL of iodinated GLP-1 was added to all of the tubes.  All tubes 
were vortex mixed, covered and incubated in the 3.5oC refrigerator for 22 – 24 hours.    
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On the third day, 10 µL of guinea pig immunoglobulin carrier was transferred to all 
tubes except for the TOT.  All tubes except for the TOT were placed into a ice bath (at 
<4oC) and 1000 µL of cold precipitating reagent added.  All of the tubes were vortex 
mixed, covered and incubated at 3.5oC for 20 minutes.  The TOT tube was put aside 
and the remaining tubes placed into the refrigerated centrifuge and spun at 4500g for 
30 minutes at 4oC.  After centrifuging, these tubes were carefully inverted and 
decanted before being placed onto absorbent paper.  Great care was taken to not 
dislodge the pellet located at the bottom of each tube.  All of the tubes were then placed 
into the automatic gamma counter and the active GLP-1 program (# 20) selected to 
run.  This generated a standard curve, QCs and results for the unknown samples. 
 
2.2.6.4 The insulin RIA 
 
The Millipore HI-14K RIA kit (Millipore Corp, Billerica, MA, USA) was used to 
measure the levels of insulin from stored serum.  According to the manufacturer’s 
PIS153 the assay sensitivity with 100 µL of sample was 12 pmol/L.  The kit is highly 
selective for insulin and does not detect pro-insulin, glucagon, or insulin-like-growth 
factor 1.  For insulin concentrations of 42 – 325 pmol/L, the intra-assay co-efficient of 
variation was 2.2 - 4.4% and inter-assay co-efficient of variation 2.9 – 6% with the 
measured recovery after the addition of known concentrations of insulin into serum 
from 93 - 100%. Each insulin RIA run was conducted over two consecutive days and 
Figure 2.7 illustrates the insulin RIA.  
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Figure 2.7  The outline of the insulin RIA 
 
 
 
Reagents  
 
Prior to use the kit-provided iodinated insulin was rehydrated and together with the 
ready-to-use reagents of anti-insulin, standards and QCs kept frozen at -20oC when 
not in use.  The ready-to-use reagents of the assay buffer and cold precipitating reagent 
were stored at 3.5oC when not in use. 
 
Insulin Radioimmunoassay 
 
100 µL of stored participant serum was thawed in the 3.5oC refrigerator while plastic 
pointed tubes labelled for TOT, NSB, blank, the standard curve (12, 30, 60, 120, 300, 
600 and 1200 pmol/L), low QC (40.8 – 84.6 pmol/L), high QC (156 – 324 pmol/L) 
and for samples containing unknown levels of insulin.  Assay buffer was added to the 
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following tubes as follows: 300 µL to the NSB tube, 200 µL to the blank tube and 100 
µL for each of the standards, QCs and unknown tubes.  Following this 100 µL of 
standards, QCs and unknown samples were added to their respective tubes. Afterwards 
100 µL of iodinated insulin was added to all tubes followed by 100 µL of anti-insulin to 
all tubes except for the TOT and NSB tubes.  All of the tubes were vortex mixed, 
covered and incubated at room temperature (22-25oC) for 20-24 hours. 
 
On the second day 1000 µL of cold precipitating reagent was added to all of the tubes 
except for TOT.  The tubes were vortex mixed, covered and incubated at 3.5oC for 20 
minutes.  The TOT tube was placed aside and the remaining tubes centrifuged at 
4000g for 30 minutes at 4oC.  After centrifuging, the tubes were decanted by inversion 
and placed onto absorbent paper with great care taken to not dislodge the pellet at the 
bottom of each tube.  All tubes were then placed into the automatic gamma-counter 
with the insulin specific program selected (#15) to run.  Results were generated for the 
standard curve, QCs and samples which were then used. 
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2.3  DATA ENTRY AND STATISTICAL ANALYSES 
 
Data was entered into a series of spread sheets using Microsoft Excel for Mac 2008 
(version 12.3.1 build 110725).  Following data entry a cleaning cycle was undertaken 
that involved cross-referencing the entered data with values from the original source 
material.  Statistical analyses were performed with the IBM SPSS Statistics Version 19 
software package (IBM Corp, NY, USA).  All data entry and statistical analyses were 
carried out by the author. 
 
Data was analysed for normative distribution by the Kolmogorov–Smirnov test. 
Parametric data is reported as mean ± Standard Error Mean (SEM) while non-
parametric data as median with the inter-quartile range (IQR).  All graphed data is 
presented as mean ± SEM unless specified.  Missing data for CCK and GLP-1 was 
corrected by multiple imputation data analyses using the Marcov Chain Monte Carlo 
method.  Results were considered significant if p < 0.05 except when noted.  Twenty 
participants gave 80% power (α = 0.05) to detect a 10% change in EI after 4 days of ad 
libitum diet treatments. 
 
The Area Under the Curve or AUC (a superior comparator of serial time points than 
point-to-point or peak to trough154)  is calculated by the trapezoidal rule, which 
approximates the region under a graph of the function f(x) as a trapezoid and 
calculates the area of the trapezoid.  As the length of the Fixed Energy Meal 
experiment was 180 minutes, the AUC was defined as the sum of the trapezoids 
between 0 to 180 minutes.   
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AUCs were calculated by using a user-defined formula add-on package within 
Microsoft Excel corresponding to the above equation.   
 
AUCs were calculated for each of questions from the Appetite VAS; for each of the 
following hormones: CCK, total ghrelin, GLP-1 and insulin, and for the following 
biochemistry measures: urea, Blood Glucose Level (BGL), total cholesterol, 
triglycerides and free fatty acids.  Comparisons were made between the results whilst 
on the 10% P, 15% P and 25% P diet treatments.   
 
For parametric data, within-subject analysis was carried out using one-way within 
subject analysis of variance with repeated measures (ANOVA-RM).  Data was checked 
with sphericity using the Mauchlys sphericity test and if sphericity was violated, the 
Greenhouse-Geiser correction was applied to the F and p-values.  Post-hoc analyses 
used the Bonferroni correction method for multiple, pair-wise comparisons. 
 
For non-parametric data, within-subject differences were analysed using the Freidman 
test.  Post-hoc analyses were performed on significant results through multiple pair-
wise Wilcoxon signed-rank tests with the Bonferroni correction applied to these 
results.  They were considered significant only if they met their revised alpha level.  
 
To evaluate the relationship between insulin and total ghrelin, Spearman rank order 
coefficients were calculated based on 15 pairs of data (5 time points, 3 treatments) and 
between the AUCs for each variable based on 22 observations (22 subjects). 
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2.4  RESULTS 
 
2.4.1 Four days of ad libitum feeding of diets differing in % P 
 
The Fixed Energy Meal Experiment was a component of the larger project designed to 
test the Protein Leverage Hypothesis in humans with this author a sub-investigator in 
that larger project.  This author’s duties included: assisting in the recruitment and 
screening of subjects, supervising participants in the long-stay facility, implementing 
experimental protocols, collecting blood samples and performing hormone analyses; 
manuscript drafting, editing and revision.  This author is recognised as a co-author of 
the initial article arising from the larger project:  “Testing Protein Leverage in Lean 
Humans”148.  The results from the overall project are essential in providing context for 
the results of the Fixed Energy Meal Experiment and are summarised below. 
 
The total EI and specific macronutrient intake over the four-day study period differed 
according to the diet treatments.  EI was highest on the 10% P diet while P intake was 
lowest.  Figure 2.8 demonstrates the changes to total energy intake and P intake on 
the 10%, 15% and 25% P diet treatments. 
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Figure 2.8  Lean humans increase energy consumption on a lower percent
    protein diet 
 
Cumulative P (triangles) and total energy (circles) intake (MJ) for participants during the 4-day 10% P 
(white), 15% P (grey) and 25% P (black) ad libitum study periods.   
NB: From Gosby et al148 with the kind permission of the author. 
 
The four-day EI (as Megajoules MJ) for the 10% P | 15% P | 25% P diet treatments 
were 41.5 ± 2.4, 37.1 ± 2.1, 37.1 ± 2.2 MJ and significantly different (F (2,42) = 6.7; p = 
0.002).  Post-hoc analyses demonstrated that the greatest difference was between the 
10% P vs 15% P diet treatments (p <0.0001) though 15% P vs. 25% P was also 
significantly different (p = 0.00o3).   
 
The Four day Protein Intake (as MJ) for the 10%P | 15%P | 25%P diets were: 4.5 ± 0.3, 
5.7 ± 0.3, 9.2 ± 0.5 MJ and also significantly differed (F (2,42) = 125.6; p <0.0001).   
Post-hoc analyses showed differences between the intakes of 10% P vs 15% P, 15% P vs 
25% P and 15% P vs 25% P (all p <0.0001). 
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When the 10% P diet treatment was compared to the 15% P diet treatment, 
participants consumed 4.34 MJ more energy with a net result of a 3% reduction in the 
intake of P (-1.24 MJ EI from P) and a 15% increase in the intake of carbohydrates and 
fat (+5.59 MJ EI from CHO+F).  
 
Comparing the 10% P diet treatment to the 25% P diet treatment, participants 
consumed 4.38 MJ more energy with this the net result of a 12% reduction in the 
intake of protein (-4.47 MJ EI from P) and a 25% increase in the intake of 
carbohydrates and fat (+9.15 MJ EI from CHO+F).  
 
With the increase from the 15% P to 25% P diet treatment, the macronutrient intake 
altered with an increase in the EI by P of +3.5 MJ (15% P vs. 25% P: p <0.0001) that 
was balanced by a reduction in the EI by CHO+F of -3.57 MJ (15% P vs. 25% P: p 
<0.0001).  This resulted in no change to the net total EI (15% P vs. 25 P%: p = 1).   
 
Changes in food intake were evident by the third day, but did not reach significance 
until the fourth day.  No changes to body weight were noted. 
 
In summary the results from the overall experiment demonstrated increased energy 
intake on the diets that contained lower % P, which was consistent with the Protein 
Leverage Hypothesis.  However, no differences in the EI between the medium and 
high P diets nor changes to body weight and satiety were found and the duration of the 
study may have been insufficient to test these aspects of the PLH.  
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2.4.2  Fixed Energy Meal Experiment:  Appetite Visual Analogue Scores  
 
For Appetite VAS Questions 1 – 4 the results according to diet treatments are 
presented in Figures 2.9.1 - 2.9.4.  All graphed data is presented as mean ± SEM 
unless specified otherwise. 
 
The results of the baseline and AUCs analyses of VAS Question 1 - 4 are presented in 
Table 2.2. 
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Figure 2.9.1 Appetite VAS Question 1 (Hunger) per %P diet treatment 
 
 
 
Figure 2.9.2 Appetite VAS Question 2 (Fullness) per % P diet treatment 
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Figure 2.9.3 Appetite VAS Question 3 (Desire to eat) per % P diet treatment 
 
 
Figure 2.9.4 Appetite VAS Question 4 (Prospective Consumption) per % P diet
   treatment 
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Table 2.2  Appetite VAS Q1 - 4:  Baseline and AUCs per % P diet treatment 
Appetite VAS 
per % P diet 
treatments 
Baseline (mm) 
 
Analysis 
 
AUC (mm.min) 
 
Analysis 
 
Question 1 
10% P 
15% P 
25% P 
 
57 ± 6.9* 
56.4 ± 6.4 
48.6 ± 7 
 
F (2,40)=0.78 
p = 0.47 + 
 
4095 (2482.5, 6772.5)^ 
3915 (2467.5, 6592.5) 
5055, (1867.5, 6255) 
 
X2 (2) = 0.38 
p = 0.83 ‡ 
Question 2 
10% P 
15% P 
25% P 
 
20 (8, 34) ^ 
19 (4,25) 
16 (6.3, 40.8) 
 
X2 (2) = 1.51 
p = 0.47 ‡ 
 
8709.6 ± 941.1 * 
10755.7 ± 935.6 
9393.4 ± 846.7 
 
F (2, 40) = 2.37 
P = 0.10+ 
Question 3 
10% P 
15% P 
25% P 
 
54.1 ± 7 * 
55.6 ± 6.7 
45.1 ± 6.6 
 
F (2, 40) = 1.49 
p = 0.24+ 
 
3907.5 (2366.3, 5298.8)^ 
2955 (1230, 6397.5) 
3367 (1293.8, 4638.8) 
 
X2 (2) = 0.71 
P = 0.7 ‡ 
Question 4 
10% P 
15% P 
25% P 
 
54.3 ± 5 * 
49.9 ± 5 
47.1 ± 5.3 
 
F (2, 40) = 1.18 
p = 0.31 + 
 
3547.5 (2508.8, 6930) ^ 
4057.5 (1901.3, 7477.5) 
3742.5 (2381.3, 5325) 
 
X2 (2) = 1.54 
p = 0.46 ‡ 
* mean ± SEM;   ^ median, IQR 
+
 ANOVA with RM  ‡ Freidman’s Test 
 
There were no significant baseline differences for any of the Appetite VAS questions, 
nor significant differences for any of the Appetite VAS AUCs.  However, a non-
significant trend towards difference for the AUC of Q2 (fullness) was noted. 
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2.4.3  Fixed Energy Meal Experiment: Cholecystokinin  
 
The levels of CCK at baseline to 180-minutes and the CCK AUCs per diet treatment are 
presented as Figures 2.10 – 11.  All graphed data is presented as mean ± SEM unless 
specified otherwise.  CCK descriptive data and the results of analyses are presented in 
Table 2.3. 
 
Figure 2.10  CCK: Baseline to 180 minutes per % P diet treatments 
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Figure 2.11  CCK AUCs per % P diet treatments 
 
 
 
Table 2.3  Descriptive data and statistical analyses for CCK per %P diet  
   treatments 
CCK  
per % P diet 
treatments 
Baseline 
(pmol/L) ^ 
Analysis ‡ AUC  
(pmol.min/L) * 
Analysis + 
 
10% P 
15% P 
25% P 
 
0.37, 0.30 - 1.29 
0.33, 0.29 – 0.67 
0.39, 0.31 - 0.76 
 
X2 (2) = 0.69 
p =0.71 
 
292.12 ± 34.96 
464.18 ± 47.79 
368 ± 50.09 
 
F (2,44) = 7.29 
p =0.002 
 
* mean ± SEM;   ^ median, IQR  
+
 ANOVA with RM  ‡ Freidman’s Test 
 
No significant differences were found when baseline CCK was ranked according to diet 
treatment (p = 0.71).   
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A significant difference was found when CCK AUCs were assessed according to the diet 
treatments (p = 0.002).  Post-hoc testing demonstrated a significant mean difference 
between 10% P vs. 15% P diet treatments (I – J = -172.06, p = 0.001) but not between 
15% P vs. 25% P (p = 0.12) or 10% P and 25% P diet treatments (p = 0.44). 
 
Concentrations of CCK rose after the consumption of the meal. For 10% P, levels 
peaked at 60 minutes while for 15% P and 25% P, they peaked at 120 minutes. and 
when AUCs were compared, there was at least a 23% difference in the AUC for the 10% 
P and other diet treatments.   
 
2.4.4  Fixed Energy Meal Experiment: total Ghrelin 
 
The baseline to 180-minutes levels and AUCs of total ghrelin per diet treatment are 
presented in Figures 2.12 – 13.  All graphed data is presented as mean ± SEM unless 
specified otherwise.  Total ghrelin descriptive data and the results of analyses are 
presented in Table 2.4. 
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Figure 2.12  Total ghrelin to 180 minutes per % P diet treatments 
 
 
 
Figure 2.13  Total ghrelin AUCs per % P diet treatments 
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Table 2.4  Total ghrelin descriptive data and statistical analyses per % P diet
    treatments 
Total ghrelin 
per % P diet 
treatments 
Baseline 
(mmol/L) * 
Analysis + AUC  
(mmol.min/L) * 
Analysis + 
 
10% P 
15% P 
25% P 
 
238.39 ± 25.75 
160.07 ± 5.38 
151.77 ± 4.77 
 
F (1.05, 23.10) = 9.89 
p = 0.004 
 
 
27794.52 ± 825.10 
30719.88 ± 1361.50 
30508.13 ± 1074.40 
 
F (2, 44) = 4.15 
p = 0.02 
 
* mean ± SEM;   +  ANOVA with RM 
 
A significant difference was found for baseline total ghrelin per diet treatments 
(p=0.004 with the Greenhouse-Geisser correction).  Post-hoc analyses demonstrated 
the mean differences were between the 10% P vs. 15% P treatments (I – J = 78.2, p = 
0.026) and the 10% P vs. 25% P treatments (I – J = 86.6, p = 0.007) but not between 
the 15% P vs. 25% P diets (p = 0.38). 
 
Post-prandial total ghrelin concentrations decreased on all three diet treatments.  For 
the 10% P and 15% P treatments, levels reached their nadir at 120 minutes while for 
the 25% P treatment; nadir was reached at 180 minutes.   
 
There was at least 10% different between the highest and lowest AUCs for total ghrelin 
per % P diet treatments.  Analyses showed significant differences between the AUCs 
according to the diet treatments (p = 0.02) with post-hoc analyses demonstrating a 
mean difference between the 10% P vs. 25% P treatments (I – J= -2713.61, p = 0.017) 
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but not between the 10% P vs. 15% P diets (p = 0.11) nor between the 15% P vs. 25% P 
diets (p = 1). 
 
2.4.5  Fixed Energy Meal Experiment: Glucagon-Like Peptide-1 
 
Levels of GLP-1 at baseline to 180-minutes and AUCs are presented in Figures 2.14 – 
15.  All graphed data is presented as mean ± SEM unless specified otherwise.  The 
descriptive data and results of analyses for GLP-1 are presented in Table 2.5. 
 
Figure 2.14  Baseline to 180 minutes levels of GLP-1 per % P diet treatments 
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Figure 2.15  GLP-1 AUCs per % P diet treatments 
 
 
 
Table 2.5  GLP-1 descriptive data and analyses per % P diet treatments 
 
GLP-1  
per % P diet 
treatments 
Baseline 
(pg/mL)^ 
Analysis ‡ AUC  
(pg.min/mL) ^ 
Analysis ‡ 
 
10% P 
15% P 
25% P 
 
19.60 (11.4, 33.14) 
19.13 (13.10, 23.28) 
19, (11, 25) 
 
X2 (2) = 0.35 
p = 0.84 
 
3642.6 (2906.7, 4558.95) 
3670.20 (2548.35, 4176.15) 
4058.4 (3165.3, 5250) 
 
X2 (2) = 0.78 
p = 0.68 
^ median, IQR    ‡ Freidman’s Test 
 
No significant differences were found for baseline levels of GLP-1 ranked according to 
the diet treatments, (p = 0.84). 
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For all the diet treatments, post-prandial concentrations of GLP-1 increased and then 
fell.  For the 10% P treatment, levels fell below baseline while for the 15% P and 25% P 
treatments at 180 minutes, they remained above baseline.  On the 10% P treatment 
GLP-1 concentrations peaked by 30 minutes while on the 15% P and 25% P treatments 
the post-prandial levels of GLP-1 followed a bimodal pattern, peaking at 30 minutes 
then falling at 60 minutes and then rising again to a secondary peak by 180 minutes.  
 
There was only a small difference of ~1% between the GLP-1 AUCs per diet treatment 
and when ranked accordingly, GLP-1 AUCs did not significantly differ (p = 0.68). 
 
2.4.6  Fixed Energy Meal Experiment:  Insulin 
 
The baseline to 180-minutes levels and AUCs of insulin per diet treatments are 
presented in Figures 2.16 – 17.  Insulin descriptive data and the results of analyses 
are presented in Table 2.6. 
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Figure 2.16  Baseline to 180-minute levels of insulin per % P diet treatments 
 
 
 
Figure 2.17  Insulin AUCs per % P diet treatments 
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Table 2.6  Descriptive data and results of analyses for insulin per % P diet
    treatments 
Insulin  
per % P diet 
treatments 
Baseline 
(mmol/L) * 
Analysis + AUC  
(mmol.min/L) * 
Analysis + 
 
10% P 
15% P 
25% P 
 
80.44 ± 3.64 
93.7 ± 6.42 
74.49 ± 5.67 
 
F (2, 44) = 5.20 
p < 0.01 
 
63744.5 ± 19145.4 
54079.8 ± 12645 
56370.2 ± 20555.2 
 
F (2, 44) =4 
p = 0.03 
* mean ± SEM;   +  ANOVA with RM 
 
Significant differences were found between levels of baseline insulin according to the 
diet treatments (p = 0.009).  Post-hoc analyses demonstrated a mean difference 
between the 15% P vs. 25% P treatments (I – J = 19.21, p = 0.04), a non-significant 
trend towards a mean difference between the 10% P vs. 15% P treatments (I – J= 
-13.26, p = 0.09) but no difference between the 10% P vs. 25% P diets (p = 0.77). 
 
For all diet treatments post-prandial levels of insulin rose and peaked by 30 minutes 
before declining for the rest of the experimental period.  Insulin AUCs were highest on 
the 10% P treatment and there was at least an 18% difference between the 10% P and 
the other treatments.   
 
Insulin AUCs also differed according to the diet treatments (p = 0.03) with post-hoc 
analyses demonstrating a mean difference between 10% P vs. 15% P treatments (I – J = 
9664.76, p = 0.03), a non-significant trend between the 10% P vs. 25% P treatments  
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(I – J = 7374.33, p = 0.10) but no mean differences between the 15% P vs. 25% P 
treatments (p = 1.0). 
 
2.4.7  Fixed Energy Meal Experiment: Total Ghrelin x Insulin 
 
Spearman’s rank correlation coefficients were calculated to examine for any 
interaction between levels of total ghrelin and insulin. Pair-wise analyses were made 
for the five measured time points (0, 30, 60, 120 and 180 minutes) and the AUCs per 
diet treatment.   
 
With the exception of the 120 minute point on the 10% P diet treatment (which just 
met significance at p = 0.049), no significant correlations, nor trends towards 
significance were found between total ghrelin and insulin for any paired observations 
on any diet treatment (all p values >0.11).  In addition, when the total ghrelin and 
insulin AUCs for each diet treatment were compared, no significant correlations were 
found (10% P diet treatment p = 0.14; 15% P diet treatment p = 0.23; 25% P diet 
treatment p = 0.36).  
 
2.4.8 Fixed Energy Meal Experiment: Urea and Glucose  
 
The results to 180 minutes of testing for urea and glucose according to the diet 
treatments are presented in Figures 2.18 and 2.19 respectively.   
 
Descriptive data and analyses for the baseline and AUCs are presented in Table 2.7 
for urea and Table 2.8 for glucose. 
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Figure 2.18  Urea per % P diet treatment 
 
 
 
Table 2.7  Baseline, AUCs and analyses for Urea per % P diet treatments 
Urea per % P 
diet treatments 
Baseline 
(mmol/L) * 
Analysis + AUC (mmol.min/L) ^ Analysis ‡ 
 
10% P 
15% P 
25% P 
 
3.34 ± 0.14 
4.6 ± 0.21 
6.32 ± 0.29 
 
F (2, 36) = 76.32 
P<0.0001 
 
583.5 (400.5, 618) 
802.5 (714, 907.5) 
1249.5 (897, 1360.5) 
 
X2 (2) = 23.68 
P<0.0001 ‡ 
 
* mean ± SEM;   ^ median, IQR 
+
 ANOVA with RM  ‡ Freidman’s Test 
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For urea, baseline and AUC levels increased very significantly according to % P diets 
(both p <0.0001).   
 
For fasting differences, post-hoc analyses confirmed significant mean fasting 
differences between all the diet treatments [10% P vs. 15% P (I - J= -1.44, p <0.0001); 
for 15% P vs. 25% P (I-J=-1.69; p<0.0001); and for 10% P vs. 25% P (I-J= -3.13; 
p<0.0001)]. 
 
For differences between the AUCs according to the diet treatment post-hoc analyses 
(with a Bonferroni correction that generated a revised alpha significance level of p = 
0.018) indicated the main difference was between the 10% P vs. 25% P diets (Z = -3.74, 
p <0.0001) and near significant differences existed between 10% P vs. 15% P and 15% 
P vs. 25% P (both p = 0.02). 
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Figure 2.19  Serum glucose per %P diet treatment 
 
 
 
Table 2.8  Serum glucose: Baseline and AUCs per %P diet treatments 
Serum glucose 
per %P diet 
treatments 
Baseline 
(mmol/L) * 
Analysis + AUC (mmol.min/L) ^ Analysis ‡ 
 
10% P 
15% P 
25% P 
 
4.72 ± 0.09 
4.87 ± 0.07 
5.09 ± 0.15 
 
F (2,21.75) = 3.45 
p = 0.07 
 
923.25 (670.1, 1038.8) 
849 (780, 905.6) 
861 (817.9, 961.1) 
 
X2 (2) = 0.8 
p = 0.67 
* mean ± SEM;   ^ median, IQR  
+
 ANOVA with RM  ‡ Freidman’s Test 
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For glucose, baseline measures did not significantly differ (although a non-significant 
trend for glucose to increase according to % P diet was noted, p = 0.07) while AUCs 
ranked according to the diet treatments also did not differ (p = 0.67). 
 
2.4.9 Fixed Energy Meal Experiment: Triglycerides, free fatty acids and total 
cholesterol 
 
The serum levels to 180 minutes for free fatty acids (FFAs), triglycerides (TG) and total 
cholesterol (TC) according to diet treatments are presented in Figures 2.20 – 22 
respectively. Descriptive data and the results of analyses for fasting levels and the 
AUCs for FFAs, TG and TC are presented in Table 2.9 – 11. 
 
Figure 2.20 Serum Free Fatty Acids per % P diet treatment 
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Table 2.9  Free Fatty Acids: Baseline and AUCs per % P diet treatment 
 
FFAs per % P 
diet treatments 
Baseline 
(umol/L) * 
Analysis + AUC (umol.min/L) * Analysis + 
 
10% P 
15% P 
25% P 
 
218.7 ± 35.08 
280.35± 40.88 
324.87 ± 44.91 
 
p = 0.03 
 
16610.22 ± 2721.59 
18730.44 ± 23356.48 
19043.48 ± 2165.55 
 
p = 0.58 
* mean ± SEM;   +  ANOVA with RM 
 
For FFAs, the fasting baseline measures significantly increased according to % P diet 
treatments (p = 0.03).  AUCs did not differ according to % P diet treatments (using the 
Greenhouse-Geisser correction p = 0.58). 
 
The fasting post-hoc analyses demonstrated a significant mean difference between the 
10% P vs. 25% P diets (I - J= -106.17, p = 0.04) but not for the other diets (10% P vs. 
15% P: p = 0.18, 15% P vs. 25% P: p = 0.92). 
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Figure 2.21  Serum triglycerides per % P diet treatment 
 
 
 
Table 2.10  Serum triglycerides: Baseline and AUCs per %P diet treatment 
TGs per % P diet 
treatments 
Baseline 
(mmol/L) * 
Analysis + AUC (mmol.min/L) * Analysis + 
 
10% P 
15% P 
25% P 
 
1.51 ± 0.26 
1.14 ± 0.14 
1.07 ± 0.11 
 
F (1.57,44) = 3.45 
p = 0.06 
 
283.67 ± 60.61 
229.73 ± 36.61 
196.89 ± 32.43 
 
F (2,42) = 2.80, 
p = 0.07 
* mean ± SEM;   +  ANOVA with RM Test 
 
For TGs, neither the fasting baseline measures nor the post-prandial AUCs 
significantly differed, although non-significant trends for levels of TGs to be inversely 
associated with % P were noted for both (baseline using the Greenhouse-Geisser 
correction: p = 0.06 / AUCs: p = 0.07). 
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Figure 2.22 Serum total cholesterol per % P diet treatment 
 
 
Table 2.11  Total Cholesterol: Baseline and AUCs per %P diet treatment 
TC per % P diet 
treatements 
Baseline 
(mmol/L) ^ 
Analysis ‡ AUC (mmol.min/L) ^ Analysis ‡ 
 
10% P 
15% P 
25% P 
 
3.85 (3.05, 4.38) 
4 (3.7, 4.5) 
4.2 (3.8, 4.9) 
 
p =0.10 
 
642 (76.5, 742.5) 
724.5 (279, 849) 
726 (270, 885) 
 
p = 0.045 
 
^ median, IQR    ‡ Freidman’s Test 
 
For TC the fasting baseline measures ranked according to the diet treatments did not 
differ, although a non-significant trend for levels to increase with % P was noted (p = 
0.10) while AUCs significantly increased according to % P diet treatments (p = 0.045).
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The post-hoc AUC analyses used a Bonferroni correction that set a revised alpha value 
to p<0.017 and showed a significant difference between the 10% P vs. 25% P diets (Z = 
2.72, p = 0.006) but not the other two diet combinations (10% P vs. 15%:  
p = 0.19, 15% P vs. 25% P: p = 0.42). 
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2.5  DISCUSSION 
 
2.5.1  Protein Leveraging  
 
When compared historically to dietary CHO and F, the contribution of P to the 
development of overweight and obesity has been relatively under explored.  Insights 
gained from research into the diet of invertebrates and mammals led to Simpson and 
Raubenheimer developing the Geometric Framework84, which placed animals in a 
model that accounted for nutrient intake and the dietary environment.  This in turn led 
to the Protein Leverage Hypothesis42, which postulated that food consumption is 
regulated to maintain a target intake for dietary P and that relatively small changes in 
the availability of dietary P will result in large changes to the intake of CHO and F.  As 
CHO and F are more energy dense than P what follows is that, if the increased energy 
intake is not offset by an increase to energy expenditure, weight gain is inevitable.  To 
date, the evidence supporting the Protein Leverage Hypothesis in humans has been 
inferred indirectly from observational studies and the mechanisms behind protein 
leveraging remain unknown. 
 
“Testing the Protein Leverage hypothesis in humans” was rigorously designed to 
determine whether humans would leverage their intake of dietary P as predicted by the 
Protein leverage Hypothesis42.  The study demonstrated that lean humans who 
followed four days of ad libitum diets that differed in their % P (10% P, 15% P or 25% 
P) in a random order had the highest EI on the lowest % P diet.  The 4-day total EI on 
the 10% P treatment energy intake (see figure 2.8) was made up of a significantly 
increased intake of CHO+F (+15 to +25% compared to 15% P and 25% P diets 
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respectively) and a decreased intake of P (-3 to -12 % compared to 15% P and 25% P 
respectively).   
 
The results show that lean humans will, by the fourth day, react to a changed dietary 
environment by prioritising their intake of dietary P at the expense of increasing their 
total energy intake in a fashion as predicted by the Protein Leverage Hypothesis. 
While the results did not demonstrate that four-day leveraging is associated with 
changes to body weight nor that protein leveraging occurs over longer periods what 
can be inferred is that if subjects had been maintained on a 10% P diet without a 
sustained increase in energy expenditure, weight gain would have been inevitable.   
 
When these results are reviewed in light of the secular trends reported locally and 
internationally, namely increased total EI from CHO and F and static or decreased 
intake of dietary P79-83, the value of the Protein Leverage Hypothesis in explaining part 
of the aetiology of the global epidemic of overweight and obesity is hard to deny. 
 
2.5.2  Subjective measures of appetite and satiety 
 
In the current study, there were no fasting or post-prandial differences found for 
subjective hunger, fullness (satiety), desire to eat (appetite) and prospective food 
consumption between the three diet treatments as assessed by the Appetite VAS. The 
lack of differences in the fasting state was reported in the article “Testing Protein 
Leverage in Lean Humans”148.  
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The lack of fasting differences was not unexpected for while Weigle et al73 reported 
that higher P diets were associated with increased satiety and decreased hunger under 
fasting conditions using the same Appetite VAS instrument, their experimental 
protocol consisted of two weeks of a baseline weight maintaining diet (50% CHO, 15% 
P) followed by two weeks of an isocaloric diet (50% CHO, 30% P) and then 12 weeks of 
an ad libitum diet (50% CHO, 30% P) and as importantly, the authors also reported 
that during the ad libitum diet phase the Appetite VAS measures returned to baseline.  
This suggests that while higher P diets reduce subjective assessment of hunger and 
improve satiety while fasting, it may only become evident under non ad libitum 
experimental conditions and in dietary interventions that are longer than four days 
and in meals with % P greater than that found in the current study. 
 
The lack of post-prandial differences is also in keeping with the inconsistent results 
that are reported in the current literature.  At least two studies that used the single 
meal test diet protocol and same Appetite VAS instruments have demonstrated that 
higher P meals are associated with post-prandial changes of increased satiety and 
decreased hunger.  Smeets et al72 found that the AUC to 180-minutes on the Appetite 
VAS satiety question was significantly higher on the 30% P compared to the 10% P 
liquid/solid lunch while Bowen et al74 demonstrated that 100% P compared to 100% 
CHO (glucose) liquid pre-loads were associated with reduced appetite on the Appetite 
VAS instrument and decreased food intake from the buffet lunch provided afterwards. 
 
However in contrast to the above studies, others using the same Appetite VAS 
instrument have found no significant differences between diet treatments differing in 
%P.  Raben et al68 compared mixed meals of differing macronutrient compositions 
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(including a 32% P / High P) following an overnight fast and failed to demonstrate any 
changes to VAS satiety or hunger over the 300 minutes of post-prandial testing.  Blom 
et al125 compared 47% CHO vs. 58% P breakfasts that followed an overnight fast and 
also reported no significant post-prandial changes on any Appetite VAS measure.   
 
When the positive and negative studies are compared, points of differences that 
emerge include the time of day chosen to assess appetite and hunger, the types of 
experimental meals chosen and their macronutrient composition.  The current study’s 
experimental protocol is more similar to Raben et al and Blom et al in the use of mixed 
meals over liquid pre-loads or meals and testing after an overnight fast and it may be 
that the effects of higher P diets on post-prandial appetite and satiety are stronger 
between meals rather than after an overnight fast.   
 
Finally, while the Appetite VAS appetite instrument is a well-recognised, validated and 
widely used research tool to measure subjective experiences of satiety and hunger, 
several limitations that reduce the sensitivity of the instrument are well known56,149.   
 
One is that participants may score the 100mm scale according to a bi or tri-modal 
pattern, clustering their responses at the extremes and mid-point rather than treating 
the response line as a linear continuum155.  This was a phenomenon seen in a minority 
of this study’s Appetite VAS response score-sheets.   Another issue is that the ideal 
period of time to score the Appetite VAS is still unclear with some suggesting a 
duration of four hours149.  While this issue was considered during our protocol 
development stage, for logistical reasons that included the effects of a longer period on 
the storage and transfer of blood and tissue samples, maintaining participant co-
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operation at the end of a four day experimental period and after reviewing the 
protocols from published studies such as Bowen et al74 and Smeets et al72, we chose to 
complete the Fixed Energy Meal Experiment in three hours.  However this may mean 
that the sensitivity of the Appetite VAS instrument was reduced for our experiment. 
 
In order to clarify whether higher % P diets are associated with decreased appetite and 
increased satiety, a future study design that assessed the over-night fasting state and 
then over several meal time inter-meal periods, whilst allowing participants to select 
and initiate their own meal time and providing a wide range of % P meals, would 
address all of the above issues. 
 
2.5.3  Dietary P: Hormonal and metabolic markers 
 
The relationships between dietary P, the hormones that modulate appetite & satiety 
and the biochemical markers of metabolism were assessed in “Testing Protein 
Leverage in lean humans” and the Fixed Energy Meal Experiment.  We demonstrated 
that after four days of ad libitum feeding from diet treatments differing in % P, 
significant differences were found for the fasting levels of total ghrelin, insulin, FFAs 
and urea.  None of the following results were published in “Testing Protein Leverage 
in lean humans”148. 
 
The fasting levels of ghrelin were highest and fasting levels of urea lowest on the 10% P 
diet treatment; fasting levels of insulin were highest on the 15% P diet treatment and 
fasting levels of FFAs and urea highest on the 25% P diet treatment.  Non-significant 
trends were noted for the fasting levels of glucose (lowest on 10% P treatment) and 
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TGs (highest on the 10% P treatment).  There were significant relationships found 
between dietary P and fasting levels of CCK, GLP-1 and TC. 
 
The Fixed Energy Meal Experiment assessed the relationship between dietary P and 
the post-prandial secretion of the same hormones and metabolic markers.  The study 
showed that diets differing in % P were associated with significant changes to the post-
prandial AUCs (to 180 minutes) for CCK, total ghrelin, insulin, urea and TC.  
 
The post-prandial AUCs for CCK, total ghrelin, urea and TCs were lowest following the 
10% P diet treatment while the post-prandial AUC for insulin highest. The post-
prandial AUC for TGs were also highest following the 10% P diet treatment, though 
this was a non-significant trend.  There were no significant differences for the different 
diet treatments and the post-prandial AUCs for GLP-1, glucose or FFAs. 
 
These results show that by the fourth day of ad libitum diets that differ in % P, 
significant differences are found in both the fasting and post-prandial secretion of 
several hormones involved in the regulation of appetite, satiety and food intake; and 
for several markers related to the metabolism of food and dietary P.   
 
2.5.3.1  Cholecystokinin 
 
When compared to higher P diet treatments the 10% P treatment was associated with 
the lowest post-prandial AUC and the most attenuated post-prandial rise of CCK (see 
figures 2.10 and 2.11), suggesting that that diets higher in % P are associated with 
greater CCK secretion in the post-prandial period. 
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The post-prandial secretion of CCK is mediated by the breakdown products of the 
three macronutrients: glucose, amino acids and FFAs for respectively CHO, P and F.  
Among these nutrients the hierarchy that ranks their relative potency placed amino 
acids and FFAs above glucose but debate exists regarding the relative potencies of the 
first two nutrients96.   
 
As the % F in this study’s diet treatments was fixed at 30%, the results from this study 
do not directly address this question, but as amino acids are more potent stimulators 
of post-prandial CCK secretion than glucose, we can conclude the observed differences 
in CCK secretion were probably attributable to the changes in dietary P rather than to 
the changes in dietary CHO.  
 
While previous single meal test studies67,74 demonstrated that high (80-100%) 
compared to no to medium (0- 20%) P meals are associated with increased and 
prolonged post-prandial CCK secretion, our study is among the first to demonstrate 
the relationship with solid mixed meals rather than with liquid pre-loads that preceded 
a standardised meal or liquid only meals as reported in the other studies.   
 
Another strength of our experimental protocol is that compared to the studies listed 
above, the range of % P in our protocol (10 - 15- 25 % P compared to 0 - 51 – 70 - 100 
% P) is much closer to the % P currently being consumed by the general 
population80,81.  Furthermore the differences in % P between the diet treatments were 
smaller in our study than those in the above studies.  When this is considered 
alongside the physical form of our experimental meals we are confident that our 
results are not only robust but more applicable to the general dietary setting.   
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In our study no differences were found for fasting CCK after four days of ad libitum 
diets differing in %P.  Differences in fasting CCK have only been reported in a single 
study156 by Robertson et al. of healthy participants who consumed a standardised 
dinner high either in F (62% F) or CHO (77% F) with a constant % P (7%) which was 
followed by an overnight fast.  The authors reported higher fasting levels of CCK the 
morning after the high F dinner, which was attributed to differences in the % F of the 
evening meal.   
 
When compared to Robertson et al, our protocol had a much lower magnitude of the 
difference in % EI by macronutrients (∆P between high and low P diet treatment 15% 
compared to ∆ F between high and low F treatments for Robertson et al 42%) and as 
we kept % F constant, it was not unexpected that differences in fasting CCK were not 
found.  Differences in the levels of fasting CCK could be demonstrated when the diet 
treatments have a greater magnitude of difference in % P, however when extreme 
macronutrient ratios are used, whether the associated observed differences have any 
general applicability is debatable.  
 
Studies have previously examined the clinical potential of CCK as a novel anti-obesity 
therapy. Levels of CCK have been increased by intravenous infusion103 while studies 
have reported on agents that activate the CCK receptor97,157. However all of these 
studies had only modest effects on appetite and weight and to date, the development of 
an effective clinical agent that modulates level of CCK for the treatment of overweight 
and obesity has proven elusive.   
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Our findings may point to great value in exploring and understanding the relationship 
between dietary P and CCK as an alternative means of influencing CCK secretion and 
modulating its physiological actions.  If future studies validate these findings it would 
confirm that relatively modest increases in the % P of a diet will lead to a significantly 
increased and prolonged post-prandial CCK secretion.  Given what is known about 
CCK’s and its physiology effects on reducing meal size and initiating meal 
termination95,100, this may have important implications for the treatment of the 
overweight and obese.  
 
2.5.3.2 Ghrelin 
 
Comparing four days of ad libitum feeding from the different diet treatments, fasting 
ghrelin was found to be highest on the 10% P treatment (see figures 2.12 and 2.13).  
This study would be among the first to demonstrate that fasting ghrelin is affected by 
several days of ad libitum feeding from diets differing in their % P.   
 
To date only three studies126,158,159 were identified that examined the longer-term 
effects of dietary manipulation on fasting ghrelin in the non-pathological state.  The 
results from all three studies showed no link between their diet treatments and fasting 
levels of ghrelin.  It is worth noting that these three studies significantly differed from 
our own on several grounds.   
 
Firstly, while all studies used healthy subjects, the study populations differed on mean 
age, gender and whether the overweight were included.   
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Secondly studies differed in the duration and nature of their dietary interventions and 
the type of dietary intervention.  In particular Beasley et al126 examined three periods 
of 6-week isocaloric feeding from high CHO, high P or high F diets; Zhang et al158 
examined four weeks of a weight-maintaining low-glycaemic index or healthy eating 
diet while Vortuba et al159 examined six days of a weight maintaining healthy diet that 
was followed by three days of ad libitum overeating from a multiple choice cafeteria 
diet.   
 
Thirdly, while Beasley et al and Zhang et al assessed the effects on fasting ghrelin from 
changing the macronutrient composition of the diets, Vortuba et al examined the 
effects of both changed macronutrient composition and increased EI. 
 
When these negative studies are compared to the current study, the macronutrient 
portions used by Beasley et al (% CHO |% P |% F:  High P:  48% | 25% | 27%, High 
CHO: 58% | 15% | 27%; High F: 48% | 15% |37%) were those that most closely 
resembled the diet composition used in this study. While these many protocol 
differences make direct comparisons between the studies problematic, the novelty of 
our finding may be attributed to factors that include the inclusion of only lean subjects 
in our study and that the observed short-medium term changes in fasting ghrelin 
demonstrated by our study may become attenuated in studies with a longer duration of 
diet treatment. 
 
As morning fasting ghrelin is known to play an important role in initiating meal 
consumption109,110 the higher levels of fasting ghrelin seen with the lowest % P diet 
treatment may represent part of a physiological adaption to the reduced protein 
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content of the current dietary environment.  The physiological effects that could arise 
from these changes may be earlier meal initiation and speculatively, an increase in the 
meal size but the fixed timing and EI of our dietary intervention prevented an 
assessment of the effects of increased fasting ghrelin on subjects’ voluntary eating 
habits.   
 
The finding that the highest levels of fasting ghrelin were associated with the lowest 
%P diet treatment is consistent with the Protein Leverage Hypothesis, as altered 
ghrelin secretion may be one of the mechanisms that contributes to the predicted 
increase in food seeking behaviour that is the consequence of placing an animal in a 
food environment low in dietary P.   
 
This study also demonstrated that the lowest post-prandial AUC for ghrelin was 
associated with the 10% P diet treatment, the treatment that showed the greatest post-
prandial suppression of ghrelin (38% reduction from baseline as compared to a 25% 
and 28% reduction for the 15% P and 25% P diets respectively).  This raises the 
question of whether this was due to the P or CHO content of the diet treatments. 
 
When the macronutrients are assessed for their effects on post-prandial ghrelin 
release, F has consistently been demonstrated to have the weakest effect89-93 with the 
ranking between CHO and P still unclear.  Several studies122-124 in normal and 
overweight humans using single meal tests have found that CHO rather than P has the 
greatest effect on suppressing post-prandial ghrelin secretion. However this finding 
has not been consistently replicated as seen by the results of two studies in normal and 
overweight humans; one using a single mixed breakfast (% CHO| P | F:  55% | 10% | 
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35% vs. 55% | 25% | 20%)71 and the other liquid pre-meal pre-loads (100% CHO or 
100% P)74.  Neither study reported any significant differences for post-prandial ghrelin 
suppression between the meals.  A third study of normal weight men125 compared a 
high P or high CHO mixed breakfast (47.3% | 19.3% | 33.4% vs. 14.1% | 58.1% | 27.8%) 
in a cross over fashion and reported that it was P that most powerfully suppressed 
post-prandial ghrelin. 
 
These studies differed in their macronutrient ratios and as to whether %F was kept 
constant.  In contrast, this study kept %F constant with macronutrient ratios differing 
only in % CHO vs. % P, adding to the robustness of our study protocols.  The results of 
the current study also support those that found it is CHO rather than P which has the 
greatest effect on post-prandial ghrelin secretion73-75.   
 
Taken together, these results suggest that the relationship between dietary P and 
ghrelin is mediated more by changes to fasting ghrelin rather than by changes to post-
prandial ghrelin secretion.  Furthermore, these changes become manifest over a period 
of as little as four days and can be elicited by a relatively modest change to the % P in 
the diet.  Whether the relationship between dietary P and ghrelin has any “real world” 
implications for the dietary advice given to the overweight and obese will require 
longer-term studies to confirm the strength and duration of the relationship, with 
specific focus on whether the relationship is attenuated in the overweight and obese. 
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2.5.3.3 Glucagon-Like Peptide-1 
 
Following four days of ad libitum diet treatments differing in % P, no differences were 
found for fasting GLP-1, nor were there any differences in post-prandial GLP-1 AUCs 
following the fixed energy intake, varying in % P breakfasts of the Fixed Energy Meal 
Experiment (see figures 2.14 and 2.15).   
 
The lack of differences between the %P treatments and post-prandial GLP-1 secretion 
stands in contrast to three studies that have reported positive findings.  The first 
study70 assessed 24 hours of dietary interventions and found that the 30% P compared 
to the 10% P dinner (and for men lunch) was associated with increased GLP-1 
secretion.  The second study67 compared 70% P vs. 87% CHO liquid preloads which 
were followed by ad libitum standardised buffet-style lunches and reported increased 
post-prandial GLP-1 secretion following the high P preload.  Finally the third study68 
reported on 32% P vs. 65% CHO and 65% F breakfasts given as a single meal test 
experiment and found higher post-prandial GLP-1 secretion following the high P 
breakfast.   
 
However the evidence for GLP-1 secretion and dietary P is not consistent with two 
studies reporting no relationship between high P diets and GLP-1 secretion.  In the 
first study69 24 hours of a 10% P vs. 30% P diets were compared while in the second 
study 25% P vs. 10% P lunches as a single meal test experiment were compared72.  Both 
studies reported no association between the higher P diets and changes to post-
prandial GLP-1 secretion.  
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Among these five conflicting studies, the results from the study which used liquid pre-
loads67 can be discarded for three reasons:  firstly it was the only study to include 
overweight and obese participants; secondly it was the only study to use liquid pre-
meal pre-loads and thirdly, the diet interventions had significantly divergent 
macronutrient ratios when compared to all other studies.  When the results of this 
study are removed, the balance of evidence is evenly poised as to whether higher P 
diets have effects on GLP-1 secretion. 
 
When the results are considered collectively, the current study shifts the balance of 
evidence to suggest that higher P diets have little effect on fasting or post-prandial 
GLP-1 secretion.  This conclusion is supported by the known increased potency of 
dietary CHO and F relative to P on the post-prandial secretion of GLP-1137.  Another 
implication of this negative finding is that contrary to the findings presented in 
Westerterp-Plangenta et al70, any increased satiety associated with higher P diets is 
unlikely to be mediated by the post-prandial secretion of GLP-1. 
 
2.5.3.4 Insulin 
 
Following four days of ad libitum feeding of the diet treatments differing in % P, the 
lowest levels of fasting insulin were associated with the 25% P diet.  All fasting insulin 
results were within the normal range and not at levels consistent with insulin 
resistance (see figure 2.16). 
 
As the diet treatments in this study had fixed % F it follows that the treatment highest 
in % P is also the diet treatment lowest in % CHO.  This means that another 
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interpretation of the insulin results is that fasting insulin was lowest following the diet 
lowest in % CHO, which is consistent with the known and central role of dietary CHO 
in influencing insulin secretion143.   
 
Studies in the overweight and obese comparing diets differing in their ratios of 
macronutrients have consistently reported that reductions in fasting insulin are 
proportional to the loss of body weight rather than to the macronutrient content of the 
experimental diets77,160-162.  Uniquely among these four studies Leidy et al162 focused 
on the role of dietary P by comparing isocaloric weight-maintaining diets differing in % 
P (14% P vs. 25% P) but fixed in % F, with the authors reporting that there were no diet 
related changes to fasting insulin.   
 
Unlike our study, the above studies were conducted with overweight and obese 
subjects.  It is well-known that overweight and obesity is associated with 
hyperinsulinaemia and insulin resistance, which in turn leads to an increased risk of 
metabolic co-morbidities such as diabetes mellitus and cardiovascular disease163.  It 
has also been established that weight loss reduces insulin secretion and improves 
peripheral insulin sensitivity, which reduces the rates of these same metabolic 
complications164,165.  It is likely that in studies with overweight and obese subjects, the 
powerful relationship between body weight and insulin secretion will overshadow the 
more subtle effects on fasting insulin secretion that arise from altered macronutrient 
ratios. 
 
We also found that the 180-minute post-prandial AUC for insulin was highest 
following the 10% P breakfast, corresponding to the diet treatment with the greatest % 
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CHO (60% and see figure 2.17).  This result is consistent with the strongly validated 
finding that in both normal weight and overweight populations, post-prandial insulin 
secretion is strongly associated with the dietary CHO71,121-123,125.   
 
Intriguingly Veldhorst et al71 was one of the few studies to assess the role of dietary P 
and post-prandial insulin secretion by fixing their experimental diets in % CHO (55%) 
but varying them in % P and % F.  The authors reported that compared to the high % F 
& low % P breakfast, the high % P & low % F breakfast was associated with higher post-
prandial insulin secretion and increased satiety, which suggests that between P and F, 
P has the greater effect on post-prandial insulin secretion.   
 
However this finding has not been replicated in Weigle et al73 where normal to 
overweight subjects were given two weeks of a weight maintaining diet (50% CHO| 
15% P |35% F) followed by two weeks of an isocaloric diet and then twelve weeks of an 
ad libitum diet (both diets 50% CHO| 30% P| 20%F).  This study also kept %CHO 
constant while %P and %F varied.  Unlike Veldhorst et al these authors found no 
differences for on fasting and post-prandial AUC insulin measures between their diets 
treatments but as the EI of this study’s experimental diets differed so considerably, a 
direct comparison between the two studies is problematic. 
 
Overall these results buttress the evidence that it is CHO much more than P and F that 
influences the fasting and post-prandial secretion of insulin. 
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2.5.3.5 Ghrelin and Insulin 
 
No significant correlations, either for AUC measurements or for the paired time points, 
were found between levels of total ghrelin and insulin across any of the diet 
treatments. 
 
Soon after the discovery of ghrelin in 1999, it was noted that the post-prandial 
suppression of ghrelin closely mirrored the post-prandial elevation of insulin, which 
led to suggestions that insulin played a role as a post-prandial inhibitor of ghrelin 
secretion109.  However the results from studies, conducted in both normal and 
overweight subjects, that have specifically examined this topic have thus far been 
mixed.   
 
Two studies reported the presence of the inverse correlation between post-prandial 
ghrelin and insulin after the consumption of meals that were made up of all 
macronutrient groups in a conventional balanced ratio121,128.  In contrast, one study 
found the correlation only after the consumption of meals dominant in CHO but not 
after meals dominant in P or F123 while a fourth study that examined meals dominant 
in CHO and P found no evidence of post-prandial correlations between the two 
hormones125.    
 
The results from our study support the notion that for diet treatments modestly 
varying in % P and % CHO, no significant correlations exist between the post-prandial 
rise of insulin and the post-prandial suppression of ghrelin. 
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2.5.4  Dietary P and urea, glucose, free fatty acids, triglycerides and  
  cholesterol 
 
The changes to levels of fasting and post-prandial urea were linearly associated with 
the changes to the % P of the diet treatments, which is in keeping with the knowledge 
that for healthy subjects, the metabolism of urea linearly corresponds to the intake of 
dietary P (see figure 2.18). The fact that a higher intake of P increases the metabolic 
pathways leading to increased levels of urea in the serum and in the urine has been 
well-established166-168.   
 
When compared to the subjects’ habitual pre-study intake for P, which was assessed 
prior to each four-day ad libitum diet intervention by the completion of a four-day 
food recall dairy148 (mean %P: 18.5%), the changes to serum urea provide biochemical 
confirmation that the manipulation of the subjects’ diets (and P intake) was being 
achieved. 
 
No significant changes were found for fasting and post-prandial glucose for any diet 
treatment (see figure 2.19).  This is unsurprising as all the fasting and post-prandial 
glucose (and levels of fasting insulin) levels remained in the non-pathological range 
and all of the subjects were lean and healthy.  The glucose results are entirely 
consistent with the known effects of post-prandial digestion and absorption on serum 
glucose169. 
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It was demonstrated that fasting levels of FFAs were highest after four days of ad 
libitum feeding on the 25% P diet and lowest after four days of ad libitum feeding on 
the 10% P diet (see figure 2.20).   
 
A 1966 study170 was the first to demonstrate that prolonged fasting was associated with 
progressively higher levels of FFAs, which in turn are correlated with a decrease in 
urinary nitrogen excretion that measures the metabolism of urea.  The suggested 
relationship between FFAs and P metabolism, with higher levels of FFAs altering the 
metabolism of P to favour anabolic pathways and suppress catabolic pathways has 
been confirmed in more contemporary studies171.  
 
While the current study’s period of fasting was shorter than the over 24 hours of 
fasting in both studies, the direction of our findings, which showed that levels of FFAs 
were correlated with the %P in the diet, remain consistent with the direction of the 
earlier studies.  
 
Intriguingly, the changes to levels of FFAs lends support to the Protein Leverage 
Hypothesis.  As predicted by the PLH, the over-consumption of CHO and F in a low 
dietary P environment should lead to changes in the metabolic pathways that regulate 
body protein stores to favour processes that increase plasma levels of amino acids at 
the expense of breaking down stores of protein. If this were to occur, it would be 
marked by suppressed fasting levels of FFAs, as was demonstrated in our study. 
 
The post-prandial levels of FFAs did not significantly differ across the diet treatments.  
This was not unexpected as levels of FFAs have traditionally been assessed under 
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conditions of fast or after the infusion of metabolically active agents170-172 with little 
evidence supporting significant changes following the consumption of food.  It is only 
in T2DM, where post-prandial FFAs are increased by the underlying metabolic 
derangement from the condition, that there is a suggestion that post-prandial FFAs 
play a role in pathogenesis of cardiac disease173.  However there is no evidence to show 
that this process has any clinical significance in the absence of T2DM.   
 
No differences were found between the three diet treatments for fasting TC.  However 
post-prandial levels of cholesterol significantly differed according to diet treatment 
with the lowest levels on the 10% P diet (see table 2.11).  The 18% difference between 
the lowest to highest cholesterol AUC cannot be explained by any dietary variation in 
the breakfast meals as they did not vary according to food types or in the % F content 
(all 20%).  In addition, variation in the ingestion of food can be excluded as all of the 
participants consumed the entirety of their breakfasts within 15 minutes of 
commencing the Fixed Energy Meal Experiment. 
 
Studies174,175 that have examined the effects of consuming low fat meals (defined as 
≤35% F) on post-prandial fat and lipid metabolism have found generally reported that 
the fat content of the meal is correlated with post-prandial triglycerides rather than 
with post-prandial levels of total cholesterol.  However in a 2005 study176 that 
compared 6 weeks of feeding from diets that were isocaloric and fixed in % F (30%) but 
varying in % P (14% P vs. 25% P) the low-P diet was shown to be associated with a 
significantly higher (85%) post-prandial release of chylomicrons.   
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While our experiment did not measure cholesterol sub-fractions, the finding of higher 
post-prandial levels of total cholesterol on the lowest % P diet is not inconsistent with 
the results of the 2005 study.  However the strength of this putative relationship 
remains unknown as does whether the finding is associated with any clinical 
significance, although it should be noted that there exists a strong and well validated 
relationship between levels of total cholesterol and cardiovascular disease177. 
 
2.5.5  Additional comments: strengths, limitations and other issues 
 
It is inherent in their design that despite the best efforts of researchers, experimental 
dietary interventions do not reflect eating conditions experienced in the real world 
and food consumption is modified accordingly154.  Many aspects of our experimental 
protocols such as ad libitum food consumption, variety and the choice built into the 
food menu and the organising of subjects into small groups for the purposes of food 
consumption closely mimicked normal eating behaviours and this was done so that the 
obtrusiveness of the experimental protocols was reduced.  However, despite these 
efforts, for most of this study’s subjects it remained very obvious that they were 
involved in a scientific experiment. 
 
Compared to the large majority of single meal test studies that have been discussed in 
this chapter, one of the strengths of our protocol was the utilisation of same % P 
dietary treatment for 4 days prior to the start of the test.  This allowed for the 
standardisation of the pre meal-test dietary environment and improved the robustness 
of the findings. 
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One additional limitation to our study worth highlighting was the lack of overweight 
and obese subjects.  As can be seen in the baseline participant demographics, the 
subjects in our study were younger and leaner than the general population and 
whether our findings can be generalised to older, overweight and obese populations 
still needs to be determined. 
 
Related to the time intensiveness of the experimental protocol, we found that this 
aspect was a deterrent to potential subjects in paid employment and had the practical 
result of limiting recruitment to subjects with larger amounts of unstructured or 
leisure time, favouring the young (and lean).  Over the process of recruitment, it 
became evident that the numbers of potential subjects who were overweight and obese 
was much smaller than lean subjects, which would have reduced the statistical power 
to assess food intake in the overweight and obese so a joint decision was made by the 
investigators to not enrol overweight and obese subjects into the study.  
 112 
2.6  CONCLUSIONS 
 
The design of our experimental protocols allowed for a rigorous comparison of diet 
treatments that were made up of four days of ad libitum feeding and a fixed energy 
intake breakfast, which varied in their % energy intake by protein.   We found that the 
low protein diet treatment was associated with the highest levels of fasting ghrelin and 
lowest post-prandial levels of cholecystokinin.  Furthermore, changes to post-prandial 
levels of total ghrelin and to the fasting and post-prandial levels of insulin were 
demonstrated, which corresponded to the meal’s macronutrient composition.   
 
These results demonstrate that relatively modest increases to dietary protein are 
associated with changes to hormone secretion that broadly favour reduced hunger and 
increased post-prandial satiety, though it should be noted that no subjective changes to 
measures of hunger and appetite were found.   
 
Whether such changes are present, whether similar hormonal changes are present in 
the overweight and obese, and whether these hormonal changes are associated with 
alterations to body weight can only be answered with future research. 
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CHAPTER 3 
 
Testing the Protein Leverage Hypothesis in lean and obese 
mice 
 
 
3.1  INTRODUCTION 
 
3.1.1 Animal studies in the development of the Geometric Framework and 
Protein Leverage Hypothesis  
 
Simpson and Raubenheimer’s research in aphids178, locusts179,180 and grasshoppers86 
demonstrated that many different invertebrate species consumed food to meet targets 
for total energy intake and macronutrients.  Using this research, they developed a 
model of food intake which they termed the Geometric Analysis of Nutrient Intake 
later shortened to the Geometric Framework.  
 
In a series of articles181,182,87,183 they argued that their schematic representation of an 
animal’s food intake and dietary environment, which incorporated macronutrients as 
the vertical and horizontal axes, provided a unifying schema that not only took into 
account energy intake and dietary composition but also had the power to predict how 
changes to the availability of macronutrients would affect the animal’s food intake and 
body weight.  They concluded that the Geometric Framework model provided the 
theoretical underpinning to the evidence presented in their invertebrate studies, which 
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demonstrated that the intake of food was regulated not just by the energy content but 
also by the macronutrient content in the diet, with the priority being the intake of 
dietary protein (P). 
 
In 1997 Simpson and Raubenheimer published the Geometric Analysis of 
macronutrient selection in the rat87, the first vertebrate-based study to incorporate 
these ideas.  The authors re-examined previously published rat and food intake studies 
within the context of the Geometric Frameworks.  Two studies examined 12 isocaloric 
but differing macronutrient ratio food pairings184 and 12 low P vs. high P food 
pairings185 in young rats while a third study examined young to mature rats given a 
choice of diets that contained 100% pure macronutrients186.  Reviewing the data 
through the Geometric Framework, the authors demonstrated that ad libitum food 
intake is regulated by the intake of P and non-P macronutrients rather than by total 
energy content. 
 
In 2005, they published the Protein Leverage Hypothesis42 which developed these 
ideas further to posit that firstly, the intake of P was prioritised and regulated above 
the other macronutrients; secondly, that changes to the availability of dietary P 
resulted in changes in food intake and thirdly, a relatively small reduction in the 
availability of dietary P would lead, as the animal tries to meet their P target, to a 
significant increase in total food intake that in turn predisposes the animal to weight 
gain.  While the PLH remains a theory, if it is validated, there would be important 
implications for the study of the decades-old global trend of increased overweight and 
obesity. 
 115 
More detailed information on the Geometric Framework and Protein Leverage 
Hypothesis can be found in Chapter 2: Section 2.1.2.1-2 and Figure 2.1 for an 
illustration of the Framework. 
 
3.1.2  A mouse model for human obesity and testing the PLH  
 
The mouse has long been used as an experimental model for many human diseases 
and as it shares 99% of the same genetic material as humans this relationship remains 
just as relevant today187.  In the current context the C57BL/ 6J mouse has been 
identified as a strain that readily develops obesity, hyperinsulinaemia, hyperglycaemia 
and hypertension188 in response to the ready availability of a high fat diet189,190.  This 
Diet Induced Obesity (DIO) C57BL/ 6J mouse model has become a validated and 
widely used tool for the study of human obesity and the metabolic syndrome191. 
 
In the first published study that tested the Protein Leverage Hypothesis model 
prospectively, Sorensen et al192 carried out two concurrent proof of concept dietary 
experiments in young and lean C57BL/6J mice.  In the first experiment, the mice were 
provided with 20 days of an ad libitum diet that was made up of paired isocaloric foods 
which varied in the ratio of dietary P to non-P (9% P vs. 49% P, 9% P vs. 31% P, 17% P 
vs. 48% P and 23% P vs. 48% P).  The results showed that the mice regulated the 
consumption of their food by balancing the intake of the two different chows to reach a 
protein target of ~23% energy intake by P (hence abbreviated to X% P).   
 
In the second experiment separate groups of mice were fed one of the 5 diets varying in 
%P in a no-choice, ad libitum format for 32 days.  The results of this experiment 
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demonstrated that lower the ratio of P in the diet, the higher the intake of food, 
suggesting that mice consumed their food not to reach a caloric target but to maintain 
a target for P.  Taken together, these experiments demonstrated that food was eaten to 
prioritise dietary P and not caloric content, consistent with and predicted by the 
Protein Leverage Hypothesis.  
 
For the secondary outcomes of the study, no significant relationships between % P 
intake and body composition were found except for one in a subgroup of mice from the 
second experiment fed the 9% P diet, who developed a significantly higher % body fat 
than their littermates fed the higher % P diets.   
 
Previous studies in obese rats have demonstrated they balance their macronutrient 
intake under free choice conditions193 and that their body composition is affected by 
the macronutrient composition of fixed diets, with adiposity being related to the diet’s 
fat (F) and carbohydrate (CHO) content194.  However these studies did not focus on the 
role of dietary P, nor were they designed to test for protein leveraging carefully or to 
test whether the phenotype of the animal had effects on their macronutrient intake or 
body composition.   
 
Given the potential implications of the Protein Leverage Hypothesis in explaining the 
aetiology of the recent exponential increase in global rates of overweight and obesity, a 
carefully designed study to assess these issues in the obese animal is warranted. 
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3.1.3  The DIO mouse and the secretion of gut hormones and adipokines 
 
As the DIO C57BL/6J mouse is one of the major animal models for studying obesity, 
understanding the abnormalities that develop in the DIO C57BL/ 6J mouse to the 
secretion of key obesity related gut hormones and adipokines may shed light on the 
associated hormonal abnormalities in obese humans. 
 
In a longitudinal study by Bullen et al195 in C57BL/6J mice initially aged 3 - 5 weeks 
provided with ad libitum access to either standard chow (SC) (SC: %CHO| %P| %F: 
56%| 27%| 17%) or high fat chow (HFC) (HFC: 43%| 15%| 42%), it was demonstrated 
that HFC fed mice developed significant and progressive weight gain compared to their 
baseline weight and to the SC fed mice.  Changes to the circulating levels of 
adiponectin, insulin, and leptin were assessed over the course of the study.   
 
For adiponectin, by week 8 serum levels significantly differed, increasing two and 
three fold in the SC and HFC fed mice respectively, before falling (more rapidly in the 
HF group) back towards baseline.  Serum insulin levels doubled in HFC fed mice and 
by 8 weeks were significantly higher than levels in the SC fed mice.  Finally for serum 
leptin, both HF and SC fed mice developed increased serum leptin levels compared to 
baseline and by week 6, the levels in the HFC group were significantly greater than the 
SC fed group.  Interestingly there were no time or chow related changes of significance 
in the non-fasting levels of glucose, which remained relatively stable through the 10-
week study. 
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Perreault et al196 conducted a 20 week study in C57BL/6J mice aged 4 weeks fed either 
SC or HFC, for 16 weeks to create lean (LE) and obese (OB) phenotypes.  The mice 
were then fed either a low F or a high F diet and fasting and random levels of ghrelin 
were measured.  The authors reported that obesity was associated with reduced levels 
of fasting ghrelin and a reduced response to exogenously administered ghrelin but that 
weight loss in the OB mice restored their sensitivity to the effects of ghrelin.   
 
In another 10-week longitudinal study by Moesgaard et al197, female C57BL/6J mice 
aged 3 weeks at the start of the study were fed SC (%CHO| %P| %F: 63% | 26% | 11%) 
or HFC (27% | 16% | 59%) with changes to fasting and random levels of ghrelin, 
glucose and insulin the study end points.  While the HFC fed mice gained significantly 
more weight than SC fed mice, there were no differences found between the groups for 
fasted levels of ghrelin, glucose and insulin.  However, the HFC fed group had 
significantly lower random levels of ghrelin and higher levels of glucose. 
 
Varady et al198 examined alternative day caloric restriction vs. DIO feeding in 
C57BL/6J mice aged 3 weeks at start of the study.  After 7 weeks of intervention 
feeding, adiponectin levels were found to be inversely related to adiposity in all mice. 
 
In the first of two studies examining serum leptin in C57BL/6J mice, Van Heek et al199 
demonstrated that serum leptin was highest in the heaviest mice.  In the second study 
Shi et al200 showed that HFC fed C57BL/6J mice had significantly higher levels of 
leptin compared to littermates fed HFC but who then lost weight after being placed on 
a SC diet and a control group of SC fed mice.  The results of both studies clearly 
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demonstrated that DIO fed C57BL/6J mice develop hyperleptinaemia in response to 
weight gain, as seen in humans201. 
 
Studies utilising other rodent models of obesity such as the HFC fed obese Zucker 
rat202-204 and the OB/OB mouse205 have also consistently reported that obese 
phenotypes are associated with elevated levels of fasting leptin and reduced levels of 
fasting ghrelin. 
 
Given what is known about human physiology and the secretion of these same 
hormones (See Chapter 2 Section 2.1.3.2 for ghrelin, Section 2.1.3.4 for insulin and 
Chapter 4 Section 4.1.4.1 for adiponectin and Section 4.1.2.3 for leptin) it is apparent 
that the DIO fed obese C57BL/6J mouse exhibits the same hormonal response to the 
secretion of adiponectin, leptin, insulin and glucose as humans (though this may be 
less so with ghrelin). 
 
This suggests that it is valid to draw conclusions from the changes in the secretion of 
these hormones in response to an intervention in DIO C57BL/6J mice that may be of 
use in predicting responses in obese humans. 
 
It is hypothesised that obese mice, when presented with diets differing in percent P, 
will display the same protein prioritising behaviour as lean mice and preserve energy 
intake by protein over total energy intake.  As a secondary aspect in the study, it will be 
examined whether body composition and the secretion of glucose, adipokines and gut 
hormones are affected by diets that vary in P and whether these changes are modified 
by phenotype.   
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3.2  MATERIALS AND METHODS 
 
This experiment had two phases.  Phase I was the induction of obesity in half the 
available mice by six weeks of a high fat chow conditioning diet.  The primary aim of 
the study was examined in Phase II, which was to compare in obese and lean mice, 
their daily food intake of experimental diets that differed in % P.  The following 
secondary outcomes were assessed: body weight, body composition and fasting levels 
of glucose, ghrelin, adiponectin and leptin. 
 
3.2.1  Animals and Ethical Considerations 
 
50 inbred 8-week old C57 Black/ 6J male mice were ordered from the Animal 
Resource Centre, Canning Vale Western Australia.  However within the timeframe 
available to conduct the experiment, only 6-week old male mice were available and 
thus, these mice were used.  This strain of mice has been used in the previous PLH 
mouse study192 and develops obesity on feeding with a high F diet189.  
 
The number of mice used in this study was calculated paying attention to the principle 
of reduction, to ensure an adequately powered study while minimising animal wastage 
through the unnecessary processing of a larger number of animals. Power calculations 
demonstrated that 10 mice would be sufficient to detect a 10% difference in food 
intake. 
 
The study was carried out under the auspices of the Animal Ethics Committee, 
University of Sydney as Protocol Number: L02/10-2010/1/5375.  Resource and 
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equipment funding was provided by the grants awarded by the Sydney University 
Nutrition Research Foundation and Small Equipment Scheme of the School of 
Molecular Biosciences.   
 
Figure 3.1 presents the experimental protocol in diagrammatic form.  
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Figure 3.1 Overview of the study of the Protein Leverage Hypothesis in 
Obese mouse 
 
Legend  LE = lean, OB = obese, HFC = high fat chow, SC = standard chow,   
  LP = low protein, HP = high protein 
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3.2.2  Animal housing and husbandry 
 
The experiment was conducted in the Animal House of the School of Molecular 
Biosciences, University of Sydney.  Throughout the experiment, the mice were 
maintained at an ambient temperature of 24 – 26o C and a relative humidity of 53 – 
56% under a 12: 12 hour light-dark photoperiod.  Lights were turned on at 0730.  All 
the mice were housed on two shelves located in the same room with the position of 
their cages rotated randomly on a weekly basis.   
 
Each mouse was individually housed in a standard Macrolon Cage Type 2 (Length: 23 
cm, Weight: 17 cm, Height: 14 cm) and had ad libitum access to water.  A double layer 
of elephant filter (48 x 58 cm2) was provided for bedding material.  This was changed 
twice weekly.  Small metal rings, tissue paper and small cardboard tubes were attached 
or added to the cages to provide environmental enrichment and material for nesting.   
 
A purpose built food spillage collector made of clear plastic was placed into each cage. 
The collector allowed for an accurate assessment of food intake.  Food was placed into 
the grooves beside the water bottle and in order to eat, mice had to jump into the 
insert.  Food was otherwise out of reach.  This design allowed for the author to collect 
and measure all spilled or incompletely eaten food. See Figures 3.2 (a) and (b) 
below. 
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Figure 3.2 (a) Macrolon Cage Type 2 with insert and environmental enrichment.   
NB:    The red arrows show where mice sat inside of the insert in order to feed 
 
Figure 3.2 (b) Macrolon Cage Type 2 with insert, chow and water bottle 
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Before the intervention began, the mice had a seven-day period of acclimation during 
which they were kept under experimental conditions and provided with ad libitum 
access to standard chow.  Throughout the entire experiment, only two Animal House 
staff or the author handled the mice. 
 
3.2.3 Phase I:  Conditioning diets and the induction of obesity 
 
At the beginning of the first phase of the experiment, the 50 mice were randomly split 
into equal groups of 25 prior to the commencement of the conditioning diets.  
Randomisation was performed according to an open sourced HTML based program.  
One group of mice was provided with Standard Chow (SC) while the other group was 
fed High Fat Chow (HFC).  This was done to generate two phenotypes of mice:  Lean 
(LE) and Obese (OB).  During the Phase I/ conditioning diet period, all of the mice had 
ad libitum access to their chow, which was changed and refilled on a second daily 
basis.   
 
The SC conditioning diet was Irradiated VS Meat free Rat and Mice Diet by Speciality 
Feeds, Western Australia.  This diet had the following nutritional parameters:  Energy 
(E): 14KJ per gram with the content: %(E) CHO 59.4%, % P 23%, % F 12%. 
 
The HFC used was SF03-002 36% Fat Modification of AIN93G by Speciality Feeds, 
Western Australia.  This diet had the following nutritional parameters:  E: 22.8 KJ per 
gram with the content: % CHO 17.6, % P 15%, % F 59%. 
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During Phase I, the mice were weighed every seven days, which was performed by 
placing each mouse in a small wire-cage on top of a set of Mettle Toledo scales (PL602-
S, max load 601 g (grams); readability 0.01 g; repeatability 0.008g). To ensure 
standardisation of weighing and to minimise the distress of the mice, the procedure 
was carried out in the morning and on the same day of the week in staggered small 
groups of mice.   
 
At the beginning of the final week of Phase I (week 6) the special plastic feeding inserts 
(see Figure 3.2) were added to each cage in order to give mice an opportunity to 
familiarise themselves with the new feeding apparatus prior to the beginning of the 
experimental diets. 
 
At the end of the Phase I five mice fed SC and five mice fed HFC were randomly 
selected to be euthanised and their anthropometric data and body tissues collected 
(see Section 4.2.5 below for details).  This provided the opportunity for baseline 
measures (body composition, adiposity and fasting levels of glucose and hormones) to 
be established for both LE and OB mice prior to the experimental diets. 
 
3.2.4 Phase II:  Experimental diet treatments differing in percent Protein 
 
At the conclusion of the conditioning diets (end week 6) the experiment moved to 
Phase II, which involved two 2-week feeding periods where mice were provided with 
ad libitum access to one of two experimental diet treatments in a random order.  The 
1st Feeding period was weeks 7 and 8 while the 2nd Feeding period was weeks 9 and 10.  
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Prior to commencing Phase II, the remaining 20 mice from the LE group and 20 mice 
from the OB group were randomly split into two subgroups of equal size (10 mice) (i.e. 
the 20 LE mice into two sub-groups of n=10; the 20 OB mice into two subgroups of 
n=10) to allow for a comparison of the effect of the order of the experimental diet 
treatments. 
 
The experimental diet treatments consisted of custom manufactured High Protein 
(HP) or Low Protein (LP) chow.  The two experimental diet feeds were isocaloric but 
differed in % E by dietary P and were prepared according to the recipes reported by 
Sorenson et al192.  Manufacture was by Gordon’s Speciality Stock Feeds (Bargo NSW), 
who had prior experience in making the chow in 2007, when they prepared the same 
feeds following the same recipes for a published experiment that tested the Protein 
Leverage Hypothesis in mice (Personal correspondence; Simpson SJ 15th Dec 
2009206, Huang X, 29th March 2011). 
 
The experimental feeds were a semi-synthetic chow manufactured in the form of dried 
pellets and made up of the following ingredients:  casein, cornstarch, wheat starch, 
sucrose, sunflower oil, cellulose powder, a mineral mix and a vitamin mix.  Both 
isocaloric chows had a similar composition except for the ratio of casein to starch, 
which determined the % P content.   
 
The nutritional composition of the LP diet treatment was E: 3.8 kcal per gram with the 
content: % CHO: 71.8%, % P: 9% and % F: 7.8%.  The nutritional composition of the 
HP diet treatment was E: 3.8 kcal per gram with the content: % CHO: 57.4%, % P: 
23%, %F: 7.8%. 
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For both LE and OB mice, now split into two equally sized sub-groups of 10 mice, one 
sub-group was randomly allocated to start their 1st feeding period (14 days) with HP 
chow to be followed in their 2nd feeding period by LP chow.  The other sub-group was 
allocated the LP for their 1st feeding period followed by HP chow for their 2nd feeding 
period (see Figure 3.1 for details). 
 
During this phase of the experiment, the mice were weighed at the beginning and end 
of each week.  Fresh, pre-weighed portions of chow were placed into each mouse’s cage 
on a 2nd daily basis with enough food provided to ensure that mice had access to chow 
at all times.  The plastic feeding inserts were changed on a twice-weekly basis except 
during the cross-over period from HP to LP chow or vice versa.  At these times, before 
dispensing the new chow, all of the uneaten old chow was discarded (after weighing) 
and both the Macrolon cage and plastic insert changed.   
 
During each distribution of food the remaining chow (uneaten and spilled) was 
collected from inside the plastic insert and its weight tallied (Mettler Toledo PL602-S 
scales) before being discarded.  The intake of food for each mouse was calculated as the 
difference between food given and food remaining with the daily intake calculated by 
averaging food intake over 7 days (1/2 feeding period).   
 
At the end of Phase II and the experimental diet feeding (end week 10) all of the mice 
were euthanised and blood and body tissues collected (see Section 3.2.5 below).   
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3.2.5  Assessment of glucose, euthanasia and the collection of blood and 
   body tissues 
 
After an overnight fast where food but not water was removed by 1700 of the preceding 
day, the mice were euthanised.  At 0800, immediately prior to euthanasia, the mouse’s 
fasting blood glucose level was measured by the method of tail docking.  At least 0.6 uL 
of blood was applied to an Accu-Chek Performa Electrode strip attached to an Accu-
Chek Performa blood glucose meter (Roche Diagnostics Pty Ltd, Australia).  At the 
beginning (week 0), during the middle (week 6) and at end of the experiment (week 
11), the performance of the Accu-Chek Blood Glucose meter was assessed with 
reference to the Accu-Check Performa Control solution. 
 
The mice were individually euthanised in a room separated from their littermates to 
minimise their potential distress.  The author performed the euthanasia of all the mice 
and also performed all the procedural work to collect their blood and body tissues. 
 
Each mouse was killed by cervical dislocation.  Their weight was promptly recorded 
and immediately thereafter at least two millilitres of whole blood was collected by 
intra-cardiac puncture.  For plasma collection at least 1 mL of blood was placed into a 
K2-EDTA containing micro-container and for serum collection, at least 1 mL of whole 
blood was placed into a SST Gel micro-container  (BD Micro-containers with micro-
guard closure; Becton, Dickson & Company Diagnostic Pty Ltd, Australia).  The BD 
micro-containers were stored in a refrigerator (set at 2oC) for no longer than 20 
minutes before being centrifuged in an unrefrigerated device for five minutes at 
10,000RPM. The supernatant plasma or serum was transferred into individual 
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eppendorfs that were then placed into the freezer (-20oC) prior to their same day 
transfer to a specialised -80oC sample refrigerator.  Samples were kept in this unit 
until they were removed for biochemical or hormone analysis. 
 
For the final step of this process, each mouse was dissected following the validated 
Reed 1 project protocol207 to assess body composition and adiposity.  Firstly, the 
abdominal cavity was exposed.  Secondly the bilateral retro-peritoneal and peri-renal 
fat pads were identified and removed.  No attempt was made to isolate and discard 
vessels, ureters or the adrenal gland from the adipose tissue.  Thirdly, the gonadal fat 
pads were identified with reference to their proximity to the epididymis and vesicular 
gland and then resected.  Both groups of fat pads were weighed with total gonadal fat 
pad mass, total peri-renal fat pad mass and total abdominal adiposity recorded (the 
latter the sum of gonadal fat and peri-renal fat).  
 
3.2.6  Measuring Adiponectin, Ghrelin, Insulin and Leptin 
 
Adiponectin, total ghrelin, insulin and leptin were all measured by manual 
radioimmunoassay (RIA) technique.  The RIAs were performed over consecutive days 
with samples subjected to 4 or fewer freeze / thaw cycles.  All of the mice RIAs were 
kindly performed by senior hospital scientists with the Endocrinology Laboratory of 
Royal Prince Alfred Hospital, NSW (Ms. Marilyn Brown for adiponectin and leptin and 
Mr. Kim Lee for ghrelin and insulin).   
 
Controls and QCs were assayed in duplicate while unknowns were assayed as 
singletons.  However to assess the precision of the assays, at least 5% of the unknowns 
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were assayed in duplicate.  The intra-assay CV% from these duplicate samples were all 
<10%.  Further details regarding the methodology of RIAs can be found in Chapter 2, 
section 2.2.6. 
 
Adiponectin 
 
Mouse adiponectin was measured with the MADP-60HK kit (Millipore, Billerica, MA, 
USA).  As per the manufacturer’s product information statement (PIS)208 the minimal 
volume of plasma or serum for this assay is 5 µL of sample, which must be diluted 
prior to being processed.  4995 µL of assay buffer was added to 5 µL of the unknown 
sample, which prepared a 1:1000 dilution.  100 µL of the diluted unknown sample was 
then assayed.  Using 100 µL of a 1:1000 dilution, the stated recovery is 97-114% and 
the lowest level of adiponectin detectable by the assay 1 ng/mL.   The MADP-60HK 
assay has a 100% specificity for mouse and rat adiponectin and has an intra-assay 
precision of 3.73- 4.43 %CV and an inter-assay precision of 8.24 – 7.13 %CV (for 
sample concentrations of 3 and 12 ug/ml).  Figure 3.3 outlines the procedure for the 
mouse adiponectin RIA. 
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Figure 3.3  Outline of the Adiponectin RIA 
 
 
Plastic pointed tubes were prepared TOT, NSB, blank, the standard curve (0.78, 1.56, 
3.125, 6.25, 12.5, 25 and 50 ng/mL), low QC, high QC and for unknown samples.  Assay 
buffer was to the following tubes as follows: 300 uL to the NSB tube, 200 uL to the 
blank tube and 100 uL for each of the standards, QCs and unknown tubes.  Following 
this 100 uL of standards, QCs and 100 uL of the 1:1000 dilution of unknown serum 
samples were added to their respective tubes.  Next, 100 uL of iodinated ADP was 
added to all tubes followed by 100 uL of anti-ADP to all tubes except for the TOT and 
NSB tubes.  Finally, all of the tubes were vortex mixed, covered and incubated at room 
temperature (22-25oC) for 20-24 hours. 
 
On the second day 10 uL of rabbit carrier was added to all tubes except for TOT.  
Following on, 1000 uL of cold precipitating reagent was added to all of the tubes 
except for TOT.  The tubes were then vortex mixed, covered and incubated at 3.5oC for 
20 minutes.  The TOT tube was placed aside and the remaining tubes centrifuged (HD 
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Scientific / Hettich Zentrifuger Rotixa 50RS refrigerated centrifuge) at 4000g for 30 
minutes at 4oC.  After centrifuging, the tubes were decanted by inversion and placed 
onto absorbent paper with care taken to not dislodge the pellet at the bottom of each 
tube.  All tubes were then placed into the automatic gamma-counter and the ADP 
specific program selected to run.   
 
(Total) Ghrelin 
 
Mouse (total) Ghrelin was measured using the GHRT-89HK kit (Millipore, Billerica, 
MA, USA).  As per the manufacturer’s PIS151 this kit has a 100% specificity for rodent 
ghrelin.  50 µL of plasma is the minimal volume of unknown sample that can be 
assayed while still ensuring assay validity.  Further details regarding the RIA of ghrelin 
can be found in Chapter 2, Section 2.2.6.2. 
 
Insulin 
 
Mouse insulin was measured with the RI-13K kit (Millipore, Billerica, MA, USA).  As 
per the manufacturer’s PIS209, 50 µL of plasma or serum is the minimal volume that 
can be assayed to ensure assay validity.  The assay has an 100% specificity for mouse 
insulin with the lowest sensitivity at 0.1 ng/mL.  The intra-assay precision is 1.4 – 4.6 
%CV with the inter-assay precision 8.5 – 9.4 %CV using concentrations of insulin of 
0.5 – 3.7 ng/mL. The normal fasting range was reported to be 0.5-2 ng/mL.  Further 
details regarding the RIA of insulin can be found in Chapter 2, section 2.2.6.4. 
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Leptin 
 
Mouse leptin was measured using the ML-82K kit (Millipore, Billerica, MA, USA).  As 
per the manufacturer’s PIS210, 50 µL of plasma or serum is the minimal volume that 
can be assayed while ensuring assay validity.  The intra-assay precision is 4 – 11.2 %CV 
with the inter-assay precision 3.3 – 14.6 %CV using concentrations of leptin of 0.4 – 
5.4 ng/mL.  Figure 3.4 outlines the procedure for the mouse leptin RIA. 
 
Figure 3.4  Outline of the mouse leptin RIA 
 
 
Pointed polypropylene tubes prepared for TOT, NSB, blank, the standard curve of 
known concentrations of leptin (0.3125, 0.625, 1.25, 2.5, 5, 10 and 20 ng/mL), the low 
and high QCs and for the unknown samples.  Assay buffer was transferred into the 
NSB tube (300 uL), blank tube (200 uL) and into each of the tubes for standard curve, 
QCs and unknown samples (100 uL).  100 uL of standards, QCs or unknown samples 
were transferred into the corresponding tubes followed by 100 uL of mouse leptin 
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antibody to all tubes except the TOT and NSB.  The tubes were then vortex mixed, 
covered and incubated in the refrigerator at 3.5oC for 20 - 24 hrs. 
 
On the second day, 100 uL of iodinated mouse leptin was added to all of the tubes.  The 
tubes were then mixed, covered and incubated at 3.5oC for 22 - 24 hrs.   
 
On the third day, 1000 ul of cold precipitating reagent was added to all tubes except for 
the TOT, which was placed aside.  The tubes were vortex-mixed and incubated for 20 
minutes at 3.50C.  These tubes were then centrifuged at 3000g for 20 minutes at 4oC 
(HD Scientific / Hettich Zentrifuger Rotixa 50RS refrigerated centrifuge) with the 
supernatant decanted by carefully inverting the tubes onto absorbent paper.  All of the 
tubes were then placed into the automatic gamma counter and the mouse leptin 
specific program run. 
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3.3  DATA ENTRY AND STATISICAL ANALYSES 
 
Data was entered into a series of spread-sheets using Microsoft Excel 2008 for Mac 
(version 12.3.1 build 110725).  Following data entry, the computerised data underwent 
a cleaning cycle that consisted of cross-referencing spreadsheet figures back to the 
original source material.  All of the statistical analyses were performed using the IBM 
SPSS Statistics Version 19 software package (IBM Corp, NY, USA).  The author 
performed all of the data entry and all of the statistical analyses. 
 
Data was checked for normality through the Kolmogorov–Smirnov test and is reported 
as mean ± Standard Error Mean (SEM) unless otherwise stated. Statistical results were 
considered significant if p < 0.05 except when noted.  A sample size of 10 mice was 
calculated to provide 80% statistical power (α = 0.05) to detect a 10% difference in the 
primary end point, which was total daily energy intake. 
 
For the RIAs of adiponectin, ghrelin, insulin and leptin three data points (6% of the 
data) were missing due to insufficient volume of samples.  One data set for adiposity 
(2% of the data) was incomplete due to difficulties with dissection of the animal.  All 
the missing data sets have been treated as reversion to the mean.  There were no other 
examples of missing data.  
 
Between group differences in body weight, food intake, glucose, adiponectin, ghrelin, 
insulin and leptin were assessed by independent sample t-tests.  In addition, for food 
intake, within-group analyses were carried out using one-way within-subject repeat 
measures analysis of variance (ANOVA-RM).   
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Data was initially checked for sphericity using the Mauchlys sphericity test and if this 
was violated, the Greenhouse-Geiser correction was applied to the F and p values.  
When relevant, post-hoc analyses were calculated with the Bonferroni correction 
method applied for the multiple, pair-wise comparisons.  To assess for the effects of 
the order of the experimental diets, ordering was added as a co-factor to the ANOVA-
RM. 
 
As the mice supplied were younger than that originally planned and as the age of a 
mouse affects the degree of weight gain (see Section 3.5.2), a sub-group analysis was 
conducted out of body weight and food intake data from the top and bottom quartile of 
mice for weight.  This was carried out to ensure that the direction of the findings for 
the overall cohort remained consistent to that of mice at the extremes of body weights. 
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3.4  RESULTS 
 
3.4.1  Phase I: The conditioning diet and the induction of obesity 
 
Table 3.1 shows results for weight at the beginning and conclusion of the conditioning 
diets.   
 
Figure 3.5 displays the mean weekly weight during the period of the conditioning 
diets.  All figures presented as mean + SEM. 
 
Table 3.1  Body weight before and after conditioning diets for LE and OB 
   mice 
Weight (gms) LE mice OB mice Analyses 
Pre conditioning diet 
(week 0) 
23.57 ± 0.27 24.02 ±0.28 p = 0.25 
Post Conditioning diet 
(week 6) 
26.37 ± 0.3 27.70 ± 0.36 p = 0.001 
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Figure 3.5  Mean weekly weight during Phase I/ conditioning diets 
 
 
Mean weight was assessed at the beginning and end of Phase I.  At the beginning there 
were no significant differences for weight mice (Feed/Group: Weight (gms); SC/LE: 
22.8 ± 0.27; HFC/OB: 23.5 ±0.28; p=0.25).  By the end of Phase I the OB mice were 
significantly heavier than the LE (+5% or +1.33 gms, p = 0.01). 
 
Significant within-group differences were also found for both LE and OB mice when 
weight at the beginning was assessed against weight at the end of the conditioning 
diets.  (Δ Wgt (gms): LE: +3.6 ± 0.21, p <0.0001; OB: +4.2 ± 0.16, p <0.0001).   
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3.4.2 Phase I baseline measures: body composition, fasting glucose, 
adiponectin, total ghrelin and leptin 
 
Baseline measures  
 
These results were derived from the 5 LE and 5 OB mice sacrificed at the end of the 
conditioning diet.  The LE mice were significantly lighter and (non-significantly) 
increased total-abdominal adiposity with significantly lower levels of fasting leptin and 
a trend towards higher levels of adiponectin.  Table 3.2 shows baseline results for LE 
and OB mice. 
 
Table 3.2  Baseline characteristics at the end of the conditioning diet:  
   LE and OB mice 
Group / 
Measures 
LEAN 
N=5 
OBESE 
N=5 
Analyses 
Length (mm) 80.8 ± 0.8 84.4 ± 1.7 p >0.1 
Weight (gms)  24.7 ± 0.7  27.9 ± 0.7 * p = 0.01 
Abdominal adiposity (gms) 0.6 ± 0.1 0.7 ± 0.1 p >0.1 
Glucose (mmol/L) 6.0 ± 0.4 6.5 ± 0.3 p >0.1 
Adiponectin (µg/mL) 44.6 ± 9.0 17.9 ± 1.7 p = 0.07 
Total ghrelin (ng/mL) 5.9 ± 1.5 4.9 ± 1.1 p >0.1 
Insulin (ng/mL) 0.9 ± 0.2 1.4 ± 0.3 p >0.1 
Leptin (ng/mL)  2.9 ± 0.4  4.8 ± 0.2  p = 0.006 
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3.4.3  Phase II:  experimental diets and food intake 
 
Table 3.3 presents Food Intake (FI) and Energy Intake per diet treatment per mouse 
for LE and OB mice. 
Table 3.4 presents mean daily FI according to diet treatment order for the subgroups 
of LE and OB mice.  
Table 3.5 presents total FI per chow per feeding period for LE and OB mice. 
 
Figure 3.6 displays total FI per feeding period for the LE and OB mice.   
Figure 3.7 shows FI per ½ week and according to diet treatment order for LE and OB 
mice. 
 
Over the 2 feeding periods (each 2 week duration) of Phase II / experimental diet 
feeding, both phenotypes consumed a greater intake for LP chow compared to HP 
chow.   
 
Mean Food Intake per feeding period per mouse for LP chow vs. HP chow was:  
LE mice: 53.8 vs. 47 gms / +14% LP chow/ 204.4 vs. 178.6 kcals; p <0.0001. 
OB mice: 56.3 vs. 51.2 gms/ +10% LP chow/ 213.9 vs. 197.0 kcals; p <0.001. 
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Table 3.3  Phase II Experimental Diets: Food and Energy Intake per mouse  
 
Food Intake 
(gms)/ 
Energy Intake 
(kcal) 
LEAN 
N=20 
OBESE 
N=20 
LP chow 
(N=20) 
HP Chow 
(N=20) 
LP Chow 
(N=20) 
HP Chow 
(N=20) 
Mean FI per mouse 
1st Feeding period  
24.3 ± 1.6 23.3 ± 1.6 27.6 ± 1.6 24.9 ± 1.5 
Mean FI per mouse: 
2nd Feeding period 
29.5 ± 1.5 23.7 ± 1 28.7 ± 1.7 27 ± 1.4 
Total FI per mouse 53.8 ± 2.7 47.0 ± 2.8§ 56.3 ± 3.6 51.2 ± 3.2¥ 
Total EI per mouse 204.4 ± 10.4 178.6 ± 10.6 213.9 ± 13.6 197.0 ± 12.2 
Statistical Differences:  ¥ = p <0.001   § = p<0.0001 
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Table 3.4  Mean daily FI by week per diet treatment order for LE and  
   OB mice 
 
Mean Daily 
Food Intake 
(gms) by week  
LEAN 
N=20 
OBESE 
N=20 
Subgroup  
LP –> HP 
N=10 
Subgroup 
HP –> LP 
N=10 
Subgroup 
LP –> HP 
N=10 
Subgroup 
HP –> LP 
N=10 
Week 7 LP 3.3 ± 0.1 HP 3.1 ± 0.1 § LP 4.0 ± 0.1 HP 3.7 ± 0.1 § 
Week 8 LP 3.5 ± 0.1 HP 3.4 ± 0.1 § LP 3.8 ± 0.1 HP 3.4 ± 0.1 § 
Week 9 HP 3.4 ± 0.1 LP 4.3 ± 0.1 § HP 3.9 ± 0.1 LP 4.2 ± 0.1 § 
Week 10 HP 3.3 ± 0.1 LP 4.1 ± 0.1 § HP 3.7 ± 0.1 LP 4.4 ± 0.1 § 
Statistical Differences:  For both groups:  Within-group weight vs. Time § = p <0.0001 
 
Figure 3.6  Total FI per ½ feeding period (1 week) per chow for (a) LE and 
   (b) OB mice 
 
(a) LE mice      (b) OB mice 
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For LE mice in detail:  Analyses indicated significant differences for the total intake of 
LP vs. HP chow and for averaged daily FI per week.  The latter remained significant 
after the order of diet treatments was added as a co-factor to the analyses: F (3, 1.2) = 
20.9, p <0.0001.   
 
For OB mice in detail:  Analyses also indicated differences for total intake of LP vs. HP 
chow and for averaged daily FI per week, which also remained significant after the 
order of diet treatments was added as a co-factor to the analyses:  F (3, 0.7) = 24.26,  
p <0.0001.   
 
Effects of the order of the diet treatments 
 
Table 3.5  Total FI per chow according to feeding period for all LE and  
   OB mice 
 
Total Food Intake 
(gms) 
LEAN 
N=20 
OBESE 
N=20 
LP HP LP HP 
1st Feeding Period  485.3 465.6 551 497 
2nd Feeding Period 589.8 473.2 573.8 539.6 
Total FI (2 feeding 
periods) 
1063.1 951.3 1124.8 1036.6 
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Figure 3.7  Food Intake per 1/2 week according to treatment order for  
   (a) LE and (b) OB mice 
 
(a) LE mice 
 
(b) OB mice 
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The magnitude of the difference between the intake of LP and HP chow was affected by 
the order in which the feeds were presented.  In particular, a greater increase in LP 
chow was seen when the diet treatment order was HP then LP than vice versa.  This 
also meant that when either LP or HP chow were given in the 2nd Feeding Period (i.e. 
weeks 9 and 10), a greater amount was consumed.   
 
However, the differences in total food intake and mean averaged daily intake per week 
remained significant even after the order of the diet treatments was added as co-factor 
to analyses.   
 
This phenomenon can be seen in Tables 3.4 and 3.5 and with particular reference in 
Figure 3.7 by comparing the mean FI per diet treatment by feeding periods. 
 
3.4.4  Phase II:  Experimental diets and body weight 
 
Table 3.6 presents weight over time during the period of experimental diets.   
 
Figures 3.8 and 3.9 display the changes in weight per subgroup of LE and OB mice 
according to the experimental diet. 
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Table 3.6  Phase II:  mean weight per week for LE and OB mice 
 
Phase II per 
week:  
Weight (gms) 
LEAN 
N=20 
OBESE 
N=20 
Week 7  25.7 ± 0.4 § 27.1 ± 0.4 § 
Week 8 25.8 ± 0.4 § 27.1 ± 0.4 § 
Week 9 27.0 ± 0.4 § 28.6 ± 0.4 § 
Week 10 27.3 ± 0.4 § 29.1 ± 0.5 § 
Statistical Differences:  For both phenotypes within group weight vs. time § = 
p<0.0001 
 
Figure 3.8  Phase II:  ∆ Weight per week per chow for    
   (a) LE mice and (b) OB mice 
 
(a) LE mice     (b) OB mice 
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Figure 3.9  Phase II: Weight vs. time per treatment order for   
   (a) LE and (b) OB mice  
 
(a) LE mice 
 
(b) OB mice 
 
NB: Experimental diet treatments switched over at Week 8 
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At the beginning of Phase II, there were no significant within group differences for 
weight. By the end of the 2 feeding periods, when weight over time was assessed, both 
groups had gained weight over Phase II (LE +1.6gm, +6%, OB: +2g, +7%; unadjusted p 
<0.0001) but when diet treatment order was added as a co-factor to the analysis, the 
weight changes only remained significant for the OB group.    
 
For LE mice: Weight over time was significantly different but when diet treatment 
order was added as a co-factor to the analysis, differences were no longer significant 
(adjusted F (3, 0.9) = 0.3, p =0.8). 
 
For OB mice: when week over the time was assessed, a significant difference was found 
which remained significant after diet treatment order was added as a co-factor: 
(adjusted F (1.96, 1.70) = 3.29, p =0.03 with the Greenhouse-Geisser correction).  
 
3.4.5  Phase II:  Experimental Diets and Secondary Outcomes 
 
When considering secondary outcomes by the end of Phase II, the LE mice weighed 
less, were shorter and had higher levels of adiponectin than the OB mice. 
 
Tables 3.7 and 3.8 show the secondary outcomes at the end of Phase II per 
phenotype and according to the order of the diet treatments respectively. 
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Table 3.7  End of Phase II: Secondary measures per phenotype 
 
Group /  
 
Measures 
LEAN 
N=20 
OBESE 
N=20 
Analyses 
Length (mm) 81.9 ± 0.5 84.0 ± 0.6 p = 0.02 
Weight (gms) 26.6 ± 0.3  28.3 ± 0.5 p <0.01 
Total Abdominal 
Adiposity (gms) 
0.7 ± 0.1 0.8 ± 0.1 p = 0.45 
Glucose (mmol/L) 6.7 ± 0.3 6.9 ± 0.2 p = 0.53 
Adiponectin (µg/mL) 59.0 ± 7.9 37.7 ± 4.4  p <0.01 
Total Ghrelin (ng/mL) 9.3 ± 0.8 9.4 ± 0.8 p = 0.97 
Insulin (ng/mL) 1.0 ± 0.1 1.3 ± 0.2 p = 0.22 
Leptin (ng/mL)  6.7 ± 0.6 7.8 ± 0.6 p = 0.16 
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Table 3.8  End of Phase II: Secondary measures according to order of  
   diet treatments 
Group / Treatment 
order 
 
Measures 
LEAN 
N=20 
OBESE 
N=20 
LP –> HP 
N=10 
HP –> LP 
N=10 
LP –> HP 
N=10 
HP –> LP 
N=10 
Length (mm) 80.8 ± 0.6 83.0 ± 0.8 * 84.9 ± 0.6 83.0 ±1.0 
Weight (gms) 26.0 ± 0.4 27.1 ± 0.4 28.9 ± 0.7 27.7 ± 0.6 
Abdominal Adiposity (gms) 0.6 ± 0.1 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 
Glucose (mmol/L) 6.2 ± 0.3 7.1 ± 0.4 6.3 ± 0.4 7.4 ± 0.2 * 
Adiponectin (µg/mL) 83.6 ± 8.5 65.0 ± 7.3 28.4 ± 3.3  46.9 ± 7.1 * 
Total Ghrelin (ng/mL) 7.6 ± 0.9 11.0 ± 1.1 * 9.8 ± 1.4 8.9 ± 0.7 
Insulin (ng/mL) 1.1 ± 0.2 0.9 ± 0.2 1.4 ± 0.3 1.1 ± 0.2 
Leptin (ng/mL)  5.2 ± 0.5 8.1 ± 0.8 ¥ 7.5 ± 1.0 8.1 ± 0.6 
Statistical Differences: All p>0.05 except for: * p <0.05 ¥ p <0.01 
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3.4.5.1  Anthropometric Measures 
 
In detail, when between phenotype comparisons were made of the anthropometric 
measures at the end of Phase II, all measures were greater for the OB mice but only for 
two reached significance:  length (∆ LE vs. OB: -2.1 ± 0.8 cm, p=0.02) and weight (∆: -
1.7 ± 0.6 gm, p <0.01).  All of the other anthropometric measures non-significantly 
favoured the OB mice (see Table 3.7). 
 
Within group analyses were performed to determine if there were any effects from the 
order of the diet treatments (see Table 3.8).   
 
For the LE mice significant differences were found for length (p=0.04) and gondal fat 
pad mass (p = 0.02), which favoured the HP -> LP fed group.  There were also non-
significant trends for weight (p = 0.07) and peri-renal fat pad mass (p = 0.07) which 
also were greater for the HP -> LP group. Total abdominal adiposity (p = 0.19) also 
favoured the HP -> LP group but was not significant.   
 
For the OB mice when the anthropometric measures were analysed according to the 
order of the diet treatments, the differences were greater for the LP -> HP sub-group 
although all were non-significant.  
 
Finally, when measures at the end of Phase II were compared to baseline (see Tables 
3.2 and 3.6), for the LE mice the changes were greater for the Phase II mice but only 
body weight (p = 0.02) and gonadal fat pad mass (p = 0.02) were significant.  For the 
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OB mice while all measures favoured the Phase II mice, no significant differences were 
found except a non-significant trend for gonadal fat pad mass (p = 0.07). 
 
3.4.5.2 Glucose, adiponectin, ghrelin, insulin and leptin  
 
When between phenotype comparisons were made of these measures at the end of 
Phase II, all measures, except adiponectin, were higher in the OB group but only the 
difference for adiponectin was significant (p = 0.001) (See Table 3.7).  
 
Within-group analyses based on the order of the diet treatments (see Table 3.8) 
demonstrated for the LE mice significant differences for ghrelin (p = 0.04) and leptin 
(p <0.01), which favoured mice fed HP chow first.  The non-significant differences for 
adiponectin and glucose also favoured HP -> LP feeding while the non-significant 
difference for insulin favoured LP -> HP feeding.  
 
For the OB mice, BGL (p = 0.02) and adiponectin (p = 0.03) were significantly higher 
in the mice fed LP chow first with leptin also (non-significantly) favouring the HP -> 
LP group. The non-significant differences for ghrelin and insulin favoured the LP -> 
HP group.   
 
Finally on comparisons of Phase II to baseline (see Tables 3.2 and 3.6), for the LE 
mice all differences favoured the Phase II mice but only leptin (p = 0.003) was 
significant.  Trends towards difference were noted for adiponectin (p = 0.06) and 
ghrelin (p = 0.07).  
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For the OB mice all differences were greater in the end Phase II mice (except for 
insulin) but significant differences were found for ghrelin (p = 0.01) and leptin (p = 
0.01) only with a non-significant trend towards difference also noted adiponectin (p = 
0.07).  
 
3.4.6  The “Top 10” mice:  A re-analysis of the 10 most obese versus the 
  10 leanest mice 
 
Data from the bottom and top quartile of mice for weight, which were the 10 leanest 
mice from the LE group and the 10 heaviest mice from the OB group (hence “Top 10” 
mice), was used in a sub-group analysis.  The “Top 10” mice were re-analysed to 
reassess differences in food intake during Phase II and differences in body weight.   
 
The weight and food intake data from the “Top 10 mice” re-analyses are presented in 
Tables 3.9 and 3.10 respectively. 
 
Selection of the Top 10 lean and obese mice was based on their weight at the end of 
Phase I (week 6, end of the conditioning diet).  For each group of Top 10 mice the five 
leanest or most obese mice were selected from each the subgroups (5 from subgroup: 
LP -> HP and 5 from subgroup: HP -> LP).   
 
The results from the re-analyses are congruent with the results from the main analysis; 
namely that for both phenotypes there was greater consumption of LP chow compared 
to HP chow although compared to the main analyses, there was an increased 
leveraging effect for the LE mice but a decreased effect in the OB mice. 
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Mean Food Intake per feeding period per “Top 10” mouse for LP chow vs. HP chow 
was:  
LE mice: 53.4 vs. 44.0 gms / +16.2% LP chow/ 203.1 vs. 174.8 kcals; p = 0.001. 
OB mice: 57.0 vs. 53.4 gms/ +7% LP chow/ 216.6 vs. 202.8 kcals; p = 0.02.   
 
Table 3.9  Weight of the LE10 and OB10 mice 
Weight  
(gms) 
LE10 OB10 Analyses 
Pre-conditioning diet 
(week 0) 
22.1 ± 0.2 24.0 ± 0.3 p <0.0001 
Post-conditioning diet 
(week 6) 
24.8 ± 0.5 29.1 ± 0.3 p <0.0001 
 
Table 3.10  Mean daily food intake per mouse for the LE10 and OB10 mice  
Mean Daily Food 
Intake (gms) 
LE10 OB10 
LP - HP HP - LP LP - HP HP - LP 
Week 7 LP 3.3 ± 0.1 HP 3.2 ± 0.1 
¥ 
LP 4.1 ± 0.1 HP 3.9 ± 0.1 § 
Week 8 LP 3.3 ± 0.1 HP 3.5 ± 0.2 
¥ 
LP 3.8 ± 0.1 HP 3.5 ± 0.2 
§ 
Week 9 HP 3.2 ± 0.1 LP 4.3 ± 0.1 ¥ HP 3.9 ± 0.1 LP 4.4 ± 0.2 § 
Week 10 HP 3.2 ± 0.1 LP 4.1 ± 0.1 ¥ HP 3.8 ± 0.1 LP 4.0 ± 0.2 § 
Statistical Differences: Mean daily Food Intake over time:  ¥ p<0.01 § p<0.0001 
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3.4.6.1 “Top 10”: Body weight and adiposity 
 
The mean weight of the LE and OB Top 10 mice (LE10 and OB10), taken at week 1 prior 
to the beginning of the conditioning diet, was compared and found to significantly 
differ by +9%, favouring the OB10 (LE10 vs. OB10: 22.1 ± 0.2 vs. 24.0 ± 0.3 gms, ∆wgt 
+1.9 gms; p <0.0001).   
 
By the end of the Phase I the LE10 mice had increased their weight by 13% while the 
OB10 mice had increased by 21%.  On a direct comparison of weight, the OB10 were 17% 
heavier than the LE10 mice (24.8 ± 0.5 vs. 29.1 ± 0.3 gms, ∆wgt +4.3 gms; p <0.0001) 
and had greater adiposity (defined as total fat pad mass), which was just not significant 
(0.7 ± 0.1 vs. 1.1 ± 0.2 gms, ∆total adiposity +66%, p = 0.05). 
 
“Top 10” vs. Baseline weight and adiposity 
 
Weight and total abdominal adiposity for the Top 10 mice were compared to the 
baseline (obtained from the five LE and five OB mice culled at the end Phase I).  For 
the LE10 there was a non-significant trend towards greater weight and a non-
significant increased adiposity (LE10 ∆wgt +1.8 gms, p = 0.06, ∆total adiposity +0.05 
gms, p = 0.2). For the OB10 there was a significant increase in weight and a non-
significant increase in total adiposity (OB10 ∆wgt +4.1 gms, p = 0.01, ∆total adiposity 
+0.3 gms, p = 0.4).  No other secondary outcomes were reassessed. 
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3.4.6.2 “Top 10”: Experimental Diets and Food intake 
 
The intake of the experimental diets over time were re-analysed for the “Top 10” mice.  
Like in the main analyses, for both groups mean daily intake over time differed as did 
total intake over both feeding periods, both of which favoured LP chow.  The increase 
in LP chow intake remained more prominent in the LE group.   
 
In detail, for the LE10 group, both the total intake per chow (p = 0.001) and the mean 
daily food intake over time were significantly different.  The latter remained so after 
diet treatment order was a co-factor in the analysis (F (1.4, 1.2) = 11.63, p <0.003).  
Post-hoc analyses confirmed that the main significant differences were between the 
intakes of week 7 vs. 9 (I – J = -0.5, p = 0.001), 7 vs. 10 (I – J = -0.41, p = 0.002).  
 
For the OB10 mice, both the total intake per chow (p=0.02) and mean daily intake over 
time were significantly different with the latter remaining so after diet treatment order 
was added as a co-factor to the analysis (F (3, 0.5) = 23.0, p <0.0001).  Post-hoc 
analyses confirmed that main differences in the mean daily intakes were for weeks 7 
vs. 8 (I – J = 0.3, p = 0.02), 7 vs. 9 (I – J = -0.3, p = 0.01), weeks 8 vs. 9 (I – J = -0.5, p 
<0.0001) and 8 vs. 10 (I – J = -0.3, p = 0.04).  
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3.5  DISCUSSION 
 
The aim of this study was to determine whether obese mice, as lean mice do, prioritise 
their intake of food according to the P content.  In a two-phased experiment, the first 
phase was the generation of two phenotypes of C57BL/ 6J mice, lean and obese, 
through 6 weeks of conditioning diets.  It was demonstrated that under ad libitum 
feeding conditions obese mice, like their lean littermates, consumed significantly more 
low protein (LP) than high protein (HP) chow and as the experimental chows were 
isocaloric, this meant that while on the LP chow, both phenotypes significantly 
increased their energy intake.   
 
These findings supports the main concept of the Protein Leverage Hypothesis42, which 
is that the dietary P is prioritised, even at the expense of increasing caloric intake and 
that this occurs in obese as well as lean animals.  The finding was emphasised by 
consideration of the results from mice at the extremes of weight, the leanest and most 
obese. 
 
We also found that during the feeding of the experimental treatments, modest 
increases in body weight were reported for both phenotypes though the order of the 
experimental diets moderated the changes for the lean mice.  Finally for both 
phenotypes greater bodyweight was associated with increased fasting levels of leptin 
and ghrelin and for OB mice decreased levels of adiponectin.   
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3.5.1  Protein Leveraging in obese mice 
 
As this experiment is among the first to test the Protein Leverage Hypothesis in an 
obese phenotype prospectively we took care to follow the experimental protocols laid 
out in Sorensen et al192.   This included using the same strain of mouse and the same 
protein-content modified bespoke chow manufactured according to the recipes laid out 
by a proposer of the Hypothesis. 
 
Both phenotypes of mice ate more low P chow than high P chow, thus prioritising their 
intake of P at the expense of increasing their energy intake (see Section 3.4.3, Table 
3.3 and Figure 3.6).  These findings, which support the Protein Leverage 
Hypothesis, have not previously been reported in the literature. 
 
The PLH also predicts that adverse consequences will arise from the long-term 
consumption of lower P diets.  As the animal must sustain a trade-off of increased 
energy intake to meet their P targets, unless this is matched by a similarly sustained 
increase in the animal’s energy expenditure, weight gain will result.  In our study the 
weight changes over the period of the experimental diets were modest and only 
significant for the lean mice.  However the period of feeding of the low P diets was of 
short duration and the cross-over design may have mitigated against larger changes in 
weight.   
 
While overall obese mice consumed more of both chows than their lean littermates, 
when the differences in energy intake between LP to HP chow were considered, for the 
lean mice it was +14% while for the obese mice only +10%.  Whilst acknowledging that 
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a 4% relative difference is relatively modest, this suggests that obesity may blunt 
protein leveraging.   
 
Interestingly, the “Top 10” sub-analysis showed a larger leveraging effect (+16%) for 
the 10 leanest mice but a reduced effect (+7%) for the 10 fattest mice.  This widened 
the relative differences in protein leveraging between the phenotypes to 9% and lends 
support to the idea that protein leveraging is blunted by obesity.  This intriguing 
finding should be reassessed in longer-term studies of obesity and if borne out would 
have important implications in regards to dietary management in obesity. 
 
3.5.2 Caveats:  Diet Induced Obesity, puberty, the order of the diet treatments 
and variety in the diet 
 
Diet Induced Obesity 
 
Whilst at the end of the conditioning diet the OB mice were significantly heavier than 
the LE mice, the absolute difference in body weight (+1.3 gms/ +5.1%) was relatively 
modest. 
 
Three studies190,191,199 that validated the high fat diet/ diet induced obesity C57BL/ 6J 
mice model for diabetes and cardiovascular disease research tracked weight changes 
for mice fed HFC and SC for up to six months.  Reporting on mice aged 5-8 weeks at 
the beginning of the studies, the studies showed that the changes in weight in the HFC 
groups consisted of three phases:  the first was accelerating weight gain that peaked at 
12 - 15 weeks of feeding, the second was decelerating but still above control group 
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weight gain until 20-24 weeks of feeding with the third being plateaued weight changes 
from 25 weeks onwards.   
 
During the first 6 weeks of HFC feeding, all three studies reported modest but 
significantly increased weight, as in this study. 
 
Another comparator against which the OB mice should be referenced are the weight 
tables published by the Jackson Laboratory, the originator of C57BL/ 6J strain of 
mice211.  When referenced against the corresponding weight-for-age table for male 
C57BL/6J mice fed standard chow, our OB mice were on average +7% heavier.   
 
Thirdly, the “Top 10” subgroup re-analyses of the heaviest and leanest 10 mice 
demonstrated not only the expected larger differences in weight by end of the 
conditioning diet (+4.3 gms / +17%) but more importantly that the direction of the 
findings for food intake on the experimental diets were the same as the main analyses.  
 
Taken together, these additional findings increases confidence that the weight 
trajectory for the HFC fed mice in this study was as expected in the literature.  It also 
follows that our conclusion of a reduction in protein prioritisation among the OB mice 
may indeed be due to the differences between the phenotypes, although this needs to 
be borne out in future studies.  
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Acclimatisation, puberty and the order of the diet treatments & variety 
 
In this study both groups of mice clearly ate to a dietary target for P but the magnitude 
of leveraging in both phenotypes was less than the 15% difference in energy intake 
between the chows reported by Sorensen et al192.  While obesity itself may impact on 
protein leveraging, there are three other explanations for this discrepancy.  
 
Acclimatisation 
 
Firstly, Sorensen et al. reported that the results from their first experiment (two choice 
diet of high and low P chow) revealed conflicting shifts in eating patterns that only 
became evident by day 20.  In the groups offered 9% P vs. 31% P or 48% P the shift 
favoured an increased intake of the low P chow while for the groups offered 17% P vs. 
48% P and 23% P vs. 48% P the shift favoured the higher P food.  In the second (no-
choice diets) experiment mice offered 9%P chow also increased their intake ½ way 
through the 32-day experiment.  These changes in the eating pattern of the mice were 
thought to represent acclimatisation and increased familiarity with the chow which our 
shorter period of experimental diet feeding (14 days vs. 32 days) mitigated.  The net 
result may have been a reduction of the differences in food intake.   
 
Puberty 
 
Secondly, male rodents are known to alter their preferences for macronutrients as they 
experience and then leave puberty186.  To meet the increased metabolic demands of 
this period, there is a marked peak in the intake for P, increased F intake and a relative 
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decrease in the intake of CHO at puberty then for two weeks following puberty, this 
changes again with the intake of CHO increasing at the expense of F and to a lesser 
extent P.  Afterwards, macronutrient preferences stabilise and thereafter remain 
relatively steady. 
 
The C57BL/ 6J mice used in the PLH experiments reach puberty between the ages of 5 
to 8 weeks with puberty lasting 1-2 weeks212.  The current study protocol sought to 
avoid the known puberty associated changes in macronutrient preferences by starting 
the study with mice aged 8 weeks.  By providing them with a week of acclimatisation 
and 6 weeks of conditioning diet the mice would have been aged ~15 weeks before the 
start of the experimental feeds, which was deemed to be old enough to be well beyond 
any lingering puberty related effects on appetite.   
 
However due to logistical issues with the supplier the mice received were aged 5 to 6 
weeks at the start of the study which resulted in the mice being 12 to 13 weeks of age at 
the start of the experimental feeding and therefore, within the window of post-puberty 
related appetite changes.   
 
Mitigating this is that puberty related appetite changes favour increased CHO intake at 
the expense of F and P whilst in our study, a reduced leveraging effect was noted 
compared to Sorensen et al192.  Indeed, and as acknowledged by the authors, puberty 
related changes in food preferences may have enhanced the degree of protein 
leveraging reported in the original study and our findings of 10 - 14% differences in 
energy intake may represent a truer measure of protein leveraging in the adult mouse. 
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The effects of diet order and variety  
 
Thirdly a phenomenon not seen in the original study was observed; the total intake for 
either chows was lower when it was given in the 1st feeding period compared to when it 
given in the 2nd feeding period (see Section 3.4.3: Table 3.5 and Figure 3.7).  This 
treatment ordering effect was only observed because we utilised a cross-over diet 
design in the experimental protocol. 
 
The ordering effect was noted in both phenotypes of mice and had an unclear net 
result on protein leveraging.  While the differences in energy intake were at least twice 
as great in the subgroups of mice given HP chow first compared to those given the 
chows in reverse order (hereby enhancing protein leveraging), this should be balanced 
against the groups given LP and then HP diets, which may have resulted in an 
increased intake of the HP chow thereby reducing the extent of dietary P prioritisation.   
 
However as the overall direction of food intake demonstrated an increased intake of LP 
chow regardless of treatment order and as the statistical analyses took treatment order 
into consideration, we can remain confident in the conclusion that the prioritising of 
protein over total energy intake is a genuine phenomenon.   
 
One explanation of the ordering effect is to consider the role that choice in food plays 
in regulating appetite and food intake.  There is evidence that animals and humans 
prefer variety in their choice of food and respond to an increased number of food 
options by increasing total energy consumption.  This in turn is associated with an 
increased risk of overweight and obesity213.
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In a major review of this topic, Raynor and Epstein214 summarised the relevant animal 
and human studies that have examined the role of variety and increased palatable food 
choices and their effects on food intake, weight and body fat to postulate that sensory-
specific satiety exists and influences food intake.  They argued that the sensory 
characteristics of food are more powerful than the food’s energy density or 
macronutrient content and that this influences the development of overweight and 
obesity.  More recently Remick et al215 reviewed the subsequent research and while 
acknowledging methodological issues clouded much of the research, concluded that 
the evidence supported the concept of sensory-specific satiety, albeit in a modified 
form. 
 
While the current study was not designed to test this alternative hypothesis of a driver 
for food intake, it did switch food choices three times in four weeks and altered the 
palatability of the chow.  This suggests we provided the mice with choice that 
influenced their food intake.  Taken together, the effects of ordering / variety may have 
moderated or undermined the underlying drive towards protein prioritising and could 
explain the observation of reduction in food intake that was noted in the first week of 
experimental diet feeding regardless of the type of chow being consumed.   
 
However the response to variety in food is more nuanced than that proposed by the 
above authors.  The more qualified response to variety is illustrated through the results 
of three studies that examined food variety in rodents.  Firstly, Rolls et al216 showed 
that increased food consumption was seen only in the mice offered simultaneous 
highly palatable options and not in the mice offered sequential highly palatable food 
offerings.  Secondly, Armitage et al217 demonstrated that rats offered sequentially 
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differing food options decreased their food intake for several days after the withdrawal 
of a palatable food choice before returning to baseline.  Thirdly, Zylan et al218 reported 
that rats offered sequential single-choice palatable food versus multiple-choice 
palatable foods in a cross-over fashion did not, as expected, increase their food intake 
after the first switch over / feeding period but only after the second switch over. 
 
In this study, while the experimental feeding was associated with increased weight in 
both groups, there were also plateaus in weight gain during the first week of the 
experimental diets for both groups and for the OB mice, diet treatment order rendered 
the increase in weight non-significant (see Figures 3.8 and 3.9).  This was likely to 
be effects from diet treatment order and variety; in particular a moderating of food 
intake associated with the switch-over from the conditioning chows (which were 
probably considered more palatable chow by the mice) and / or the temporary 
reduction in food intake in response to the first switch over of chows as noted by Zylan 
et al218. 
 
The final interesting aspect of the ordering effect was that it was up to four times 
greater in lean mice compared to the obese, raising the question of how obesity affects 
the response to variety in the diet.   
 
An answer may be found in a study by Ackroff et al219, who reported on a well-designed 
series of experiments in obese adult rats comparing different types of energy rich foods 
and different means of enhancing palatability.  The strength of the study was that the 
authors used adult rats, which addressed issues related to food intake and puberty and 
took care to resolve methodological flaws noted by Remick et al such as standardising 
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pre-treatment diets, standardising palatability enhancement and testing different 
forms of palatability enhanced food.   
 
However the authors concluded that contrary to the concept of sensory-specific 
satiety, the physical form of food and its macronutrient content was more important 
than increased numbers of food choices or flavouring.  Drawing from their findings, it 
suggests that obese animals do have a differential response to variety and furthermore, 
in hierarchy of contributors to food intake, palatability and variety are important but 
macronutrient content is more so.  It is worth noting that this moves the argument in a 
direction which is tantalisingly sympathetic to the Protein Leverage Hypothesis. 
 
3.5.3  Anthropometric measures, biochemistry and hormones 
 
Anthropometric measures 
 
When the anthropometric measures at the end of Phase II for the LE and OB mice 
were compared, the OB mice were heavier, longer and had increased adiposity, but 
only the changes for weight and length were significant.  Within group comparisons to 
assess the effects of the order of diet treatments showed a significant change for length 
in the LE mice only.  Finally, within group comparisons of these measures for end of 
Phase II with baseline (end of Phase I) showed all older mice to be heavier and with 
increased adiposity but the change that met significance was weight in the LE mice 
only. 
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Although all of the measures on the between group comparisons favoured the OB mice, 
as the underlining weight difference was modest it is unsurprising that few changes 
met significance.  In addition and perhaps as important, compared to other studies 
that used the DIO C57BL/6J model and found significant anthropometric 
differences195,199,200, the duration of the conditioning and experimental diets was at the 
lower end of the range of feeding times.  Both of these issues prevented the 
development of large differences in body composition.  
 
However the Top 10 sub-group analysis of the heaviest and leanest mice found a larger 
difference in body weight and a larger and almost significant difference in adiposity.  
Finally, the original PLH study192 did report only one significant anthropometric 
measure difference, though it was only carried out in lean mice.   
 
The current study’s cross-over experimental diet design meant that the mice consumed 
each experimental chow for 1 feeding period (14 days) only but the anthropometric 
measures were collected at the end of 2 feeding periods.  It is therefore unsurprising 
that few significant differences according to the order of the diet treatments were 
found.  Taken with the original PLH study, it is concluded that for both LE and OB 
mice despite the animals consuming more energy on the LP diet treatments, 
treatments of 9% P and 23% P and less than 32 days duration are associated with few 
significant changes to body composition.  Whether longer interventions are associated 
with an increase in the number of significant changes in body composition still 
remains unknown. 
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One final note is the intriguing finding that the changes to anthropometric measures 
when assessed according to the order of the experimental diets were in opposing 
directions for the LE and OB mice.  That is for the LE mice the subgroup given HP 
followed by LP diets were heavier and had increased adiposity while the opposite held 
for the OB subgroup given LP then HP diets.  This raises the possibility that for 
differing phenotypes of mice, dietary P effects their body composition differentially but 
before taking this notion further, it should be thoroughly tested in a revised and longer 
study of the PLH in mice. 
 
Biochemistry and hormones 
 
For both phenotypes of mice, fasting levels of leptin and ghrelin were higher at the 
completion of the study (end Phase II) compared to baseline (end Phase I).  On the 
direct comparison between the phenotypes at end Phase II, levels of adiponectin were 
significantly higher in the lean mice, as might be expected.  Although the changes were 
non-significant, the direction of the findings for glucose and insulin in both the within-
group end Phase II vs. end Phase I analysis and between phenotypes at end Phase II 
analysis were again as might be expected with the heavier mice insulin resistant and 
having higher levels of glucose. 
 
The overall direction of these findings reflects the known results from studies in DIO 
C57BL/6J mice that have examined the effects of increased body weight on the 
secretion of adipokines (adiponectin195 and leptin199,200), glucose and insulin189 and 
ghrelin196,220.  The relatively small number of significant findings between the 
phenotypes is likely to be related to the relatively modest weight difference between 
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the groups, which reduced the statistical power to assess for secondary outcome 
differences and increased the likelihood of a Type II error. 
 
There exists some controversy as to how obesity and diet affect ghrelin secretion.  
There is evidence that fasting levels of ghrelin are significantly lower in obese 
compared to lean rodents (DIO C57BL/ 6J mice196 and DIO Zucker rats204) as is seen 
in humans.  However, other studies have reported that levels of ghrelin are generally 
attenuated in the obese rodent, regardless of the status of fasting197.  The role of P in 
ghrelin secretion is also unclear, some evidence points to elevated levels of ghrelin 
being associated with low P diets that are also high in CHO221, whilst others (Vallejo-
Cremades et al222) found that rats fed a high P diet, compared to the rats fed high 
CHO, high F or standard diets, had the highest levels of fasting ghrelin.  They also 
found that the high P diet was associated with the greatest prolonging of post-prandial 
ghrelin secretion and suggested that for rats, dietary P had potent ghrelin modifying 
properties.  However it should be noted that compared to the other studies Vallejo-
Cremades et al used a different species of rat (not Zucker rats) and dispensed the 
experimental feeds as fixed volumes rather than ad libitum.   
 
As many elements of our protocol were relevant to examining the interactions between 
weight, dietary P and ghrelin, it was disappointing that the study found few differences 
for ghrelin, probably due to methodological limitations.  The effects of dietary 
modifications on the secretion of adipokines and gut hormones remain an open and 
relevant area of research. 
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3.5.4  Additional comments: strengths and limitations and future directions 
 
Given the primary outcome was difference in food intake, having a high degree of 
confidence and accurately measuring food consumption were key to the study.  By 
adhering closely to the design of the original PLH study (using the same specialised 
feeding inserts to collect spilled and uneaten food, having a single investigator 
dispense and measure the experimental chow and measuring four times per week) this 
study maintained a high degree of accuracy for its food data. 
 
The results and experiences from this study will inform on-going research in this still 
very open topic.  Reflecting on the limitations in the current study that have already 
been acknowledged, the following suggestions for future mouse PLH studies are made.  
Firstly older mice should be used and they be offered a longer period of conditioning 
diets to remove any puberty and post-puberty related effects on food intake, to 
enhance the differences in body weight and to enhance phenotypic differentiation.  
Doing so would also help to confirm the extent that obesity moderates protein 
prioritisation.   
 
Secondly, the experiment should involve at least 80 mice as larger numbers would 
allow for additional comparator groups of mice which would be offered only low and 
high P diets.  This would provide the opportunity to determine the effects of differing P 
chows on the anthropometric measures accurately without the clouding of results that 
occurs in a cross-over diet design.   
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Finally the period of experimental diet feeding should be lengthened as this should 
minimise the changes in food intake and weight that resulted from the cross-over from 
conditioning to experimental diets and the second cross-over between the different 
experimental diets.   
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3.6  CONCLUSION 
 
In the current experiment we compared the intake of experimental isocaloric diets 
differing in % P in obese and lean mice.  It was shown that under ad libitum feeding 
conditions, both lean and obese mice over-consumed low P chow at the expense of 
increasing their energy intake, though the overconsumption was more marked in lean 
mice.  The findings in the obese mouse are novel.  Taken together, these findings 
support the Protein Leverage Hypothesis which states that the main driver for food 
intake is dietary P and that its intake is prioritised above total energy consumption 
though there is the intriguing suggestion that obesity blunts protein leveraging.  
 
Because of the cross-order feeding design, an ordering effect was observed for the 
experimental diets, suggesting that food variety and palatability also influence food 
intake.  However the inclusion of a cross-over comparator and the results of revised 
statistical analyses showed that this effect did not impact on the overall direction of the 
findings for food intake.   
 
The weight related changes were significant but modest and associated with 
appropriate changes in levels of fasting leptin and adiponectin.  The direction of these 
findings confirmed the known effects of obesity and body composition on the secretion 
of adipokines. 
 
Finally the finding that obese and lean mice leverage their food intake as predicted by 
the Protein Leverage Hypothesis sheds light on one of the potential drivers of the 
increased rates of human overweight and obesity.  Understanding the limitations of 
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protein leveraging and the mechanisms that underlie it should point to new directions 
for research into dietary and medical treatments that may help ameliorate overweight 
and obesity. 
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CHAPTER 4 
 
Lessons from South Korea and its diet: Lifestyle-induced weight 
loss and the secretion of appetite and body weight influencing 
hormones  
 
 
4.1  INTRODUCTION 
 
The global phenomenon of increasing overweight and obesity is a well-documented 
and serious health risk1,4,223-225.  The traditional lifestyle approach to weight loss 
involves: recommending dietary changes, increasing levels of incidental activity and 
regular physical exercise, introducing behavioural (habit) changes and providing 
psychological support.  These programs are popular with patients226, are cost- 
effective227 and are recommended by experts and national health agencies as the 
cornerstone in the clinical management of the overweight and obese17,18,228,229. 
 
However the challenges for the overweight and obese to maintain the weight lost by 
traditional methods are well known and illustrated by a fifth or fewer subjects able to 
maintain 10% weight loss for 12 months or more77,230 and average weight loss at 5 
years being little more than 3%20. 
 
These limitations stand in contrast to the literature published from studies into 
modern bariatric surgical procedures (laparoscopic adjustable gastric banding, vertical 
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sleeve gastrectomy, and gastric – duodenal bypass / switch procedures).  These clearly 
demonstrate that modern bariatric surgery is associated with greater weight loss, 
greater long-term weight maintenance 24,27,231, the remission of obesity complications 
(especially hypertension and Type 2 Diabetes mellitus [T2DM]24,232,233) and 
significantly improved 10 year survival (from reduced cardiovascular events and all-
cause mortality)234.   
 
Yet several barriers do limit the wider use of bariatric surgery: The evidence is unclear 
as to which type of bariatric surgery is most appropriate for patient groups, with the 
type of surgery left to the individual preferences of the patient and the whim or 
expertise of the surgeon while surgery itself carries a risk for morbidity and 
mortality28,234. 
 
Furthermore in Australia and other Western countries bariatric surgery is 
predominately privately funded and not available equitably30 and long-term questions 
about outcomes, complications and overall cost effectiveness remain unanswered29.   
 
Therefore the challenges in sustaining weight lost by traditional lifestyle interventions 
remains a highly relevant area of research235,236.  Historically physical, psychosocial 
and physiological factors have been considered the major contributors to weight 
regain237,238 but the counter-regulatory changes in the neuro-endocrine control of 
appetite and body weight after weight loss, and in particular to peripheral mediators, 
have increasingly been recognised as having a central role in both limiting further 
weight loss and promoting weight regain239,240. 
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4.1.1  Neuro-endocrine adaptation to weight loss and the role of peripheral
  mediators 
 
Another way to frame overweight and obesity is to consider it a physiological response 
to the chronic exposure to an environment and lifestyle that combines the ready 
availability of energy dense foods, favours the use of vehicular transportation, shifts 
paid labour away from tasks involving strenuous physical exertion and favours less 
active forms of entertainment.  Taken together there is a powerful argument that the 
post-industrial combination of lifestyle and environment is “obesogenic”48.   
 
Given these powerful environmental forces collectively favour increased energy intake 
and reduced energy expenditure it is important to examine how these factors interact 
with the homeostatic control of body weight.  In two recent reviews Chaput et al50 and 
MacLean et al240 summarised the last decade of research into weight loss and 
maintenance, focusing on the complex neuro-endocrine system that regulates appetite 
and body weight.   
 
In its simplest form, a feedback loop connects the periphery to the brain; with 
peripherally secreted hormones signalling the long-term availability of energy stores 
(predominately adipose tissue) and the short-term availability of sources of 
macronutrients and energy.  Numerous central and peripheral components are 
involved and in concert work to maintain body weight homeostasis.  However, for 
much of human existence the feedback system operated in and adapted to dietary 
environments where nutrient sources were limited48,49 and because of this, the 
homeostatic mechanisms are much more responsive to dietary states where nutrient 
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supply is scare rather than to the current post-industrial dietary state of general global 
energy excess50. 
 
As a result of these evolutionary influences, during periods of increasing weight, the 
homeostatic mechanisms react to these changes not by reversing or stopping or even 
slowing the weight gain but instead by allowing body weight to drift upwards 
unchecked and by continually re-tuning to the new levels of obesity240.   
 
In contrast significant weight loss does not occur generally without a sustained 
intentional effort to reduce food intake and increase levels of physical activity.  
However, any weight loss that is induced will lead to the development of counter-
regulatory changes in these homeostatic controls that work to prevent further weight 
loss.  This is illustrated by the well-known phenomenon of reaching a plateau in 
lifestyle induced weight loss known colloquially “hitting the wall”.   
 
To lose more weight the diet, exercise and behavioural strategies must be intensified 
and to maintain weight loss, strategies such continually altering exercise programs and 
monitoring and adjusting the diet must be applied long term230,237,240. 
 
The full details of the many mediators of the homeostatic response to weight loss is 
complex and beyond the scope of this review but in short, it involves mechanisms such 
as a disproportionate reduction in energy expenditure compared to the weight lost241, 
alterations in adipose tissue signalling that are also disproportionate to the remaining 
fat mass, reduced central sensitivity to satiety signals, and the altered secretion of 
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appetite, satiety and body weight influencing peripheral hormones240.  It is the latter 
that is the focus of the remainder of this chapter. 
 
4.1.2  Key gut hormones & adipokines and the effects of body weight 
 
The peripheral hormones of interest are the adipocyte-secreted leptin and the gut 
hormones GLP-1 and ghrelin; collectively these hormones have anorectic and 
orexigenic properties; influence the initiation, continuation and termination of food 
consumption and act as short and long term signals of energy intake and adiposity.  
The effect of reductions in body weight on the secretion of these hormones has been 
studied and the findings are reviewed below. 
 
Ghrelin was reviewed in detail in Chapter 2, Section 2.1.3.2 and GLP-1 in Chapter 2, 
Section 2.1.3.3.  Leptin will be discussed in detail below. 
 
4.1.2.1  Ghrelin and changes in body weight 
 
Compared to the levels of ghrelin at stable body weight, in the overweight and obese 
weight loss by diet or by exercise alone has been shown to significantly increase the 
fasting, post-prandial and 24 hr levels of ghrelin by at least 10%25,73,239,242-244.  In 
contrast when bariatric surgery is the method of inducing weight loss, compared to 
baseline levels of ghrelin, fasting and 24 hr profiles are either unchanged or 
reduced25,245.   
It is hypothesised that the increased levels of ghrelin seen after conventionally induced 
weight loss signal to the brain a state of energy deficit, with the subsequent result of an 
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increase in the urgency to consume food and a reduction in the interval between 
meals246.  In comparison, the attenuated or improved levels of ghrelin following weight 
loss by bariatric surgery are thought to contribute to the reductions in subjective 
measures of hunger and the superior rates of weight maintenance that are reported 
with bariatric surgery25,26,247,248.   
 
4.1.2.2 Glucagon-Like Peptide-1 and changes in body weight 
 
Unlike the other hormones of interest the effects of overweight and obesity on fasting 
concentrations of GLP-1 are still unclear.  Several studies67,249 have demonstrated that 
obesity is not associated with changes but at least one study reported that fasting levels 
were lower in the obese249.  However the effects of obesity (and T2DM) on the normal 
post-prandial increase in GLP-1 have been more clearly demonstrated, with both 
conditions attenuating the duration and magnitude of the expected rise250,251.   
 
In a well-designed study252 of post-prandial GLP-1 secretion in obesity and during 
weight loss, levels of GLP-1 were measured at baseline, after 6 weeks of weight loss by 
a very low calorie diet using liquid meal replacement products, and after 3 months of 
weight maintenance by an energy restricted diet.  Subjects lost ~8% body weight 
during the active phase but regained ~1.5% during the period of weight maintenance.   
 
Compared to the baseline levels of GLP-1, post-prandial secretion was significantly 
reduced at the end of weight loss and during the period of weight maintenance and it 
was proposed that these changes had the physiological effect of reducing satiety and 
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delaying gastric emptying, thereby shifting the regulation of appetite to favour 
increased meal consumption and weight regain.  
 
In comparison, weight loss induced by bariatric surgery has been associated with short 
and medium term increases in the fasting and post-prandial secretion of GLP-126,253; 
an enhancement of satiety and depending on the type of surgery, increased or 
decreased gastric emptying.  The net result from these changes is to shift the balance in 
the homeostatic regulation of appetite and body weight to favour further weight loss.  
These differences in GLP-1 secretion have been proposed as contributing to the 
superior rates of obesity remission seen following bariatric surgery compared to 
conventional weight loss therapies254,255. 
 
4.1.2.3  Leptin 
 
Leptin was discovered in 1994 as the result of studies into a unique strain of 
hyperphagic obese mice (known as the ob/ob mouse) which lost weight after their 
circulatory systems were attached to normal, phenotypic lean mice via parabiosis256,257.  
Leptin, originally known as the ob protein, is a 167 amino acid length molecule that 
belongs to the cytokine family of proteins.   
 
Leptin was originally thought be only secreted by white adipose tissue but while it is 
now known to be secreted by brown adipose tissue, in the gut and in the placenta258,259, 
the majority of leptin still arises from subcutaneous white adipose tissue201,260,261.   
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There are five leptin receptors with the most widely distributed being the short form, 
which is the leptin receptor iso-form present in most tissues and the form that 
facilitates its transport across the blood-brain and into the intra-cerebral circulation, 
where leptin has its main effect262. 
 
Leptin acts within the hypothalamus to trigger a signalling cascade that inhibits the 
release of orexigenic peptides, stimulates the release of anorectic peptides and reduces 
food intake.  There follows multiple effects including reduced hunger, enhanced post-
meal satiety and reduced sense of food as a positive reward201,263,264.   
 
Experiments in normal weight mice made obese by feeding of high fat chow199 then 
treated with exogenous leptin illustrate these actions.  Initially all the mice received 
peripherally administered leptin and responded by reducing their food intake.  
However as the mice became obese the response became muted, but for a sub-group of 
mice receiving leptin via their cerebral ventricles the physiological effects were 
restored.   
 
Another illustration of the biological effects of leptin is seen from studies in individuals 
and families with the rare condition of congenital leptin deficiency265,266.  These groups 
have a phenotype marked by extreme hyperphagia and extreme early-onset obesity but 
both food intake and body weight were dramatically reduced following the 
administration of exogenous leptin.  Importantly, these experiments help give rise to 
the understanding that common obesity is a state of hyper-leptinaemia but also one of 
apparent resistance to its effects267. 
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The serum concentrations and mRNA levels of leptin rapidly decrease during states of 
caloric restriction and negative energy balance, pointing to the two broad functions of 
leptin:  the first function is seen during periods of weight maintenance where increased 
levels of leptin acts as a long-term, peripherally secreted signal notifying the brain as to 
the levels of adipose tissue stores but without leading to changes in food consumption.   
 
The second function can be seen during periods where energy balance is in flux, where 
reductions to the levels of leptin act as a short-term signal to the brain, indicating an 
imbalance in energy intake and leading to increased food consumption268. 
 
While the primary role of leptin is through its actions on the central nervous system, 
its cytokine-like structure suggests a secondary, immunogenic role.  Leptin has been 
shown to increase inflammation through modulating the secretion of TNF-α and 
macrophage and platelet activation269 and based on these findings, leptin has been 
proposed to contribute to the low-grade inflammatory state that marks obesity269. 
 
Leptin and body weight 
 
In humans the concentrations of leptin in the serum and its production (as measured 
by mRNA in adipose tissue) are both highly correlated with total fat mass261,270.  Given 
the known differences in fat distribution between the genders, concentrations of leptin 
are higher in women than in men.  
 
While leptin deficiency is a well-recognised genetic cause of severe obesity, genetic 
surveys of common obesity have not demonstrated a high prevalence of mutations to 
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the leptin gene271,272 and it is widely accepted that common obesity is not a state of 
leptin deficiency but rather a state marked by leptin excess201,260.   
 
Unlike the other hormones of interest, weight loss achieved through lifestyle changes 
(diet, exercise or combined diet and exercise programs273,274) and by bariatric 
surgery245,247 (though possibly less so following bypass procedures275) have both been 
associated with reduced fasting and 24 hr secretion of leptin.   
 
It has been proposed that the net result of these changes is that of a “reduced adiposity 
signal” which is interpreted centrally to shift appetite and weight homeostasis to 
favour weight regain240.   
 
Whether the changing levels of leptin play only a short term role in appetite and body 
weight homeostasis following weight loss is unclear: the levels fluctuate proportionally 
to changes in body weight and have been reported to increase after weight regain or 
maintenance276,277 but more recent studies have brought this finding into question239. 
 
Interestingly, the administration of exogenous leptin after diet induced weight loss has 
been shown to limit the post-weight loss decline in metabolic rate278, suggesting that 
elevating levels of leptin after weight loss may be some clinical use in weight 
maintenance. 
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4.1.3  Methods of weight loss on the secretion of peripheral hormones 
 
Bariatric surgery 
 
The effects of weight loss by bariatric surgery on the peripheral mediators of appetite 
and body weight regulation have been well established: there are immediate and 
persistent reductions to the fasting and post-prandial levels of ghrelin25,245; short- to 
medium- term increases in fasting and post-prandial GLP-1 secretion245,253,275 and 
additional favourable changes to other gut hormones that influence appetite including 
Peptide YY26,247.  There are also marked reductions to the fasting and post-prandial 
secretion of leptin245,275,279 which unlike the gut hormones above, have been reported 
consistently regardless of the method of weight loss.   
 
It has been proposed that bariatric surgery itself induces the changes in the secretion 
of the gut hormones (ghrelin, GLP-1, peptide YY) which militate against the usual 
homeostatic counter-regulatory response that develops after weight loss (which can 
still be seen following bariatric surgery in the marked reductions to levels of leptin) 
and which normally leads to weight regain.  Arguably the combined effect from the 
changed secretion of gut hormones is sufficiently powerful to overcome the remaining 
counter-regulatory changes that favour weight regain and that this mechanism is one 
of the central reasons for the superior rates of long-term weight reduction observed 
after bariatric surgery254,255,280. 
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Lifestyle interventions 
 
By comparison, the number of studies that have set out to examine the effects of 
conventional methods of weight loss on the secretion of gut hormones (i.e. ghrelin and 
GLP-1) is sparse and the findings mixed. 
 
Four studies have demonstrated that in the obese, fasting levels of total ghrelin and 24 
hour ghrelin profiles following weight loss by a hypocaloric liquid diet and following 
weight stabilisation by low energy intake diets were significantly higher compared to 
levels before weight loss or to lean control populations25,242-244.  Furthermore, a fifth 8-
week study281 of an energy restricted (but not liquid meal replacement) diet also 
demonstrated that following weight loss there was a significant increase to the fasting 
levels of ghrelin.   
 
Studies on the fasting and post-prandial levels of GLP-1 following weight loss by very 
low calorie diets (by liquid meal replacement) found that, compared to lean controls, 
obese subjects had reduced fasting and post-prandial GLP-1 secretion at baseline with 
levels further reduced following weight loss249,282.  An extension of one of these studies 
but published separately252 found that after a period of weight stabilisation by 
hypocaloric diet, the changes to the fasting and post-prandial secretion of GLP-1 had 
increased but were still reduced compared to baseline.  Against these findings are the 
results of a study of weight loss and maintenance which demonstrated that both were 
associated with increased secretion of GLP-1250.  The sum of these studies is that the 
direction of the changes in the secretion of GLP-1 that develop following weight loss is 
still debatable. 
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In contrast to the number of weight loss studies examining very low calorie diets, there 
have been only two studies of the effects on peripheral mediators of appetite and body 
weight regulation by exercise-only weight loss.   
 
The first was a 12-month study283 of post-menopausal obese women, randomised to an 
exercise program or to stretching, which reported that fasting ghrelin increased 
proportionally to weight loss.  The second was a 12 week study284 of overweight and 
obese middle-aged adults who lost a mean of 5% of baseline weight by exercise only.  
While they reported no significant changes in fasting ghrelin or GLP-1, there were 
trends towards prolonged suppression of post-prandial ghrelin release and enhanced 
post-prandial GLP-1 secretion.   
 
When these two studies are considered together, the first suggests that exercise-
induced weight loss also leads to maladaptive changes in the fasting secretion of 
ghrelin that favour weight gain whilst the second suggests that exercise-only weight 
loss induces post-prandial changes in ghrelin and GLP-1 that moderate the expected 
counter-regulatory changes.  While it is possible that the direction of fasting and post-
prandial changes is in opposition, it is also reasonable to conclude that the results are 
contradictory.  When the methodologies are compared, the frequency and intensity of 
the exercise programs were the same for both studies but the subject groups differed 
with those in the second study younger and overweight but not obese.  The question of 
whether exercise-induced weight loss is associated with the same counter-regulatory 
adaptions that constrain further weight loss remains open. 
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Finally, only two studies have examined the effects of weight loss by combined diet and 
exercise on the secretion of the key peripheral mediators of appetite and body weight 
regulation with the results also mixed.   
 
The first study273 examined an overweight cohort and compared the effects of 6 
months of hypocaloric diet vs. hypocaloric diet and regular exercising.  They found that 
diet and exercise was associated with greater weight loss but for fasting leptin 
compared to baseline, there were with-in group reductions but no significant 
differences between groups.  Furthermore, by 12 months subjects had regained weight 
but unfortunately, as leptin was not measured, there was no assessment of the 
persistence of any changes to leptin. 
 
In the second study285, obese Mexican-Americans who received a 12 month 
combination diet, exercise and adjuvant pharmacotherapy program lost and 
maintained ~5% weight loss, which was associated with increases to the fasting levels 
of ghrelin at 6 months, but at 12 months fasting levels had returned towards baseline.  
 
A final point of comparison is to review the literature from studies of the management 
of adolescent obesity.  Due to the restrictions on the use of very low calorie diets and 
pharmacotherapy with this population there have been more studies of weight loss by 
combined diet and exercise interventions on the release of peripheral hormonal 
mediators of appetite and weight loss regulation.  In a recent review, Roth et al286 
examined the studies and while unable to apply conventional meta-analyses 
techniques, reported that on balance, there was good evidence to support the notion 
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that in adolescents, both during and after weight loss changes, the secretion of ghrelin 
and leptin are in similar direction to the counter-regulatory changes reported in adults.   
 
In addition, the persistence of the maladaptive homeostatic changes has recently and 
uniquely been demonstrated in a 2011 study of obese subjects who achieved and 
maintained an impressive 8% weight loss by very low calorie diet therapy239.  At 12 
months, weight maintenance was associated with persistent changes in the fasting and 
post-prandial levels of leptin, insulin, ghrelin, CCK and peptide YY, which were all 
counter-regulatory and against further weight loss.  Coupled with persistently elevated 
measures of subjective hunger, the overall direction of all these changes favoured 
weight regain.   
 
To date, this study has demonstrated the long term nature of the maladaptive changes 
to peripheral hormonal mediators of appetite and body weight and strengthens the 
main argument, which is that following conventional weight loss, there are sustained 
and persistent counter-regulatory changes to the homeostatic mechanisms of body 
weight regulation that act in concert to regain weight.  Understanding these changes 
could be of great importance to the development of more effective strategies to address 
overweight and obesity. 
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4.1.4 Body weight and inflammation:  adiponectin, insulin and C-reactive protein 
 
Obesity is not only a state of energy excess and increased adiposity, it is also a 
metabolically active state marked by low-grade subclinical inflammation that 
contributes to the development of obesity- related complications269.  In comparison, 
weight loss is associated with lower levels of C-reactive protein (CRP), increased levels 
of adiponectin and improved insulin sensitivity287,288 and as all are biological markers 
of subclinical inflammation, these improvements correspond to weight loss itself 
reducing subclinical inflammation.  It has been clearly demonstrated that the 
magnitude of these changes is dependent on the degree of weight loss rather than the 
methods used to achieve it279,287. 
 
4.1.4.1  Adiponectin 
 
Adiponectin (ADP) was fully identified in 1995289 and is an adipocyte-derived 28-kDa 
244 amino-acid protein that is abundantly found throughout human circulation.  
ADP’s physiological functions include modulating the inflammatory response, 
influencing glucose and lipid metabolism and reducing circulating levels of free fatty 
acids.  Levels of ADP are inversely associated with insulin resistance, T2DM and 
coronary artery disease and in contrast to other adipokines, increased levels of ADP 
are associated with decreased rates of overweight and obesity. 
 
ADP is predominately synthesized and secreted from white adipose tissue at 
concentrations (5 - 30 micrograms per millilitre) that are significantly higher than 
those of all other adipokines290.  Circulating ADP is found in the form of multimers 
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with the high molecular weight multimer considered the most clinically relevant291.  
ADP acts on one of two identified receptors that are expressed in varying affinities 
throughout tissues of the body, with the ADP 1 receptor found in skeletal muscle and 
vascular endothelial cells while the ADP 2 receptor is found in the liver292,293.   
 
Studies in rodents have demonstrated that low levels of ADP are associated with 
insulin resistance294,295 while other animal and in vitro studies have shown that ADP 
levels are inversely associated with increased platelet and thrombus activity296,297 and 
increased levels of the pro-inflammatory cytokine Tumour Necrosis Factor α 298.   
 
In humans levels of ADP have been found to inversely correlate with insulin resistance, 
the metabolic syndrome and the risk for T2DM299-301.  Levels of ADP are also inversely 
associated with levels of serum triglycerides and positively correlated with levels of 
high-density lipoprotein cholesterol.  These are all risk (or for HDL protective) factors 
for cardiovascular disease (CVD) and unsurprisingly, a relationship exists between 
high levels of ADP and a reduced risk for CVD, although the relationship is weak and 
attenuated by the presence of traditional CVD risk factors302,303.   
 
Clinically, increased levels of ADP are found after the use of thiazolidinediones agents 
for T2DM, which act on the peroxisome proliferator-activated receptor in skeletal 
muscle, vascular endothelium, hepatocytes and adipose tissue to reduce insulin 
resistance and improve insulin sensitivity304,305.  ADP also moderates hepatic glucose 
production by reducing the levels of phosphoenolpyruvate carboxykinase and glucose-
6-phosphatase, two key enzymes involved in hepatic gluconeogenesis306,307.   
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Physiologically, there is evidence that the beneficial effects of physical activity on 
insulin resistance are mediated by the ADP - ADP receptor pathway308. 
 
Adiponectin and body weight 
 
The secretion of ADP is affected by changes in body weight with studies reporting 
significantly lower levels of ADP in obese populations compared to lean controls, in 
conditions of normal health and in the presence of metabolic co-morbidities309-313.  
Moreover, the results of a recent meta-analysis314 clearly demonstrated that for 
overweight and obese subjects across a range of health conditions, clinically significant 
weight loss through exercise only, combined diet and behavioural changes or by 
bariatric surgical are all associated with significant increases to ADP levels. 
Furthermore, it has been proposed that the favourable metabolic changes that develop 
following weight loss are at least in part mediated by the increases to ADP287,308,313,315. 
 
Interestingly this finding appears to be proportional to the baseline weight and to the 
amount of weight loss.  Studies have found the link weaker in lower grades of excess 
weight (overweight and Grade I obesity) while other studies where weight loss was less 
than 10% have failed to replicate the finding at all287,316,317.   
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4.1.4.2 Insulin  
 
Insulin was discussed in detail in Chapter 2, Section 2.1.3.4. 
 
Insulin and body weight 
 
Overweight and obesity is associated with the hyper-secretion and impaired clearance 
of insulin, leading to elevated levels both basally and in the post-prandial period318.  
Elevated levels of insulin and the development of resistance in peripheral (especially 
adipose) tissues to its actions is thought to be a major pathway mediating the 
metabolic and cardiovascular complications that associated with overweight and 
obesity163. 
 
Greater than 5% weight loss is associated with reduced concentrations of serum 
glucose and with decreased basal and post-prandial secretion of insulin with greater 
weight loss associated with greater improvements to both239,287,313.  The greater than 
20% weight loss typically reported after bariatric surgery has been shown to be 
associated with the medium-term remission of T2DM232,287.   
 
In contrast to the other hormones of interest in the current experiment, the changes 
following clinically significant weight loss in the secretion of ADP and insulin appear to 
contribute little to weight regain and the counter-regulatory changes that develop in 
the homeostatic regulation of appetite and body weight.  Indeed, the net result of the 
changes to ADP and insulin are beneficial. 
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4.1.4.3 high-sensitivity C-reactive protein  
 
C-reactive protein (CRP) is an acute phase reactant synthesised in the liver and 
released in response to cytokines secreted by immune-mediating cells including 
adipocytes.  As the name suggests, CRP is released in response to inflammation and in 
the presence of severe inflammatory states such as sepsis, levels can increase up to 
1000-fold 319. 
 
However, persistently mild elevations of CRP (≤ 5 fold) have been noted in conditions 
of metabolic disorder such as obesity, the metabolic syndrome, insulin resistance and 
T2DM; leading to the conclusion that these are all conditions associated with chronic 
subclinical inflammation320.  Furthermore, mildly elevated levels of CRP are weakly 
correlated with an increased risk for CVD but whether this represents an independent 
risk factor or is a proxy for conventional risk markers remains unclear321,322.   
 
As weight loss improves both subclinical inflammation and the metabolic profile, it is 
unsurprisingly that CRP levels fall after weight loss with the presence of pre-existing 
metabolic disturbances and the extent of weight loss influencing the extent of the 
reduction in levels of CRP.  The greatest reductions have been reported following 
bariatric surgery in previously morbidly obese subjects with extensive metabolic 
complications287, while more modest reductions have been reported following weight 
loss by lifestyle means in the overweight and obese with few metabolic 
complications313.   
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(Finally it should be noted that high-sensitivity CRP (hsCRP) refers not to another 
form of CRP but to the laboratory technique of laser nephelometry, which allows for 
the measurement of very low levels of the protein.) 
 
4.1.5  Rationale for the experiment and summary 
 
National weight management guidelines advocate a comprehensive lifestyle approach 
that combines a hypocaloric diet, increasing physical activity and undertaking regular 
exercise and reassessing maladaptive food-related behaviours17,19,229.  While 
compliance with these forms of therapy is associated with clinically significant weight 
loss, maintaining the lost weight remains a challenge.   
 
Following weight loss, counter-regulatory changes develop in the homeostatic 
regulation of appetite and body weight that favour weight regain and studies have 
increasingly focused on the peripheral mediators of appetite and body weight 
regulation, especially ghrelin, GLP-1 and leptin.  While the effects of diet-induced 
weight loss have been relatively well studied, there are fewer studies on the effects of 
weight loss by exercise and the impact of weight loss by an integrated lifestyle 
approach on these key hormones remains poorly understood. 
 
The aim of the current study was to investigate whether in the overweight and obese, 
the changes in the peripheral hormonal mediators of appetite and body weight 
regulation that develop after weight loss by a single lifestyle modality are also seen in 
those who lose weight by a combined and comprehensive lifestyle program. 
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Working with data from a weight loss study, of main interest were changes in the 
fasting levels of ghrelin, GLP-1 and leptin, whilst of secondary interest was the change 
in the markers of obesity related to sub-clinical inflammation (adiponectin, insulin and 
hsCRP). 
 197 
4.2  MATERIALS AND METHODS 
 
4.2.1  Subject recruitment 
 
Subjects were recruited by reference to an existing clinical trials database and by 
advertisements placed in local papers and on the intranets of the Sydney South West 
Area Health Service and the University of Sydney.  Subjects were deemed eligible if 
they were aged 18 – 65 years, had a BMI between 25 – 45 kg/m2, at least 3 months of 
stable weight and in good general health.  Exclusion criteria included a diagnosis of 
diabetes mellitus or an glycosylated haemoglobin >6.5%, cardiovascular disease, renal 
or hepatic impairment, serious gastrointestinal disease or abnormal thyroid function; 
current pregnancy; or if within 6 months they had taken mediations known to alter 
body weight; or if they were vegetarians, vegans or had food intolerances; or if they 
consumed greater than 4 standard drinks of alcohol per day or 8 standard drinks per 
week.   
 
Potential subjects attended for a screening review where they completed a 
standardised questionnaire and were assessed by a medical clinician.  They had blood 
collected for screening tests of thyroid, renal and hepatic function and glycosylated 
haemoglobin.  A urinary β human chorionic gonadotropin test was performed for 
women of child-bearing potential at the screening visit and at the completion of the 
study to assess for possible pregnancy.  No positive results were recorded. 
 
Seventy subjects were recruited and commenced the study but 10 withdrew due to time 
constraints or social circumstances that prevented compliance with the protocol.  None 
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withdrew due to adverse events.  Sixty subjects completed the study and there were no 
baseline differences for weight or BMI between completers and those who withdrew.  A 
per protocol analyses was performed using data only from the 60 subjects who 
completed the study.   
 
The Human Ethics Committee of the University of Sydney approved of the study 
(Korean Diet Efficacy Clinical Trial. Ref. No.: 11-2009/12124).  Funding for the study 
was provided by the Department of Agriculture, Republic of (South) Korea.  Subjects 
provided their written, informed, signed and personally dated consent prior to 
commencing any study related activities.   
 
4.2.2 Lifestyle intervention: Diet, activity & exercise and behavioural changes 
 
The 12-week combined lifestyle intervention included prescribing a hypocaloric diet  
(-500 calories [2092 kJs] per day from resting energy expenditure as estimated by 
Harris Benedict Equations323); 120 minutes per week of regular, moderate intensity 
exercising; increased levels of incidental activity (8kms or >10,000 steps per day was 
the goal) and tailored behavioural advice focused on revising their attitudes towards 
the intake of food and alcohol and prioritising incidental activities and exercise.  
Additionally, there was an education focus regarding the nutritional content of food 
and the merits and ease of home cooking.  The primary outcome was weight loss at the 
end of the intervention. 
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At the screening visit, all subjects were also provided with a pedometer (calibrated with 
the assistance of study staff) and asked to record their daily step count to assist them to 
reach their targets for incidental activity.   
The lifestyle intervention was designed to be consistent with the Australian “Clinical 
Practice Guidelines for the Management of Overweight and Obesity in Adults” put 
forward by the peak national health body, the NHMRC17.   
 
Following the screening visit, all subjects had a comprehensive 45-minute lifestyle 
review which was followed by weekly 20-minute lifestyle reviews until the completion 
of the study.  Subject compliance was assessed during these visits with reference to the 
prescribed targets for diet and exercise.  Food and exercise related behaviours were 
also reviewed. 
 
Prior to their second (baseline) visit and week 4, 8 and 12 visits, subjects were asked to 
complete a diary of all their food intake and record their pedometer step-count for 3 
days (2 week days and 1 weekend day).  During these visits, they were also asked to 
complete the International Physical Activity Questionnaire (IPAQ) 2005 (short) 
Edition324 (see Appendix: Item E) 
 
Dietary Intervention 
 
Before their baseline visit, subjects were randomised into groups for different dietary 
treatments: the Korean Diet (KD) group and the Conventional Diet group (CD).  
Subjects in the KD group were provided with a traditional Korean lunch and dinner, 
Monday to Saturday, for the 12-week duration of the study.  The hypocaloric 
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traditional Korean meals were prepared according to standardised recipes at a 
specialist Korean cuisine restaurant (Open Korea, Camperdown, NSW).  KD main 
meals were composed of small servings of rice, meats, soups, noodles, vegetable side 
dishes (kim chi / fermented cabbage and radish) and noodles, which were placed into 
separate compartments of a customised food tray.  An example of the Korean main 
meals is seen in the Appendix: Items B(1) and B(2). 
 
Subjects in CD group were provided with a recipe book (kindly provided by the 
Metabolism and Obesity Services, Royal Prince Alfred Hospital, NSW) that contained 
forty-two recipes for hypocaloric main meals, deserts and soups.  CD subjects were also 
provided with a weekly food and grocery stipend to the value of 6 main Korean Diet 
meals. 
 
The food diaries were analysed by the computer programs FoodWorks 2007 and CAN-
pro 3.0 with mean daily energy intake (kJ) calculated for baseline and for study weeks 
4, 8 and 12. 
 
Exercise and incidental activities 
 
Levels of exercise were calculated using the IPAQ short questionnaire324.  This clinical 
research tool assesses a range of physical activities across domains including work, 
leisure time and transport time and grades physical activities into three tiers, 
generating a total score with reference to Metabolic Equivalent of Task or METs.  1 
MET is defined as the energy output of the surface area of an average person seated at 
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rest (1 kcal·kg-1·h-1).  To illustrate: walking is 3.3 METs, moderate physical activity is 
4.0 METs while strenuous physical exercise is 8.0 METs324.  
 
Pedometer counts were measured by reference to the 3-day diary and validated against 
the stored values in the electronic memory of the devices.  Mean daily step counts were 
calculated for baseline and for study weeks 4, 8 and 12. 
 
Compliance 
 
An individual subject’s progress and compliance with their lifestyle program was 
assessed by review of completed 3-day food diaries and pedometer record diaries and 
by review of completed IPAQ questionnaires.  Subjects not meeting their targets were 
counselled and provided with advice as to how to improve their performance.   
 
As an additional measure of dietary compliance, the KD group was asked to return 
food containers and uneaten food while the CD group was asked to bring in their 
weekly shopping receipts. 
 
All of the lifestyle interventions were conducted by the lead dietitian and exercise 
physiologist (NRF) or by one of three study clinicians supervised by NRF.  Entry of 
data from the food and pedometer diaries and the computerised analyses of food 
intake were all kindly performed by students from the Master of Dietetics and 
Nutrition program, University of Sydney.  A detailed description of the dietary 
interventions (including the background to the choice of Korean cuisine), 
methodology, results and conclusions was published in 2012325. 
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4.2.3  Anthropometric measures 
 
At the baseline visit, height was measured using a wall-mounted stadiometer 
(Wedderburn, Australia).  At each visit, fasting early morning body weight (in light 
clothing) was measured on the same set of digital scales (Tanita BC-418, Wedderburn, 
Australia) as was waist and hip circumferences. Waist circumference was measured at 
the mid-point between the highest point of the iliac crest and lowest point of the costal 
margin in the mid-axillary line.  Hip circumference was determined at the level of the 
greater trochanter.  Body Mass Index was calculated as body weight divided by height 
squared (kg/m2).   
 
4.2.4 Phlebotomy, measuring hormones by RIA, analysis of hsCRP and 
glucose, and calculating insulin resistance 
 
Blood samples were collected at the baseline visit and at the final (completion) visit at 
week 12.  Subjects were asked to present in the early morning following an overnight 
fast.  Blood was collected by antecubital venipuncture for (total) ghrelin, active GLP-1, 
leptin, insulin, adiponectin, glucose and hsCRP.  Serum blood samples were collected 
in BD Vacutainers (SSTII advance with gel separator) while plasma samples were 
collected in K2EDTA containing BD Vacutainers.  Blood collected for GLP-1 was 
collected in BD Vacutainers (BD, NJ, USA) containing Dipeptidyl Peptidase-IV 
inhibitor (10 µL/mL blood; Millipore Corp, Billerica, MA, USA) to prevent GLP-1 
degradation.  These containers were stored at -20oC until the morning of sampling.   
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Blood samples were immediately centrifuged for 15 min at 3000g then aliquotted and 
stored at -20oC until analysis. 
 
Radioimmunoassays of adiponectin, GLP-1, total ghrelin, leptin  
 
Adiponectin (ADP), total ghrelin (tGh) and leptin (Lep) were measured using human 
specific RIA kits manufactured by Millipore, USA (ADP: HADP-61HK; tGh: GHRT-
89HK; Lep: HL-81HK).  The RIAs for ADP and leptin (and the leptin assay’s 
characteristics) have been described in Chapter 3, Section 3.2.6 while for total 
ghrelin in Chapter 2, Section 2.2.6.2.  Though the ADP RIA kit described in Chapter 
3, Section 3.2.6 is mouse specific, the human kit follows the same assay technique but 
with the following assay characteristics:  samples assayed in a 1:500 dilution; the 
lowest sensitivity is 1 ng/mL using a 100 mL diluted sample; intra-assay %CV was 1.2 – 
6.2%; inter-assay %CV was 6.9 – 9.3%.   
 
Concentrations of biologically active GLP-1 (7-36, 7-37) were measured using a human 
specific RIA kit (GLP-1A-35HK, Millipore, MA, USA) in a process that required the 
preliminary step of alcohol-based extraction of GLP-1 from the stored plasma samples.  
The RIA for GLP-1 and its assay characteristics have been described in detail in 
Chapter 2, Section 2.2.6.3. 
 
All RIAs were performed in the Endocrinology Laboratory of Royal Prince Alfred 
Hospital, NSW and all unknowns were assayed in duplicate.  The author measured all 
of the hormones except for ADP.  This latter RIA was kindly performed by Ms. Marilyn 
Brown (Senior Hospital Scientist at Royal Prince Alfred Hospital).  
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Biochemical analysis of insulin, glucose and hsCRP 
 
Fasting insulin, serum glucose and hsCRP were all measured using the automated 
Architect ci16200 platform (Abbott Diagnostics, Il, USA) by immuno-
chemiluminometric technique at the laboratories of Douglass Hanly Moir Pathology, 
Sydney.   
 
Insulin resistance was quantified using the homeostatic model assessment (HOMA-IR) 
and calculated using the open access University of Oxford HOMA calculator326. 
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4.3  DATA ENTRY AND STATISTICAL ANALYSES 
 
Data was entered into a series of spreadsheets using Microsoft Excel 2008 for Mac 
(version 12.3.1 build 110725).  Following data entry, a data cleaning cycle was 
undertaken that consisted of cross-referencing figures in the spreadsheets back to the 
original source material.  All of the statistical analyses were calculated using the IBM 
SPSS Statistics Version 19 software package (IBM Corp, NY, USA) with the author 
performing all data entry and all of the statistical analyses.  
 
The study’s primary outcome was a clinically significant change in weight (≥5% off 
baseline).  It was calculated that 30 subjects in each study arm would give the study 
80% power (α= o.05, two-tail).  Incorporating a 20% drop out rate, the target subject 
recruitment was 72 subjects and while only 70 subjects were recruited, the dropout 
rate was lower than projected and hence the study maintained 80% power.   
 
Data was analysed for normative distribution by the Kolmogorov–Smirnov test. 
Parametric data is reported as mean ± Standard Error Mean (SEM) while non-
parametric data is reported as median with the inter-quartile range (IQR).  All data is 
presented as mean ± SEM unless specified.   
 
Parametric (normally) distributed data was analysed using the Two sample t-test to 
assess for between group differences at the completion of study and the Paired sample 
t-test used to assess for differences between baseline and completion for the entire 
cohort.  Non-parametrically distributed data was analysed using the Mann-Whitney U 
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test for differences between the groups at completion and the Wilcoxon signed-rank 
test for the differences between baseline and completion for the entire cohort.   
 
Spearman’s rank correlation coefficients were calculated to test for relationships 
between changes in weight and changes in the levels of hormones.   
 
Missing data for GLP-1 was corrected by multiple imputation data analyses using the 
Marcov Chain Monte Carlo method.  Results of statistical testing were considered 
significant at p<0.05 unless noted. 
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4.4  RESULTS 
 
4.4.1  Subjects, weight loss and lifestyle intervention 
 
4.4.1.1  Analysis per dietary intervention: KD vs. CD 
 
The disposition of the subjects in the study is presented in the Appendix: Item C.  
The results of the analyses according to dietary intervention are presented in the 
Appendix: Item D and were published in 2012325. 
 
There were no baseline differences between treatment groups (per dietary 
intervention) for any measure except adiponectin, which was higher in the KD group 
(+3.8 µg/mL, p = 0.02).  For the primary outcome of weight loss, both treatment 
groups lost at least 5.7% from their baseline weight with no significant differences 
found for weight at completion between the diet treatment groups (p = 0.93).  
 
At completion the KD group was found to have a higher daily energy intake (EI) 
(p<0.001) than the CD group but in comparison to baseline daily EI, both groups had 
significantly lowered their daily EIs at completion.  There were no significant 
differences for any other completion measure (activity levels, hormones or 
biochemistry) except for levels of fasting adiponectin (p = 0.02), which again favoured 
the KD group.   
 
As there were no between group differences for the primary outcome of weight loss or 
for any secondary measure (except fasting adiponectin) data from all subjects was 
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pooled to increase the statistical power of the analyses of the impact of weight loss on 
the fasting levels of GLP-1, tGh, leptin, hsCRP and insulin resistance.   
 
This author was a co-investigator in the overall project with duties including designing 
and drafting the clinical trial protocol and assisting in the process of ethics submission, 
conducting subject screening, implementing research protocols, performing 
phlebotomy and sample processing and analysing samples by RIA.  This author also 
co-authored the two research articles produced from the project thus far:  “A 12-week, 
randomised, controlled trial….of the Korean diet”325 and “A 12-month, randomised, 
controlled trial…..of the Korean diet….follow up analysis”327. 
 
4.4.1.2 Completion vs. baseline for the lifestyle intervention: 
Weight loss, energy intake and activity levels 
 
The baseline demographic, anthropometric, energy intake and activity and exercise 
measures for the sixty subjects (58% female) who completed the study are presented in 
Table 4.1.   
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Table 4.1  Demographic, anthropometric, activity and exercise levels at 
   baseline and completion 
 Baseline Completion P 
Gender (F/M) 35/25 32/25 - 
Age (yrs) 42.4 ± 11.7  - - 
Weight (kg) 89.5 ± 16.5 84.4 ± 15.8 <0.0001 
BMI (kg/m2) 31.2 ± 4.2 29.4 ± 4 <0.0001 
Waist Circumference 
(cms) 
98.5 ± 12.7 94.5 ± 12.6 <0.0001 
Daily mean Energy Intake 
(kJ) 
7705 6180 <0.01 
Average Daily Step Count* 7950, 4336 11550, 3732 <0.001 
MET minutes/week 2097 ± 1926 3416 ± 2186 <0.001 
NB: Data are presented as mean ± SEM and analysed by Paired t-test unless otherwise noted 
* non-parametrically distributed data as median, IQR and analysed by Wilcoxon signed-rank test. 
 
The subjects at completion of the study achieved a mean -5.7% weight loss from 
baseline (Δ Wgt: -5.1 ± 4.2 kg/ Δ BMI: 1.3 ±1.4 kg/m2; p <0.0001).  Overall 31 (50%) of 
subjects lost greater than 5% bodyweight and of those, 10 subjects lost more than 10%.  
Of the remainder 5% of subjects gained weight.  Mean daily levels of physical activity 
(as measured by the IPAQ as MET equivalents) increased significantly during the 
intervention (+63%) as did mean daily step count (+45%) while mean daily EI 
decreased (-20%). 
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4.4.2  Baseline vs. completion: GLP-1, ghrelin, adiponectin and leptin 
 
The results of the analyses of completion vs. baseline for fasting GLP-1, ghrelin, 
adiponectin, leptin, glucose, insulin and HOMA-IR are presented in Table 4.2. 
 
Table 4.2  Fasting levels of hormones and glucose at baseline and at 
   completion  
 Baseline Completion P 
total Ghrelin (pmol/L)* 304.9, 232.5 388, 260 <0.0001 
Active GLP-1 (pg/mL)* 34.6, 22.9 28.8, 12.9 0.03 
Leptin (ng/mL) 20.7 ± 1.9 12.6 ± 1.4 <0.0001 
Adiponectin (µg/mL) 12.3 ± 0.9 11.8 ± 0.8 0.67 
Insulin (mU/L) 9.7 ± 1.7 7.0 ± 0.6 0.03 
Glucose (mmol/L) 4.3 ± 0.1 4.2 ± 0.1 0.11 
HOMA-IR* 1.4, 1.3 1.1, 0.8 0.002 
hsCRP (mg/L) 3.3 ± 0.4 3.5 ± 0.5 0.07 
NB:  Data are presented mean ± SEM and analysed by Paired sample t-test unless otherwise noted 
* non-parametric distributed data as median, IQR and analysed by Wilcoxon signed-rank test. 
 
When compared to levels at baseline, at completion there was a significant increase in 
the fasting levels of the orexigenic hormone ghrelin (+28%), a significant decrease in 
fasting levels of the anorectic hormone GLP-1 (-22%) and to the fasting levels of the 
adipokine leptin (-40%).  However there was no change in the fasting levels of 
adiponectin.  
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4.4.3  Baseline vs. completion:  insulin, glucose, HOMA-IR and hsCRP 
 
At the completion of the study compared to baseline, there was a significant decrease 
in fasting levels of insulin (-38%) and a significant increase in insulin sensitivity as 
determined by HOMA-IR (Δ 30%).  However, there was no significant change for 
fasting glucose and a non-significant trend for increased levels of hsCRP. 
 
4.4.4 Correlation of weight loss with levels of GLP-1, ghrelin, leptin, 
adiponectin and insulin 
 
The change in weight was significantly correlated with the changes for fasting GLP-1 (rs 
= -0.3, p = 0.03), insulin (rs = 0.4, p = 0.005) and leptin (rs = 0.4, p = 0.001) and with 
a non-significant trend for fasting ADP (rs = -0.2, p = 0.10) but not for fasting tGh (rs = 
0.08, p = 0.58).  
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4.5  DISCUSSION 
 
The current study examined the impact of weight loss, achieved by 12-weeks of two 
different diets but the same exercise and behavioural intervention (these were 
combined for analysis and are henceforth called the combined lifestyle intervention) 
on the fasting levels of orexigenic and anorectic gut hormones and adipokines; and on 
other markers of inflammation in overweight and obese subjects. The lifestyle 
intervention was based on the obesity management recommendations of the NHMRC 
and consisted of several components: dietary education and the prescription of a 
hypocaloric diet (conventional or Korean), a focus on regular exercising and increasing 
incidental activity, and the promotion of appropriate behavioural changes. 
 
While counter-regulatory changes in the homeostatic regulators of appetite and body 
weight, including to peripherally secreted hormones (e.g. GLP-1252,282 and ghrelin281) 
have been demonstrated following weight loss by very low calorie and low calorie diets, 
there remains much uncertainty in this field and the results from the small number of 
studies of weight loss by exercise-only and combined diet and exercise programs have 
been mixed.  
 
Overall the combined lifestyle intervention achieved clinically significant weight loss 
(mean -5.7% from baseline) by increasing levels of physical activity and by reducing 
energy intake (see Table 4.1).  Following weight loss were falls in the fasting levels of 
GLP-1 and leptin, a rise in fasting levels of ghrelin, and an improvement in insulin 
sensitivity.  However the overall direction from the changes in ghrelin, GLP-1 and 
leptin were such as to limit further weight loss and promote weight regain.  
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These findings show that weight loss from a combined lifestyle intervention leads to 
maladaptive counter-regulatory changes in multiple peripheral regulators of appetite 
and body weight and to our knowledge; this is the first time that these results have 
been demonstrated following such a program. 
 
4.5.1  Lifestyle intervention and pooled analyses 
 
At the end of the combined lifestyle intervention, subjects in this study had decreased 
their EI by 20% and increased their levels of physical activity: METs by 63% and mean 
daily step count by 45%.  While the final component of the intervention, namely 
behavioural changes, were not formally quantified, the clinically significant weight loss 
(>5% from baseline) attests to the overall success of the intervention (see Table 4.1).   
 
However while subjects were originally separated into two dietary treatment groups 
data from the entire cohort was used in the analyses of the effects of weight loss on the 
secretion of hormones and markers of inflammation.  As such, comment should be 
made about the dietary interventions and on the decision to pool data. 
 
In the study subjects were divided into a Korean Diet (KD) diet treatment group, which 
received 12 main meals per week (lunch and dinner Mon-Sat); and a Conventional Diet 
(CD) group; which received shopping vouchers to the value of the meals and a 
hypocaloric recipe book.  While this component of the dietary intervention differed, 
the provision of commercially prepared low energy meals is utilised by many dietary 
programs and is recognised as a valid option in the treatment of obesity17.  
Furthermore, both groups received the same hypocaloric diet targets, the same 
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education regarding the nutritional composition of meals and the value of home 
cooking in addition to the same advice and targets for physical activity and behavioural 
changes.  
 
At completion both groups reduced their EI compared to baseline EIs (which did not 
differ) but the KD group was found to have a significantly higher EI than the CD group 
(see Appendix: Item D).  
 
One question is whether these results are genuine or whether they are due to errors in 
the subjective reporting of food intake in the 3-day food diaries.  While under-
reporting of food intake in food diaries is a known problem, the reporting of food 
intake remains consistent over time and the food diary has become a widely utilised 
and validated method of measuring food consumption in clinical trials328,329.  In 
addition, both groups received the same education about calorie counting (intended to 
up-skill the subjects and aid their compliance with the prescribed diet).   
 
Moreover, there were no baseline differences for EI (which suggests that 
randomisation of subjects did not lead to between group bias in the reporting of food 
intake).  Interestingly the group with the higher EI was the KD group, where food 
intake was also assessed directly by study staff by weighing the leftover food from the 
returned food trays and there were no significant differences in EI between that 
reported in the KD food diaries and returned food trays (not shown). 
 
Furthermore, the KD group was noted to have 20% lower levels of fasting ghrelin at 
completion than the CD group (see Appendix: Item D) consistent with the known 
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effects of food intake and levels of ghrelin see Chapter 2, Section 2.1.3.2 and Section 
4.1.2.1 above).  Taking all these factors into consideration, while an error in results for 
EI cannot be excluded, the finding is less likely a reporting error than a true finding.  
 
A possible contributory factor to the increased EI in the KD group was the nature of 
Korean cuisine.  There is a known association between novelty and variety in food 
choices and the increased consumption of food214,216 and while the KD group was 
instructed to eat ad libitum, the large number of different foods served per main 
Korean meal and the unique nature of the cuisine; coupled with the form in which the 
Korean meals were presented, may have influenced the subjects food related 
behaviours to favour over consumption (see Section 4.2.2 and Appendix: Items B).   
Conversely, part of the focus of the behavioural intervention was on appropriate food 
selection and preparation and the CD group had greater ability to choose the form and 
portion size of their main meals, which should have made it easier to reduce food 
intake.  However, whatever the balance between all these factors, it is worth restating 
that at completion both two groups lost an almost identical amount of weight. 
 
To reiterate, despite these confounders, because there were no between-group 
differences for weight or any biochemical or hormone measure at completion (except 
adiponectin), the data from the KD and CD groups were pooled to increase statistical 
power for the baseline vs. completion analyses of the secondary outcomes. 
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4.5.2  Lifestyle induced weight loss and the peripheral mediators of appetite
   and body weight regulation 
 
The findings of most interest, namely that weight loss was associated with increased 
levels of the fasting orexigenic hormone ghrelin281 and decreased levels of the fasting 
anorectic hormones GLP-1252,282 and leptin65,66; are consistent with the notion that 
weight loss induces counter-regulatory changes in the peripheral mediators of appetite 
and body weight regulation that work physiologically to limit further weight loss and 
promote weight regain.  In the situation where weight loss is being attempted and 
weight maintenance desired, such changes may be considered “maladaptive”.  This is 
the first study to demonstrate these significant changes in fasting GLP-1, ghrelin and 
leptin following combined lifestyle-induced weight loss. 
 
The changes in the hormone levels and in their overall direction are congruent to those 
reported in studies of weight loss with very low calorie and low calorie diets (see 
Section 4.1.3) and some of the results reported in the lesser number of studies into 
weight loss produced by combined diet and exercise, or an exercise only program273,286.  
However, given the paucity of the literature in this area, it is worth commenting that 
the results for ghrelin run contrary to the single study of weight loss by exercise only 
and ghrelin284.  
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Ghrelin 
 
There has been only one study of weight loss by combined diet and exercise and the 
effects on the secretion of ghrelin, by Garcia et al285.  For obese Mexican-American 
women who achieved mean weight loss ~5% after 6 months of a combined diet, 
exercise and pharmacotherapy program, weight loss was associated with elevated 
fasting levels of ghrelin, which are consistent with the results for the current study 
(both for weight loss and the findings of elevated fasting ghrelin). 
 
Interestingly, Garcia et al had an extension phase of 6 months weight-maintenance by 
low caloric diet and reported that by month 12, levels of ghrelin had returned to 
baseline despite the majority of subjects maintaining close to 5% weight loss.  They 
concluded that the post-weight loss changes for ghrelin were not persistent and 
suggested that any role ghrelin played in weight-loss counter-regulation and weight 
regain was transient.   
 
The findings at 12 months are partially in conflict with the main hypothesis but several 
factors may explain this discrepancy: firstly the improved levels of fasting ghrelin at 12 
months may have been more influenced by the subjects who had regained weight than 
those who maintained weight loss; secondly the small sample size reduced statistical 
power and made Garcia’s study more prone to Type II error; while finally there is a 
possibility (albeit remote) that the use of Orlistat as pharmacological adjuvant to the 
combined lifestyle weight loss led to an independent effect on the secretion of ghrelin 
from this drug.   
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Furthermore, the evidence from other studies does suggest that the 12 month ghrelin 
findings from Garcia et al’s are an aberration:  Sumithran et al239 demonstrated 
strongly that many peripheral regulators, including ghrelin, remain at counter-
regulatory, weight regain promoting levels 12 months after weight loss and 
maintenance while Foster-Schubert et al283 reported that obese post-menopausal 
women who achieved weight loss by exercise only had increased levels of fasting 
ghrelin in proportion with weight loss at 6 months and at 12 months after starting the 
intervention levels remained elevated.  In addition, both studies had greater subject 
numbers than Garcia et al and therefore greater statistical power. 
 
The current study found no correlation between changes in weight and changes in 
fasting levels of ghrelin which was contrary to other studies of diet induced weight loss 
and fasting ghrelin243,244.  While this was a genuine finding, one mitigating issue has 
been already acknowledged; namely the differences at completion between the diet 
treatment groups for EI and (non-significantly) for fasting ghrelin (see Appendix: 
Item D).   
 
Taken together these differences and the fact that the KD subjects made up ~45% of 
the entire cohort, the pooling of data for this particular analysis weakened the 
correlation between weight loss and changes in ghrelin.  However these factors also 
raise an intriguing possibility; that different diets may be equally efficacious in 
achieving weight loss but have differential effects on appetite hormones.  This idea was 
discussed at length in the main article arising from the original study325 with further 
research is being planned into the Korean Diet and its effects on weight loss and on the 
secretion of gut hormones.
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GLP-1 
 
Compared to the other appetite regulation hormones, there is a paucity of studies of 
the effects of weight loss by any lifestyle intervention on the secretion of GLP-1, and 
none by combined lifestyle treatments.  As such, the findings from the current study of 
reduced levels of fasting GLP-1 following lifestyle induced weight loss are entirely 
novel.   
 
These findings are supported by the results of Adams et al282 who reported that in 
obese subjects after weight loss with a very low calorie diet, there was a near significant 
trend towards reduced fasting GLP-1 and significantly attenuated post-prandial GLP-1 
secretion compared to baseline (pre-weight loss) levels.  Furthermore in an extension 
of the study that also had increased subjects252, the effects of weight loss and 
maintenance were assessed with the same post-weight loss changes for fasting and 
post-prandial GLP-1 reported (the former now significant).  Intriguingly, after 3 
months of weight maintenance by a hypocaloric but not liquid meal replacement diet, 
levels of GLP-1 were reported to have recovered to close to pre-weight loss levels. 
 
Counter to the results from this study and above, Verdich et al250 reported that weight 
loss and maintenance with a very low calorie diet led to a non-significant increase to 
fasting levels of GLP-1 and improved post-prandial secretion.  These findings are 
against the main hypothesis but mitigating them are the study’s small sample size (the 
smallest of any of the studies discussed) and that the study was carried out prior to the 
adoption of a standardised technique for the RIA of active GLP-1. 
 
 220 
While there have been no studies that utilise a combined lifestyle intervention for 
weight loss into GLP-1, our findings should also be compared against the one study of 
exercise-only induced weight loss and GLP-1.   
 
Martins et al284 reported that after weight loss by 12 weeks of regular and supervised 
exercising, overweight and obese subjects had enhanced post-prandial secretion of 
GLP-1 compared to baseline and concluded that exercise-induced weight loss may 
actually attenuate the expected counter-regulatory changes in GLP-1 secretion.  
However their subject numbers were small and the finding did not meet statistical 
significance. 
 
Given the relatively small number of studies of non-surgical weight loss and GLP-1, the 
results of a study of weight loss with bariatric surgery compared to that with a very low 
calorie diet253 should also be considered.  In a well-designed protocol, which matched 
subjects according to % weight loss, diet-induced weight loss was found to be 
associated with reduced post-prandial GLP-1 secretion and surgical-induced weight 
loss with significantly increased post-prandial secretion.  As noted in the introduction 
(Sections 4.1.2.2 and 4.1.2.3), the latter finding has been reported consistently in 
studies of bariatric surgery and GLP-1. 
 
Taking the current results and evidence from the above studies, weight loss by diet and 
exercise induces the same counter-regulatory changes in GLP-1 as seen in diet-induced 
weight loss, while for post-prandial GLP-1 secretion it would appear that on-balance 
weight loss attenuates secretion.  However as the post-prandial changes have been 
noted to recover after a period of weight maintenance, these changes in GLP-1 
 221 
secretion are shorter lived than the changes in the other hormones.  Fasting changes 
do appear to persist for longer as significantly reduced fasting (but not post-prandial) 
GLP-1 52-weeks after a weight loss intervention has been reported239. 
 
This study also found a correlation between change in weight and changes in fasting 
GLP-1, suggesting that for non-surgical weight loss, the reduction in fasting levels of 
GLP-1 are proportional to the degree of weight loss. 
 
Leptin 
 
Our findings for leptin are similar to that reported by Volpe et al273, one of only two 
studies which have examined the combined effects of diet and exercise on peripheral 
regulators of appetite and body weight regulation.  Like the current study, they 
reported that levels of fasting leptin fell and this was correlated with weight loss by 
both diet and exercise and diet only.  Additionally, compared to Volpe et al the current 
study had greater statistical power (due to a larger numbers of total subjects and due 
to the pooling of data) and a study population that was heavier (mean weight in the 
range of obesity rather than overweight). 
 
Furthermore such changes in leptin have been widely reported in studies of weight loss 
by bariatric surgery and in the small subset number of studies that directly compared 
bariatric surgery with very low calorie diets, levels of leptin have also been reported to 
decrease in proportion to weight loss248,279. 
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All these findings show that levels of leptin fall following weight loss regardless of 
whether it achieved by hypocaloric diet, combined diet and exercise or bariatric 
surgery, with the reduction in leptin proportional to weight loss.  The net result of 
these changes is to favour weight regain.   
 
These findings also support the notion that leptin has dual physiological roles with 
levels chronically increased in obesity (where it acts as a long-term signal of adiposity) 
and acutely decreased following weight loss (where it acts as a short-term signal of 
energy deficit)268.  Intriguingly, the recent finding that the changes for leptin remain 
present for 12 months after weight loss and weight maintenance239 raises the 
possibility that the post-weight loss reductions in fasting leptin continue to exert 
physiological effects for longer than would be expected for a short-term signal of 
energy deficit. 
 
4.5.3  Clinical implications: GLP-1 and leptin 
 
Agents targeting the GLP-1 pathway, such as incretin mimetics which have a high 
affinity for the GLP-1 receptor, and DPP-IV inhibitors, which prolong the life of 
endogenously secreted GLP-1, have become accepted as therapeutic options in the 
management of T2DM330,331.  In contrast to most other hypoglycaemic agents, these 
agents do not lead to weight gain and the incretin memetics (such as Exenatide and 
Liraglutide) are associated with weight reduction.   
 
Two recent meta-analyses of Exenatide use in T2DM found that compared to standard 
treatment, Exenatide was associated with dose-dependent significant weight loss that 
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persisted for at least 2 years332,333.  The unique weight loss properties of the incretin 
mimetics raise the possibility that these agents do have an adjuvantive role in the 
management of obesity.  Supporting this notion a recent study found that Exenatide, 
compared to lifestyle management alone, enhanced weight loss in obese, non-diabetic 
subjects following 24 weeks of therapy334 and Liraglutide is currently the subject of a 
Phase III study in overweight and obesity (ClinicalTrials.gov ID: NCT01272232). 
 
The administration of leptin to congenitally leptin-deficient obese individuals results 
in dramatic improvements in body weight, insulin resistance and other metabolic 
parameters265 but unfortunately trials of leptin therapy for weight loss in common 
obesity have so far been unsuccessful335.  As found in the current study and others, it 
has been established that weight loss reduces levels of leptin and (in other studies) is 
associated with increased hunger239,246.   
 
Therefore it has been postulated that the administration of leptin post-weight loss 
might help weight maintenance by ameliorating one of the counter-regulatory changes 
seen after weight loss.  This is supported by two studies, albeit with very small sample 
sizes.  In the first study336 7 obese subjects who maintained clinically significant weight 
loss by liquid very low calorie diets were administered exogenous leptin. This 
treatment was found to be associated with increased resting metabolic rates and slight, 
but significant, increases to the circulating levels of thyroxine and triiodothyronine.  In 
the second study337 leptin or placebo was administered in a cross-over fashion to 6 
subjects after they achieved 10% weight loss by liquid very low calorie diets.  The leptin 
treated subjects reduced their food consumption which was found to be correlated with 
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increased neurological activity in the areas involved in the cognitive and emotional 
control of food intake (measured by functional magnetic resonance imaging).   
 
While leptin therapy for weight maintenance remains very much in the pre-clinical 
stage and the use of leptin in common obesity yet to be established, these findings raise 
the possibility that modulating levels of leptin post weight loss may become a valid 
treatment option in the future. 
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4.5.4  Lifestyle induced weight loss and inflammation 
 
Following weight loss, subjects had significant improvements to fasting insulin and 
insulin sensitivity.  However for the other markers of obesity-related inflammation, i.e. 
adiponectin (ADP) and hsCRP, no significant changes were found.  Finally, fasting 
glucose was also unchanged at completion. 
 
Subjects in this study achieved 5.7% weight loss, generally considered a good weight 
loss result following lifestyle therapy17.  Weight loss in this range is known to be 
associated with improvements in metabolic health, including in insulin secretion17,229 
and given the strong association between insulin resistance and overweight and 
obesity (and see Section 4.1.4 above), the improvements in fasting insulin and insulin 
sensitivity were as expected.  Likewise, the lack of change in glucose is unsurprising as 
individuals with T2DM were excluded from the study and as baseline glucose was well 
within the normal range (see Table 4.2). 
 
Despite clinically significant weight loss, no significant changes were noted for ADP or 
hsCRP.  While increased ADP has been reported after weight loss by all methods, the 
association is weaker when weight loss is under 10% and in lower grades of obesity (see 
Section 4.1.4.1).  Our current results reflect both the weight loss outcomes and lower 
mean baseline BMI of subjects in our study. 
 
Secondly, as the only hormone or biochemistry difference between the diet treatment 
groups was for ADP (both at baseline and completion favouring the KD group and see 
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Appendix: Item D) the pooling of data for ADP likely increased the risk for a Type II 
error and has thus been unsuitable for this analysis.   
There was a non-significant trend of a small increase of hsCRP at completion.  For this 
study population the finding was considered unlikely to be of any clinical relevance.   
 
Generally reductions in hsCRP are expected after weight loss but the reduction is 
greater in those with greater weight loss and for those with a greater number of pre-
existing metabolic co-morbidities (see Section 4.1.4.3).  As the weight loss achieved in 
this study was modest and as the subjects had lower grade obesity without T2DM or 
active cardiovascular disease, these worked against a significant reduction in hsCRP.   
 
4.5.5  Additional comments: strengths, limitations and other issues 
 
This study successfully proved the main hypothesis, namely that counter-regulatory 
and maladaptive changes develop in the secretion of peripheral mediators of appetite 
and body weight regulation following weight loss.  Furthermore in comparison to the 
available literature into this topic, several aspects of this study enhanced the findings; 
the choice of weight loss intervention was that of a combined diet, exercise and 
behavioural program, which has rarely been tested in clinical research despite being 
the cornerstone of obesity management.  Clinically significant weight loss was 
achieved, measures of energy intake and of physical activity were recorded and there 
was a relatively large sample size with greater statistical power and a large number of 
hormonal and biochemical measures were assessed. 
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However, there were also several limitations to the current study.  This included the 
absence of a standardised appetite survey, which prevented any investigation of the 
effects of these changes on subjective appetite and hunger.  Secondly, the inclusion of a 
meal test at baseline and at completion would have provided an excellent opportunity 
to examine the effects of weight loss on the post-prandial secretion of the gut 
hormones and especially GLP-1, which is known to exert many of its physiological 
effects after food consumption.  Post-prandial testing may have also clarified one area 
of uncertainty:  whether lifestyle induced weight loss alters the secretion of these key 
hormones of appetite and body weight regulation in a similar fashion to diet-induced 
weight loss20-24 or whether, as suggested by one exercise-only weight loss study25, the 
act of exercising attenuates the changes for ghrelin and GLP-1 in the post-prandial 
period.  Given that most clinical obesity management programs utilise diet and 
exercise, these remain important unanswered questions. 
 
Finally, while the original study was extended to assess the effects of the different 
dietary interventions on weight maintenance327, there was not the opportunity to re-
measure the secretion of the gut hormones and adipokines in the extension phase.  
This was a lost opportunity to determine the persistence of the counter-regulatory 
changes which have been suggested to last for up to 12 months239.   
 
If the opportunity arises again to revisit this particular study protocol, a strong effort 
will be made to address the above limitations and if it proceeds, it would provide an 
occasion to confirm the findings while clarifying several of the outstanding issues 
raised in this discussion. 
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4.6  CONCLUSION 
 
In conclusion, 12 weeks of a combined diet, exercise and behavioural program 
produced clinically significant weight loss associated with changes in the fasting levels 
of ghrelin, GLP-1 and leptin.  The net result of these changes would be to mitigate 
against further weight loss and encourage weight regain.   
 
These findings suggest that all methods of non-surgical weight loss are associated with 
counter-regulatory changes in the peripheral homeostatic regulators of appetite and 
body weight and as a combined lifestyle intervention remains the recommended first 
line of obesity management our findings have important “real world” implications. 
 
These findings raise the possibility that treatments targeting these hormonal changes 
can affect clinical outcomes.  The (to-date) limited use of GLP-1 receptor agonists for 
weight loss appears to be a promising first step in this new therapeutic direction.   
 
Additional research could provide important therapeutic options in the non-surgical 
management of overweight and obesity and may give clinicians additional 
pharmacological tools to help individuals maintain long-term weight loss.  
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CHAPTER 5 
 
Aspects of obesity: lessons learnt  
 
 
5.1  INTRODUCTION 
 
Overweight and obesity, the 5th leading risk for global death, is a well-recognised 
international health challenge1.  In Australia over 25% of children6 and over 63% of 
adults are overweight or obese, moreover the prevalence continues to increase2.  The 
conditions are a significant drain on national budgets with recent local estimates of the 
annual direct health costs in the order of $8 billion.  When indirect costs such as lost 
productivity are considered, this rises to a staggering $45 billion annually13,14  
 
While the scale of the conditions, their costs and their associated morbidity and 
mortality have been the subject of much research and are all well understood, the 
mainstay of clinical treatment, the combined lifestyle intervention (which comprises a 
hypocaloric diet, increased physical activity, behavioural change and psychological 
support) has its antecedents in methods developed by physicians of antiquity15,16.  
Moreover combined lifestyle interventions are associated with only modest weight loss 
and a high rate of recidivism20.   
 
There have been advances made in the field of clinical treatments for obesity and this 
includes the use of pharmacological agents to induce weight loss.  However while these 
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agents have generally had modest efficacy21,22, they also have been troubled with 
significant side-effect profiles338,339 and questionable cost-effectiveness340.   
 
The most successful modern advance has been contemporary bariatric surgery, which 
is associated with significant weight loss, long-term weight remission and improved 
mortality24,27,234.  Nonetheless, unanswered questions remain about bariatric surgery’s 
long-term safety and overall cost-effectiveness27,29.  
 
There remains much on-going research in the field of overweight and obesity and 
recently, novel insights regarding the aetiology of overweight and obesity have brought 
a renewed focus on two hitherto underexplored factors: the role of dietary protein in 
driving food intake and the physiological changes that develop after weight loss.  
Underlying both are the peripherally secreted mediators of appetite and body weight 
regulation.  
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5.2  THE EXPERIMENTS 
 
The role of dietary protein in influencing food intake was examined in the first 
experiment and the Protein Leverage Hypothesis rigorously assessed in lean humans.  
The larger experiment covertly presented subjects with the same isocaloric food items 
but the diets differed in % protein.  The results demonstrated that the subjects’ intake 
of protein was prioritised above that of the other macronutrients, even at the expense 
of increasing their total energy intake.   
 
In the associated experiment, 4 days of ad libitum diets differing in % protein followed 
by a meal test resulted in changes to the fasting and post-prandial secretion of key gut 
hormones in a direction favouring decreased hunger and increased satiety.  
 
In the final experiment, the prioritisation of dietary protein according to the Protein 
Leverage Hypothesis was tested in an obese phenotype.  In the first report of this kind, 
obese mice demonstrated the same priority for maintaining their intake of dietary 
protein, even at the expense of increasing their intake for total energy, as was found in 
their lean counterparts.  However the degree of protein prioritisation and the effects 
from variety and novelty in the diet were less powerful than that seen in lean mice, 
suggesting that the state of obesity itself may modulate the usual regulators of food 
intake.   
 
In the third experiment, which examined weight loss and remission in an obese cohort, 
for the first time clinically significant weight loss by a combined lifestyle program was 
shown to be associated with changes in the fasting secretion of several key gut 
 232 
hormones and adipokines that regulate appetite and body weight.  The overall 
direction from these changes would be to act to limit further weight loss and to 
promote weight regain. 
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5.3  IMPLICATIONS FOR FUTURE RESEARCH AND CLINICAL
  DIRECTIONS 
 
Implications for research 
 
There are studies currently underway involving humans and mice into the Protein 
Leverage Hypothesis.  While this author is not directly involved in these studies, the 
new studies have acknowledged the limitations that arose from the current 
experiments and have addressed many of the limitations discussed in Chapters 2 and 
3. 
 
For testing the Protein Leverage Hypothesis in lean humans (Chapter 2), at the 
completion of the current study a revised protocol was developed that addressed 
practical limitations such as refining participant instructions for the Appetite Visual 
Analogue Scale and streamlining the collection of samples.  A major protocol change 
was the incorporation of four diet treatment cycles, which give the new study an 
opportunity to explore the role of variety and the relative power of carbohydrates and 
fat in modifying protein leveraging.  The revised study commenced recruitment in the 
middle of 2012. 
 
The experience gained from testing the Protein Leverage Hypothesis in obese mice 
(Chapter 3) has helped inform the on-going mice studies.  Protocol changes include 
increasing subject numbers, lengthening the duration of the conditioning diets and 
diet treatments and increasing the number of treatments.  These changes allow for 
statistical power to be maintained despite the increase in diet treatments and provide 
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sufficient time for the development of more differentiated phenotypes.  The larger 
number of comparator groups will provide a clearer assessment of the effects of low 
and high protein diets on body composition and on the secretion of orexigenic and 
anorexigenic hormones while maintaining the ability to directly compare food intake 
between the different protein diets. 
 
There will be an extension of the study performed and described in Chapter 4, 
providing the opportunity to continue the investigation as to the effects of weight-loss 
on the secretion of peripheral mediators of appetite and body weight regulation.  
Firstly, a subjective measure of appetite and hunger will be added, to help determine 
whether changes in hormones are correlated with changes in subjective hunger.  
Secondly, the addition of a standardised meal test will allow for the measurement of 
the post-prandial secretion of hormones at baseline and at completion.  Thirdly, 
measuring hormones during the period of weight-maintenance will allow for an 
assessment of the persistence of the counter-regulatory changes.  Fourthly, an 
increased number of hormones will be measured (such as the gut hormone peptide 
YY).  Finally, better control of the energy intake during the dietary intervention should 
prevent any differences in energy intake from clouding the results. 
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Clinical directions 
 
The results of the three experiments point to novel insights into different aspects of 
obesity.  While further and more detailed research is needed before this translates into 
changes to clinical practice, it is foreseeable that validation of the Protein Leverage 
Hypothesis could lead to changes in national dietary recommendations, which could 
assist in reducing the incidence of overweight and obesity.  Moreover a deeper 
understanding of the effects of dietary protein on gut hormone secretion may also alter 
the dietary recommendations for weight loss.  A more complete understanding of the 
changes which develop in peripheral mediators of appetite and body weight regulation, 
which could open up new areas for targeted pharmacotherapy with the goal of 
enhancing both weight loss and weight maintenance. 
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5.4  FINAL CONCLUSIONS 
 
The first two experiments help to confirm the central role that dietary protein plays in 
the regulation of food intake and that protein leveraging occurs regardless of 
phenotype.  When contrasted to the secular trends in the consumption of 
macronutrients and increased energy intake, the Protein Leverage Hypothesis offers a 
fresh perspective to the aetiology of the increase in global overweight and obesity while 
potentially offering a novel approach to its dietary management. 
 
The third experiment demonstrated that following weight loss by conventional lifestyle 
strategies, the same physiological homeostatic counter-regulatory changes develop as 
has been reported following diet-induced weight loss.  The cumulative direction of 
these changes is to limit further weight loss and promote weight regain.  These novel 
findings help provide the physiological underpinning to the high rates of recidivism 
that follow weight loss by conventional combined lifestyle methods and as such, has 
“real world” implications. 
 
When the three experiments are taken together, they highlight the important role of 
gut hormones and adipokines in mediating changes in appetite, changes in food intake 
and ultimately changes in body weight both during periods where body weight is stable 
and during periods when it is in flux.  Further research exploring these concepts may 
assist in the development of an integrated obesity treatment paradigm, which involves 
prescribing both diet and pharmacotherapy to induce weight loss and to target changes 
in key hormones to both facilitate weight loss and to help maintain reduced body 
weight. 
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CHAPTER 7  
 
Appendix 
 
 
Item A The principle of the technique for Radioimmunoassays 
 
The principle of the RIA technique follows: 
 
A fixed concentration of labelled tracer antigen is incubated with a constant dilution of 
antiserum so that the concentration of antigen binding sites on the antibody is limited 
(e.g. only 50% of total tracer concentration may be bound by antibody).  Unlabelled 
antigen is added, which leads to competition between labelled tracer and unlabelled 
antigen for the limited number of antibody binding sites.  The amount of tracer bound 
to antibody decreases as the concentration of unlabelled antigen increases and so a 
standard curve generated.  When unknown samples are prepared with antibody and 
tracer and measured against the standard curve, this method allows for the value of the 
unknown sample to be calculated against the known values arising from the standard 
curve. 
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The following pieces of laboratory equipment were used for all RIAs:  
 
• 10 - 1000 µL pipettes with disposable tips,  
• 10 - 1000 µL repeating dispenser (Eppendorf Multi-pipette),  
• a vortex mixer (Ratek Model MTV1),  
• a Ratek rolling column mixer, a refrigerated swing bucket centrifuge (HD Scientific 
/ Hettich Zentrifuger Rotixa 50RS),  
• an automated gamma-counter (Perkin Elmer Wallac Wizard 1470 Automatic 
Gamma-counter; MultiCalc v 3.6), 
• refrigerators (set at -80 oC, -20 oC and 3.5oC) were used to store reagents and 
samples, to thaw frozen reagents and samples and to incubate samples during the 
RIA runs. 
 
For the RIAs for total ghrelin and insulin, samples were placed into pointed 
polypropylene tubes (12 x 75 mm). 
 
For the RIAS for CCK and GLP-1, the assay technique required a preliminary process 
of extraction of hormone from stored plasma.  This involved the use of a 96% EtOH 
solution and a 36-well heating block with a 32-tube glass gas collector and distributor 
attached to a central source of nitrogen oxide.  The extraction of GLP-1 from the frozen 
plasma samples also used Eppendorf microfuge tubes (1.5mL). Extracted and 
rehydrated samples were then placed into in borosilicate glass tubes (10 x 70 mm) for 
analysis. 
 
 
 267 
Item B(1) An example of a main meal for the Korean Diet group 
 
Rice   e.g. Kimbap (sushi rice), Bibimbap (combination rice dish) or Kimchi 
bokkeumbap (Kimchi fried rice)  
Kimchi  e.g. Tongbaechu-kimchi, Kkakdugi  
Soup   e.g. Tteok Mandu-guk, Kongnamulguk  
Side dishes e.g. Beoseot Bokkeum (mushroom), Kongjaban (black bean) or Gyeran 
jjim (egg roll)  
Others  e.g. Kimchi Jeon (Kimchi pancake), Haemul pajeon (seafood pancake) or 
tteokbokki (rice cake) 
Meats e.g. Bulgogi (BBQ beef) or Satae pyeon yuk (beef) 
Noodle  Kongguksu (noodle soup), Memil-guksu (buckwheat noodle) or Japchae 
(potato noodle) 
Tea drinks  e.g. Green tea or Sikhye (rice beverage) 
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Item B(2) Images of traditional Korean meals  
 
   
Traditional Korean vegetable sides  kimchi 
 
   
Glass noodles with sautéed vegetables  Bokkeumbap    stir fried kimchi, egg and rice 
 
 
 
NB: Images obtained under the Creative Commons license from flickr – Korea.Net
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Item C  CONSORT diagram:  Disposition of subjects for the Korean Diet Study 
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Item D Measures at completion (week 12) per dietary intervention 
 
 Korean Diet Conventional 
Diet 
P 
Number 
%Female 
25 
72% 
35 
54% 
 
0.14 
Δ %Weight loss  
(% from baseline) 
-5.8 ± 4.7 -5.7 ± 41 0.93 
Δ BMI (kg/m2) -1.7 ± 0.1 -1.7 ± 0.10 0.92 
Δ Waist 
circumference (cms) 
-5.1 ± 3.9 -3.4.0 ± 3.6 0.11 
Step Count 
(steps/day) 
11987±5130 12284±5214 0.42 
Daily Energy Intake 
(kJ/day) 
7407.9 5300.4 <0.001 
Total Ghrelin 
(pmol/L)* 
336.0, 179.2 420.7, 275.6 0.12 
Active GLP-1 
(pg/mL)* 
25.5, 19.3 28.8, 10.3 0.26 
Leptin (ng/mL) 13.3 ± 2.5 13.1 ± 1.9 0.86 
Adiponectin (ug/mL) 13.5 ± 1.4 10.6 ± 0.8 0.02 
Insulin (mU/L)* 5.5, 4.5 6, 5 0.33 
Glucose (mmol/L) 4.0 ± 0.1 4.5 ± 0.1 0.07 
HOMA-IR* 0.98, 0.95 1.15, 0.99 0.74 
hsCRP (mg/L) 2.9 ± 0.6 4.4 ± 0.8 0.15 
 
NB:  Data are presented as mean ± SEM and analysed by Two samples t-test unless otherwise noted 
* non-parametrically distributed data as median, IQR and analysed by Wilcoxon-Mann-Whitney U test. 
!
 271 
Item E International Physical Activity Questionnaire (short form) 
 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
(August 2002) 
 
SHORT LAST 7 DAYS SELF-ADMINISTERED FORMAT 
 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. 
Long (5 activity domains asked independently) and short (4 generic items) versions for use by 
either telephone or self-administered methods are available. The purpose of the 
questionnaires is to provide common instruments that can be used to obtain internationally 
comparable data on health–related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in Geneva in 
1998 and was followed by extensive reliability and validity testing undertaken across 12 
countries (14 sites) during 2000.  The final results suggest that these measures have 
acceptable measurement properties for use in many settings and in different languages, and 
are suitable for national population-based prevalence studies of participation in physical 
activity. 
 
Using IPAQ  
Use of the IPAQ instruments for monitoring and research purposes is encouraged. It is 
recommended that no changes be made to the order or wording of the questions as this will 
affect the psychometric properties of the instruments.  
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Translation from English and Cultural Adaptation 
Translation from English is supported to facilitate worldwide use of IPAQ. Information on the 
availability of IPAQ in different languages can be obtained at  www.ipaq.ki.se. If a new 
translation is undertaken we highly recommend using the prescribed back translation methods 
available on the IPAQ website. If possible please consider making your translated version of 
IPAQ available to others by contributing it to the IPAQ website. Further details on translation 
and cultural adaptation can be downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical Activity 
Prevalence Study is in progress. For further information see the IPAQ website.  
 
More Information 
More detailed information on the IPAQ process and the research methods used in the 
development of IPAQ instruments is available at www.ipaq.ki.se and Booth, M.L. (2000).  
Assessment of Physical Activity: An International Perspective.  Research Quarterly for 
Exercise and Sport, 71 (2): s114-20.  Other scientific publications and presentations on the 
use of IPAQ are summarized on the website. 
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INTERNATIONAL)PHYSICAL)ACTIVITY)QUESTIONNAIRE)
 
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives.  The questions will ask you about the time you spent being 
physically active in the last 7 days.  Please answer each question even if you do not 
consider yourself to be an active person.  Please think about the activities you do at 
work, as part of your house and yard work, to get from place to place, and in your 
spare time for recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe 
much harder than normal.  Think only about those physical activities that you did for at 
least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
2. How much time did you usually spend doing vigorous physical activities on one 
of those days? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
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Think about all the moderate activities that you did in the last 7 days.  Moderate 
activities refer to activities that take moderate physical effort and make you breathe 
somewhat harder than normal.  Think only about those physical activities that you did 
for at least 10 minutes at a time. 
 
 
3. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles tennis?  
Do not include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
 
 
4. How much time did you usually spend doing moderate physical activities on 
one of those days? 
 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at work and 
at home, walking to travel from place to place, and any other walking that you have 
done solely for recreation, sport, exercise, or leisure. 
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5. During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during the last 7 
days.  Include time spent at work, at home, while doing course work and during leisure 
time.  This may include time spent sitting at a desk, visiting friends, reading, or sitting 
or lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
 
This is the end of the questionnaire, thank you for participating. 
 
